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Colon cancer is one of the most common internal malignancies in the developed
world and represents the 2nd cause of cancer death in Western countries.
Approximately half of all colorectal cancers show p53 gene mutation, particularly in
late stage acting as a progression step. Much of the information in carcinogenesis in
the intestine derives from studies based on the small intestine, yet the majority of the
mutations leading to cancer occur in the large intestine. To overcome some of these
issues, the use a large bowel model and in particular the primary murine colonocytes
system was preferred.
The objectives were to better understand the importance of p53 and related proteins
in the regulation of growth and responses to DNA damage in these cells. In order to
investigate both p53 dependent and independent death pathways we exposed primary
colonocytes to cisplatin.
The initial study showed that the role of p53 in preventing entry into S-phase
following colonocyte DNA damage appears crucial whereas its role in apoptosis
seems redundant. This suggests that p53-mediated apoptosis and growth arrest are
neither a major nor a unique protector of colonic epithelial cells against mutation
following DNA damage. Furthermore, the nuclear translocation of endogenous p73a
in response to DNA damage in primary colonocytes is highly suggestive of a
functional pro-apoptotic role for p73a in these cells, within the context of p53-
independent apoptosis. Moreover, in the context of p53 deficiency, p73a activation is
highly suggestive of its involvement in the p53-independent pathway of apoptosis in
these cells.
Consequently, it seemed plausible that other "early" genetic events could affect the
colonic epithelium to lead to cancer. Hedgehog developmental pathway is important
in controlling normal growth and patterning and has been recently linked to different
types of cancer. As cancer appears due to abnormal growth control it was of interest
to investigate a possible involvement of Hedgehog genes in colorectal neoplasia.
Therefore, the second part of this thesis focused on investigating the pattern of
expression of sonic hedgehog (Shh) signalling pathway in normal colon versus
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colonic lesions including hyperplastic polyp, adenoma and adenocarcinoma of the
colon. Results showed that Hedgehog signalling pathway members are expressed in
normal colonic epithelium with Shh at the top of the crypts and a few basally located
cells, patched in the neuroendocrine cells and smoothened at the brush border of
superficial epithelium. RT-PCR analysis of laser-microdissected crypts from normal
human colon confirmed that mRNAs encoding these proteins were expressed in
colonic epithelium. Expression of Shh, Ptch and Smoh was upregulated in
hyperplastic polyps, adenomas and adenocarcinomas of the colon and sonic
hedgehog expression correlated with an increased expression of the proliferation
marker Ki-67 in all lesions examined.
To address whether the Hh signalling pathway is functional in the gut, the effect of
Shh on epithelial cells in vitro was explored by treating primary murine colonocytes
with either Shh peptide or neutralizing anti-Shh antibody. The results illustrated that
exogenous Shh promotes cell proliferation in colonocytes while anti-Shh inhibits
proliferation, suggesting that sonic hedgehog is required during proliferation of
epithelial cells in vitro. Therefore, the results suggested that Shh is required during
epithelial proliferation in the colon and that there is a possible role for Hh signalling






1.1.1. Epidemiology and Incidence
Colorectal cancer represents the second most common cause of cancer death in the
developed countries [Parker S.L. and Tong T. et al., 1997], A high rate of cellular
turnover combined with environmental factors such as unhealthy diet [Flood A. and
Velie E.M. et al., 2002], colonic flora, lack of physical activity and smoking [Le
Marchand L. and Wilkens L.R. et al., 1997] give a relatively high rate of neoplasia.
Epidemiologic studies indicate that diets high in red meat and animal fat and low in
fibres are associated with an increased incidence of colorectal cancer [Giovannucci
E. and Rimm E.B. et al., 1994; Potter J.D., 1999]. Approximately 5% of the
population develops colorectal cancer and the incidence of colorectal cancer is
expected to grow, as more and more people adopt a western style diet and life
expectancy increases [Rosenberg S.A. and DeVita V.T. et al., 2001].
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1.1.2 Genetic Factors in Colorectal Cancer
Colorectal cancer develops as a series of clinical and histopathologic steps, from a
single crypt lesion, aberrant crypt foci to small benign lesions, adenomatous polyps
and finally malignant cancer. This progression involves genetic changes in the form
of activation of a number of oncogenes and/or inactivation of tumour suppressor
genes. Colonic adenomas are recognized as benign lesions but they may give rise to
carcinomas. In addition, carcinomas can also arise in patients with inflammatory
bowel disease. Adenomas can occur sporadically or as part of a familial syndrome.
Genetic inherited influences are best defined in two categories: familial adenomatous
polyposis (FAP) and hereditary non-polyposis colon cancer (HNPCC).
FAP accounts only for 1% of all colorectal carcinomas and HNPCC for
approximately 4%. Patients with FAP develop multiple benign tumours in their
twenties or thirties. Some of these polyps will become malignant, giving rise to colon
carcinomas. FAP is associated with germ-line mutations of the adenomatous
polyposis coli (APC) gene that result in a truncated version of the protein [Nishisho I.
and Nakamura Y. et al., 1991], These mutations are also implicated in breast
tumours. In the case of NHPCC, the majority of the patients inherit defects in the
mismatch repair (MMR) genes: hMSH2, hMLHl, hPMS2. These tumours are
mismatch repair-deficient and therefore genetically unstable and progress faster to
carcinomas. In addition, patients with HNPCC exhibit an increased risk of
developing cancers of other organs such as uterus, ovary and brain.
The vast majority of colorectal cancers do not have an apparent inherited
susceptibility and therefore they are grouped as sporadic cancers. However, many
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studies indicate a broader role for inheritance amongst sporadic cancers, as they
demonstrated that relatives of patients with sporadic colon cancer also have an
increased risk to develop colon cancer or associated cancers [Cannon-Albright L.A.
and Skolnick M.H. et al., 1988]. This appears to [Houlston R.S. and Collins A. et al.,
1992] suggest that many cases of sporadic colorectal cancer may have an yet
undefined genetic background.
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1.1.3. Molecular Genetic Changes in Colorectal Cancer
Epidemiological, clinical, pathological and molecular studies have shown that
colonic cancer, hereditary or sporadic, grows from pre-existing adenomatous polyps.
At least four genetic events at molecular levels seem to be responsible for the
progression of colorectal cancer: inactivation of several tumour suppressor genes
located on chromosomes 5q, 17p and 18q and the activation of ras oncogenes which
promote tumour growth.
Adenomas formation begins with the loss of function of the tumour suppressor gene
APC followed by the activation of the Kirsten-ras (K-ras) oncogene. Subsequent loss
of function of the tumour suppressor genes located on chromosomes 18q (DCC,
DPC4 and JV18-1/MADR2 genes) and 17p (p53 gene) pushes the adenomatous
lesion towards malignant growth (Figure 1).
Carcinogenesis in the colon occurs through two different mechanisms:
• chromosomal instability, when portions of chromosomes are deleted and specific
genes lose their function
• microsatellite instability when errors occur in the DNA mismatch repair system.
Chromosomal instability is responsible for approximately 80 - 85% of sporadic colon
cancers and all cases of FAP [Piard F. and Martin L. et al., 2002], while the
microsatellite instability accounts for approximately 15% of sporadic cancers and




- loss of heterozygosity
- mutation of tumour suppressor
genes (i.e. p53)
microsatellite instability: - defects (methylation/mutation) of the
DNA base mismatch repair system
Figure 1: Adenoma to carcinoma sequence, molecular etiology ofcolorectal cancer:
temporal order in which key genes are affected. Normal epithelium seems
to become hyperplastic due to age-relatedmethylation. On a hyperplastic
mucosa, defects in the APC geneforms a neoplastic process which follows
two majorpathways: - epigenetic ifmismatch repair genes are inactivated
- genetic characterized by Ki-ras mutations, p53
mutations
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1.1.3.1. Clonal Origin of Colorectal Cancer
Current theories suggest that colorectal cancer develops from a single cell that is
altered and acquires proliferative proprieties. This cell has a higher proliferation rate
compared to the surrounding normal cells. If a cell form within this population of
mutated cells acquires another mutation it creates a sub-clone and continual
sequences lead ultimately to a fully developed tumour.
The clonal origin of human cancer was first investigated using techniques based on
X-chromosomes inactivation in females using a cloned polymorphic X-chromosomal
gene and restriction endonucleases [Vogelstein B. and Fearon E.R. et al., 1985],
Three human tumours were shown to be monoclonal. Another study investigated the
monoclonal nature of colorectal cancer using polymorphic markers in 50 tumours,
adenomas and carcinomas. All tumours showed monoclonal pattern of x-
chromosome inactivation irrespective of the type, familial or sporadic [Fearon E.R.
and Hamilton S.R. et al., 1987],
1.1.3.2. Inactivation of Tumour Suppressor Gene APC
The APC gene is very important in colon carcinogenesis, being responsible for the
progression of the normal colonic epithelium to small adenoma. The gene was found
mutated in the germ line of patients with FAP [Nishisho I. and Nakamura Y. et al.,
1991]. Subsequently, somatic mutations were detected in both sporadic adenomas
and sporadic colon carcinomas [Miyoshi Y. and Nagase H. et al., 1992], All these
studies suggest that the inactivation of the APC tumour suppressor gene occurs
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frequently in early as well as late stages of colon carcinogenesis, in contrast to
mutations of ras orp53 which are detected as the tumours progress.
The role of APC in colon tumourigenesis was also investigated using murine models.
Germ line mutations of the murine Ape, result in multiple intestinal neoplasia [Su
L.K. and Kinzler K.W. et al., 1992], Mice which are heterozygous for the Ape gene
gradually develop intestinal tumors in a way that is comparable to that observed in
FAP patients [Fodde R. and Edelmann W. et al., 1994]. In addition, inactivation of
both murine Ape alleles was detected in microscopic lesions of mouse models of
colorectal cancer and also in the earliest colonic human lesions, the dysplastic crypts
[Levy D.B. and Smith K.J. et al., 1994],
All these mutations result in a truncated protein that is incapable of exerting its
function. Studies on colorectal epithelial cells revealed that the wild-type full-length
APC protein has also an apoptotic function [Morin P.J. and Vogelstein B. et al.,
1996], Apoptosis is a very important function of the colonic epithelium eliminating
damaged cells at the top the crypts, therefore protecting the colon from a neoplastic
process.
1.1.3.3. Activation of the k-ras Oncogene in Colorectal Cancer
The first leap forward in the study of colonic carcinogenesis was the identification of
the k-ras gene mutation. K-ras activation acts in a transitional stage of colonic
carcinogenesis, from a small adenoma to an intermediate adenoma. K-ras gene was
found mutated in only 9% of adenomas smaller than 1 cm [Vogelstein B. and Fearon
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E.R. et al., 1988], in contrast to 92% cases of hyperplastic polyps [Rommel C. and
HafenE., 1998],
Mutations of this gene result in a gain of function and offer a growth advantage to a
small adenoma that has already an inactivated APC gene [Yashiro M. and Carethers
J.M. et al., 2001]. K-ras mutations were also identified in 58% of adenomas larger
than 1 cm and 47% of colon carcinoma [Vogelstein B. and Fearon E.R. et al., 1988],
However, other events associated with k-ras mutations could also be important in
colon tumourigenesis, as many adenomas or colon carcinomas develop in the
absence of a ras mutation [Vogelstein B. and Fearon E.R. et al., 1988].
1.1.3.4. Loss of Function of Genes on Chromosome 18q
In 1988 Vogelstein et al. performed mutational analysis on different stages of
colorectal neoplasia and found deletions of a specific region of chromosome 18 in
73% of colon carcinomas, 47% of advanced adenomas and sporadically in earlier-
stage adenomas [Vogelstein B. and Fearon E.R. et al., 1988],
Several candidate suppressor genes were identified: DCC, DPC4 and JV-18/MADR.
It was difficult to describe a specific function and role for the protein encoded by the
DCC gene as this is not expressed in colorectal cancers at protein levels. Consistent
with its role as tumour suppressor gene, nearly all colorectal cancers fail to express
an intact DCC transcript, while the transcripts are expressed in normal colonic
epithelium [Hedrick L. and Cho K.R. et al., 1994]. Mutational analysis for DCC
revealed just few mutations or deletions. More evidence for a tumour suppressor role
came from a study based on chromosomal transfer that showed the ability of
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chromosome 18q to reduce the growth of human cancer cells [Tanaka K. and
OshimuraM. et al., 1991],
A study by Thiagalingam et al. investigated the incidence ofmutations for DPC4 in
18 colon carcinoma with 18q losses and identified one homozygous deletion, one
nonsense mutation and three somatic mutations [Thiagalingam S. and Lengauer C. et
al., 1996], The same tumours were further analyzed for JV-18/MADR and displayed
only two mutations [Riggins G.J. and Thiagalingam S. et al., 1996].
1.1.3.5. Loss of Function of the Gene Located on Chromosome 17p
p53 gene, located on chromosome 17p, was the first tumour suppressor gene to be
identified in colorectal cancers in 1979. Cytogenetic studies revealed that the short
arm of chromosome 17 is lost frequently (42-75%) in human colorectal carcinomas
[Cunningham J. and Lust J.A. et al., 1992; Lothe R.A. and Fossli T. et al., 1992;
Vogelstein B. and Fearon E.R. et al., 1988], However, multiple mutational analyses
for p53 revealed that the gene is inactivated in a higher proportion in late adenomas
[Ohue M. and Tomita N. et al., 1994] and only occasionally (about 6-12%) in early
benign adenomas [Shaw P. and Tardy S. et al., 1991; Vogelstein B. and Fearon E.R.
et al., 1988], These findings suggested that p53 inactivation occurs late in the
adenoma-carcinoma progression. Deletions of chromosome 17p were also found
frequently in other human common malignancies such as breast or non-small cell
lung cancer and oesophageal carcinomas [Hollstein M. and Sidransky D. et al.,
1991],
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Initially, p53 was considered a proto-oncogene due to its cooperation with Ha-ras
gene in transforming rat embryo fibroblasts into tumourigenic cells [Eliyahu D. and
Michalovitz D. et al., 1985]. Further studies crowned the p53 gene as the "the
guardian of the genome"[Lane D.P., 1992], p53 is now considered a tumour
suppressor gene due to its growth arrest and apoptotic functions. Wild-type p53
expression is triggered by stress signals (e.g. DNA damage, hypoxia, oncogenes etc.)
and produces either G1 arrest to permit the DNA repair machinery to repair the
damage, or apoptosis when the damage cannot be repaired. This process of
eliminating damaged cells is of great importance as such cells could give rise to
neoplastic events.
1.1.3.6. Other Genetic Factors Important in Colonic Tumourigenesis
Gene expression, gene amplification, changes in methylation and modifying loci are
factors that could also be important in colorectal carcinogenesis.
The expression of a high number of genes differs in cancer cells compared to normal
colon. It is not fully understood whether their modified pattern of expression plays a
role in tumour development or it is the effect of the malignant transformation in the
colon, but further research will probably answer some of these questions.
Mammalian DNA was discovered to be naturally methylated at 5-cytosine of 5'-CG-
3' dinucleotides. Despite many years of research in the field, the role of this DNA
methylation is still unclear. Changes in methylation of some genes such as
hypermethylation, hypomethylation or de novo methylation at previously
unmethylated CpG islands could be significant. Experiments on DNA methylation in
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cancer suggest that these changes could cause an increased oncogene expression, an
alteration in cell-cycle control or silencing of genes important in growth suppression
[Issa J.P., 2000]. Altered methylation is also an age-related process as recently
demonstrated from studies in ageing normal colonic mucosa [Issa J.P., 1999]. It is
believed that the age-related methylation precedes tumourigenesis in the colon. A
series of tumour suppressor genes such as pi6 or THBS1 are inactivated by
hypermethylation in sporadic colorectal cancers with microsatellite instability related
to hMLHl methylation [Herman J.G. and Merlo A. et al., 1995; Toyota M. and
Ahuja N. et al., 1999].
Epigenetic instability together with chromosomal instability and microsatellite
instability are now considered genetic factors required for the clonal evolution of
colorectal neoplasia.
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1.2. Histopathology of Colorectal Neoplasia
1.2.1. Histology ofNormal Colon
The normal colon has a smooth mucosa with crypts that measure approximately
0.5mm in length. The epithelial cells lining the crypt are mostly Goblet cells, with
big vacuoles in the cytoplasm, which contain mucin. Mucin secretion flows from the
crypt opening in the lumen and also covers the surface of the crypt. The cells facing
the colonic lumen are absorptive cells, which absorb water and electrolytes. A small
number of endocrine cells are found in the lower portion of the crypt towards
muscularis mucosae. Other types of cells found in the crypts are: Paneth cells,
enterochromaffin cells, M cells overlaying the lymphoid follicles and rarely T
lymphocytes (Figure 2A).
The intestinal epithelial cells are rapidly dividing, and cells are continuously
renewed. The process starts at the base of the crypt with cells dividing, migrating and
differentiating as they move towards the top and then dying by apoptosis or shedding
in the lumen. The cells located at the base of the crypt form the proliferative
compartment of the crypt. These cells are undifferentiated stem cells that give rise to
daughter cells that differentiate in all the abovementioned cells. This migration takes
3 to 8 days [Eastwood G.L., 1977].
The crypts are surrounded by sheets of myofibroblasts, which sustain their normal
morphology and cellular dynamics. Crypts are separated by lamina propria, which
consists of connective tissue containing fibroblasts, lymphocytes, macrophages and
capillaries.
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Figure 2A: Section ofnormal colonic
epithelium stainedwith
haematoxylin & eosin.
Figure 2B: Section ofcolonic adenoma
stainedwith haematoxylin
& eosin. Arrow indicates
a normal crypt surrounded
by adenomatous transformed
crypts




The other layers of the colonic wall consist of:
- submucosa with lymphatics, blood vessels, elastic tissue, nerves and
ganglions
muscularis propria with fibres of smooth muscles arranged longitudinally
and circularly and collagen fibres, all penetrated by nerves, arterial and
venous vessels




Adenomas represent benign glandular transformation of the normal colon
characterized by abnormal proliferation and incapacity to fully differentiate [Kaye
G.I. and Fenoglio C.M. et al., 1973]. Adenomas emerge from a single crypt and
grow by replacing the surrounding normal epithelium with neoplastic tissue. In
contrast to normal crypts, adenomas proliferate at their top and quite often apoptotic
cells are seen at their base. Adenomas are formed from partially differentiated Goblet
cells and absorptive cells, which are distributed erratically along the crypt (Figure
2B). Some of these cells maintain their propriety of producing mucus but some of
them become dystrophic. Multiple mitotic figures (including atypical ones) and
hypercromatic nuclei are distributed all over the entire epithelium of the crypt.
Histologically, adenomas could be classified as: tubular, accounting for 68% to 87%
in most of the studies, villous adenomas, tubulovillous adenomas, flat adenomas and
serrated adenomas.
Tubular adenomas maintain their original architecture but the normal epithelium is
replaced by dysplastic cells. Neoplastic tubular adenomas could be investigated using
an antibody to Ki-67 that will show abnormal apical proliferation. In contrast villous
adenomas contain long crypts with dysplastic epithelium extending to the colonic
lumen. Tubulovillous adenomas contain a mixture of villous and tubular structures.
Flat adenomas are an alternative of tubular adenomas but their thickness is not
exceeding too much the level of surrounding normal epithelium. They usually
display a high grade of dysplasia and cellular atypia [Riddell R.H., 1992].
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Serrated adenomas constitute less than 0.1% of colorectal adenomas. Histologic
examination discloses a pattern reminiscent of the glands in hyperplastic polyps.
However, the stratified cells lining the glands appear less mature than those found in
the hyperplastic polyps and they are dysplastic.




Colorectal carcinomas could arise from any type of the previously discussed
adenomas that show an increased grade of dysplasia, or in a colon suffering from
inflammatory bowel disease. The vast majority of colon cancers are
adenocarcinomas. They are moderately to well-differentiated tumours with high
mitotic figures and poorly differentiated cells (Figure 2C).
In a large number of cases, the superficial area of the tumour is histologically
identical with its deeper part. In some cases however, there is a histological
difference between these two parts (residual adenomatous mucosa may be present at
the edge of a malignancy, especially in small tumours). Some of the
adenocarcinomas are capable to secrete mucin and therefore are named mucinous
carcinomas.
Colon carcinomas invade the intestinal layers either expanding or infiltrating.
Usually expanding tumours are associated with an inflammatory response, which is
absent in infiltrating tumours.
Colonic carcinomas are formed from various cells: Goblet cells, Paneth cells,
endocrine cells, melanocytes, trofoblasts, and squamous cells. The proportion of cells
differs in different types of carcinoma.
Histologically colon carcinomas are classified as:
intra-mucosal carcinomas - when neoplastic cells invade lamina propria and
adjacent crypts through the membrane of the crypt. They could extend to the
whole mucosal layer but are limited to the muscularis mucosa. These tumours
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are considered invasive, but it is not well defined whether they can
metastasize or not.
invasive carcinoma - when the tumour invades the muscularis mucosa and
submucosa. The tumour cells spread into the local nodes and have access to
the blood vessels, fat, nerves and lymphatics in the submucosa. These
tumours often metastasize at distance from the primary location (liver, lungs,
bones), due to their access to blood vessels and lymphatics.
In 1932, Dukes proposed a simple method to grade rectal cancer based on invasion
into the bowel wall and the involvement of the lymph nodes [Dukes C.E., 1932]:
Stage A - lesions confined to the rectal wall (but not invading serosa)
Stage B - lesions spreading through the muscularis propria to the rectal serosa and
beyond, but not to the lymph nodes
Stage C - lesions that metastasize in the regional lymph nodes.
Subsequently, this system was extended to include the colon cancer. This staging
system was modified in 1954 when Astler and Coller [Astler V.B. and Coller F.A.,
1954] proposed two B and two C stages:
Stage B1 - extension into muscularis propria but the lymph nodes are not involved
(Figure 3B1)
Stage B2 - extension through entire wall with uninvolved lymph nodes (Figure 3B2)
Stage CI - extension through all layers of the wall and involving nodes (Figure 3C1)














Figure 3: Neoplastic progression from a small lesion confined to the mucosa to
invasive carcinoma.
3A - Carcinoma "in situ " restricted to the basement membrane ofthe colonic
crypts
3B - Extension into muscularispropria (3BI) or through the serosa (3B2) but the
lymph nodes are not involved
3C1- Invasion through the muscularispropria or serosa with limph
nodes metastasis
3C2 - Distant metastasis: liver, lungs and other sites
35
In 1954 Denoix et al. [Denoix P.F., 1954] suggested the TNM cancer classification,
which was further, adapted by Beahrs [Beahrs O.H., 1984], It is based on Dukes'
classification and also considers the number of invaded lymph nodes and the
presence or absence of distant metastases.
The Dukes classification was evaluated in 1994 by Deans et al. [Deans G.T. and
Heatley M. et al., 1994] and found to be "of greater prognostic value and more
reproducible". Both TNM and Dukes's classification are in use today and
recommended by different Cancer Authorities.
36
1.3. p53
1.3.1. The Gene for p53
The p53 gene is the most extensively studied tumour suppressor gene in recent years
[Thomas R. and Kaplan L. et al., 1983]. It was isolated in numerous mammalian
species: mouse [Oren M. and Levine A.J., 1983], rat [Coulier F. and Imbert J. et al.,
1985], frog [Soussi T. and Caron D.F. et al., 1987], monkey [Rigaudy P. and Eckhart
W., 1989] and human [Matlashewski G. and Lamb P. et al., 1984], Using cDNA
clone in the analysis of human-mouse hybrid cells, McBride et al. [McBride O.W.
and Merry D. et al., 1986] located the human p53 gene on chromosome 17p.
The initial research showed that p53 collaborates with Ha-ras oncogene to transform
embryo fibroblast and due to this association, it was postulated that p53 is a proto-
oncogene [Eliyahu D. and Michalovitz D. et al., 1985]. The p53 protein, probably a
mutant form, was found overexpressed in a wide variety of cancer cell-lines and in
proliferating untransformed cells. Usually p53 is not expressed or its levels are low
in normally growing cells.
Further studies revealed that p53 is activated following genotoxic stresses and its
activation has a protective role rather than an oncogenic one. p53 protects from
uncontrolled proliferation of damaged cells capable to trigger neoplastic
transformation, by inducing cell-cycle arrest and apoptosis in response to a wide
variety of cellular stresses [Gottlieb T.M. and Oren M., 1998],
Now, it is well accepted that the inactivation of the p53 gene is a crucial event in
carcinogenesis, p53 mutations being the most frequent genetic event in human cancer
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[Soussi T. and Dehouche K. et al., 2000], The loss of p53 function by deletion,
mutation or inhibition of its function through various mechanisms [Vogelstein B. and
Kinzler K.W., 1992] has been noticed in all types of cancer: colo-rectum, lung,
breast, bladder and hepatocellular carcinoma [Hollstein M. and Sidransky D. et al.,
1991],
Studies using knockout mice for p53 gene also confirmed the gene as an important
tumour suppressor:
mice with p53 mutations develop tumours early in life [Jacks T. and
Remington L. et al., 1994]
mice deficient for p53 display increased tumourigenesis in response to
radiation [Lee J.M. and Abrahamson J.L. et al., 1994] and chemical
carcinogens [Harvey M. and McArthur M.J. et al., 1993]
p53 deficient mice develop spontaneous tumours (sarcomas and lymphomas)
early in life [Purdie C.A. and Harrison D.J. et al., 1994] and die because of
these tumours when about 10 months old [Donehower L.A. and Harvey M. et
al., 1992],
Alterations in the tumour protein p53 occur not only as somatic mutations in human
cancers but also as germline mutations in some cancer-prone families. In reviewing
medical records and death certificates of 648 childhood rhabdomyosarcoma patients
in 1969, Li and Fraumeni identified 4 families in which sibs or cousins had a
childhood sarcoma [Li, F. P. and Fraumeni, J. F., 1969], The spectrum of cancers in
the syndrome was shown to include, in addition to breast cancer and soft tissue
sarcomas, brain tumours, osteosarcoma, leukaemia, and adrenocortical carcinoma. In
1997, Varley et al. [Varley J.M. and Evans D.G.R., 1997] stated that more than 50
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families had been identified with Li-Fraumeni syndrome caused by germline tumour
protein-53 mutations. More recently, in 2003, Varley stated that nearly 250
independent germline TP53 mutations had been reported [Varley J.M., 2003] and
that most were associated with Li-Fraumeni syndrome or Li-Fraumeni-like syndrome
and found that the most striking association between germline TP53 mutations and
cancer occurred in cases of childhood adrenocortical carcinoma (ADCC). ADCC was
identified as a component tumour of Li-Fraumeni syndrome from the earliest studies.
p53 has also been implicated in cellular differentiation, development, embryogenesis
and all these functions will be discussed in the next section.
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1.3.2. p53 Structure and Function
p53 is a 44kDa protein consisting of a N-terminal transactivation domain, a proline-
rich domain, a DNA binding domain, a tetramerization domain and a C-terminal
domain. MDM2, a regulatory gene for p53, binds to the N-terminal domain resulting
in inhibition of p53 transactivation and also in its degradation. Moreover, MDM2 is
stimulated by p53-dependent transactivation creating a regulatory feedback loop,
which controls the function of p53 under normal conditions. This interaction is
disrupted in cellular stresses when p53 activation occurs.
Several roles have been demonstrated for each of the p53 domains:
• The proline-rich domain plays a critical role in the transmission of anti¬
proliferative signals down-stream of the p53 protein and may link p53 to a
direct signal transduction pathway [Walker K.K. and Levine A.J., 1996],
Deletions or mutations within this domain affect both p53 proapototic activity
and its ability to transcriptionally activate target genes.
• The DNA binding domain is the host of the majority of the p53 mutations in
human tumours. This domain contains the sequence-specific DNA binding
activity of the p53 protein (residues 102-292), and their altered structure
results in loss of DNA binding and therefore transcriptional activity [Cho Y.
and Gorina S. et al., 1994].
• The C-terminal domain is able to bind single stranded DNA, can activate the
specific DNA binding domain and induce transcriptional transactivation of
p53 providing a signal for DNA damage [Selivanova G. and Iotsova V. et al.,
1997],
40
p53 is usually inactive in normal cells and its half life is very short, 10-20 minutes.
When the damage occurs, p53 is stabilised and activated and its function as tumour
suppressor is achieved by inducing growth arrest and apoptosis.
In addition to its tumour suppressor activity, p53 performs important functions in
normal tissues, being required for cell differentiation and apoptosis in embryogenesis
and adult life.
Several studies implicated the p53 protein in the differentiation of hematopoietic
cells [Shaulsky G. and Goldfmger N. et al., 1991] [Aloni-Grinstein R. and Schwartz
D. et al., 1995], epidermal epithelial cells [Spandau D.F., 1994], cells in the central
nervous system [Eizenberg O. and Faber-Elman A. et al., 1996] and different types
of cancer cells [Lutzker S.G. and Levine A.J., 1996] [Fagin J.A. and Tang S.H. et al.,
1996],
The involvement of p53 during embryogenesis was studied in mouse embryonic cells
[Mora P.T. and Chandrasekaran K. et al., 1980] and transgenic mice [Gottlieb E. and
Haffner R. et al., 1997], p53 is expressed in early stages of embryogenesis but not in
the late ones and this differential regulation could be associated with a possible role
for p53 in cellular proliferation and/or differentiation.
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1.3.3. DNA Damage Responses and p53 Activation
p53 is triggered in response to a variety of stress factors: bulky DNA lesions, DNA
strand breaks, nucleotide depletion, oncogene activation (c-Myc, E2F-1, ras),
hypoxia, hypoglycaemia, UV radiation, ionizing radiation, inappropriate proliferative
signals, viral infections [Giaccia A.J. and Kastan M.B., 1998] (Figure 4).
Activation of p53 in response to different stresses is modulated through different
mechanisms:
• alteration in the p53 protein half-life acquired by the interaction with MDM2;
when MDM2 is not linked with p53, the intracellular levels of p53 protein
increase, culminating in p53-dependent apoptosis and growth arrest. Some
studies have shown that DNA damage and oncogene activation of p53 are
coupled with reduced levels of MDM2-p53 complexes. Hypoxia also
increases the p53 protein levels trough hypoxia-inducible factor-la which is
able to bind and stabilize p53 [An W.G. and Kanekal M. et al., 1998],
• phosphorylation of p53 at key residues such as serine 15 or 37 induces
conformational changes of the protein that impairs the ability of MDM2 to
bind p53 [Shieh S.Y. and Ikeda M. et al., 1997], The direct contact of p53





















Figure 4: Activation ofp53 is triggered by many different stresses including
DNA-damaging and non-damaging agents. In response to thesefactors p53
regulates the expression ofdownstream genes (p21, BAX, bcl-2) and as a
consequence ofp53 activation, cells can undergo markedphenotypic
changes, rangingfrom increasedDNA repair to senescence, cell-cycle
arrest and apoptosis.
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• acetylation at the C-terminal domain activates the sequence-specific DNA-
binding activity of p53 which subsequently influences the p53 target genes. A
recent study showed that the DNA damage enhances p53 activity as a
transcription factor through carboxy-terminal acetylation of lysine 382,which,
in turn, is directed by amino-terminal phosphorylation [Sakaguchi K. and
Herrera J.E. et al., 1998].
• phosphorylation of the serine-392 residue in the human p53 protein (or
residue 389 in the murine sequence) also occurs in vivo in response to
ultraviolet radiation in cells containing the p53 protein. Phosphorylation at
this specific residue was not detected in response to y-radiation or the
treatment of cells with etoposide [Lu H. and Taya Y. et al., 1998],
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1.3.4. p53 Induced Apoptosis and Growth Arrest
In response to damage factors, p53 is activated and responds by inducing cell-cycle
arrest in G1 or G2, promotion of senescence and apoptosis. p53 activates the
transcription of responsive genes when bound to particular p53-binding sites.
A major unsolved challenge is what factors are involved in a cell's decision to
undergo cell-cycle arrest or apoptosis in response to p53 induction. Several factors
have been shown to be important in changing the balance between growth arrest and
apoptosis: cell type, the up-stream regulators of p53, the nature of damage and the
amount of the activated p53.
Normal diploid fibroblasts undertake G1 cell-cycle arrest in response to gamma
radiation induced DNA-damage [Di Leonardo A. and Linke S.P. et al., 1994], while
primary murine thymocytes undergo apoptosis following damage by ionizing
irradiation [Clarke A.R. and Purdie C.A. et al., 1993].
It seems that up-stream regulators of p53 are also implicated in mediating the p53
activity and different signals may predispose different cells to enter cell-cycle arrest
or apoptosis. Ionizing radiation induction of p53 activation is ATM dependent.
Irradiated ATM-deficient thymocytes are defective in p53-dependent growth arrest
but they still have the capacity to undergo p53-dependent apoptosis [Barlow C. and
Brown K.D. et al., 1997], suggesting that ATM could be a factor that modulates
cells' decision to undertake apoptosis or growth arrest. Overexpression of the viral
oncogene E21 in mouse thymocytes leads to p53-dependent apoptosis and not p53-
dependent growth arrest which is normally noticed following irradiation induced
damage [Lowe S.W. and Schmitt E.M. et al., 1993].
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1.3.4.1. p53 Target Genes Involved in Cell-cycle Arrest Responses
p53 has been shown to be necessary for G1 and G2 growth arrest. The G1 cell cycle
arrest is mostly mediated by p21, a cyclin-dependent kinase inhibitor. p21 protein
subsequently binds to and inhibits cyclin-dependent kinase activity, therefore
blocking cell cycle progression [El Deiry W.S. and Tokino T. et al., 1993]. Other
mechanisms are also implicated in G1 cell cycle arrest, as p21 knockout cells are
only partially defective in irradiation induced G1 arrest [Brugarolas J. and
Chandrasekaran C. et al., 1995].
p53 is involved in G2 arrest following UV damage or injury caused by alkylating
agents. This role has been suggested by the fact that GADD45 [Zhan Q. and
Antinore M.J. et al., 1999] and p21 [Bunz F. and Dutriaux A. et al., 1998], both p53
target genes, can induce G2 arrest. Following disruption of either p53 or p21, gamma
irradiated cells progressed into mitosis only because of a failure of cytokinesis.
1.3.4.2. p53 Target Genes Implicated in Apoptosis
To determine the mechanism by which p53 induces apoptosis, Polyak et al. [Polyak
K. and Xia Y. et al., 1997] examined in detail 7,202 transcripts induced by p53
expression before the onset of apoptosis. Only 14 transcripts were found markedly
increased in p53-expressing cells compared with controls. These genes were named
p53-induced genes (PIGs).
Several target genes of p53 take part in apoptotic responses following damage: bax,
Fas/APOl, KILLER/DR5 in a caspase dependent manner.
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The first p53 target gene involved in apoptosis was bax. p53 induces bax expression
but bax is neither required nor sufficient in p53-dependent apoptosis. Bax knockout
thymocytes are still capable to undergo apoptosis after gamma irradiation but p53
null thymocytes are severely affected [Knudson C.M. and Tung K.S. et al., 1995].
Fas/APOl is not required for p53-dependent apoptosis following damage, but it has
been shown to delete peripheral T lymphocytes, mediating cytotoxic T-cell apoptosis
[NagataS., 1997],
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1.3.5. p53 in Colorectal Cancer
In 1988, Monpezat el al. reported loss of p53 allele on chromosome 17 in polypoid
colorectal carcinoma [Monpezat J.P. and Delattre O. et al., 1988].
One year later, Baker et al. [Baker S.J. and Fearon E.R. et al., 1989] concluded that
p53 mutations are involved in colorectal cancer probably by inactivation of the
tumour suppressor function of the wild type (wt) p53. Loss of 17p allele and
mutations of the p53 gene are common events in human malignancy. Interestingly,
when carcinoma and adenoma areas of the same tumour were genetically screened,
mutations and loss of allele were detected in the carcinoma but not in the adenoma,
suggesting that the two events were linked together and probably occur at the
adenoma to carcinoma progression stage [Baker S.J. and Markowitz S. et al., 1990],
Overexpression of p53 by immunohistochemistry using antibodies specific for p53
was demonstrated in 50% of the colorectal cancers examined [Rodrigues N.R. and
Rowan A. et al., 1990], Benign adenomas were all negative for p53 overexpression.
This observation was also indicative of an implication of p53 in late stages of colon
carcinogenesis as previously mentioned.
In 1992, Vogelstein and Kinzler [Vogelstein B. and Kinzler K.W., 1992]
summarized five mechanisms for p53 inactivation and their occurrence in different
types of cancer. p53 is capable of activating the expression of adjacent genes that
inhibit growth and/or invasion. Deletion of one or both p53 alleles reduces the
expression of the protein, decreasing the expression of the growth inhibitory genes.
This mechanism is found in occasional tumours of several types. Nonsense or splice
site mutations that result in truncation of the protein do not allow oligomerization,
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thus resulting in a reduction of p53. This type of mutations are common in lung,
oesophagus, and other cancers. A third mechanism, which is seen in colon, brain,
lung, breast, skin and bladder cancer involves missense mutations. Their effect is a
mutant p53 protein defective in binding DNA in a sequence specific manner and
transcriptional activation of downstream target genes. The fourth mechanism by
which p53 is involved in carcinogenesis is commonly encountered in cervical
cancers, where the expression of the E6 gene of human papilloma-virus results in the
functional inactivation of p53 through binding and degradation. The fifth mechanism
implicates disruption and alterations ofMDM2. MDM2 gene is amplified in the vast
majority of human sarcomas [Oliner J.D. and Kinzler K.W. et al., 1992] and the
consequent overexpression of MDM2 may interfere with p53 activity. p53 is
phosphorylated at serine 15 (MDM2 binding area) in response to DNA damage and
this event reduces the interaction of p53 with its negative regulator MDM2 [Shieh
S.Y. and Ikeda M. et al., 1997].
Other studies focused on identifying p53 mutations in colorectal cell-lines
[Rodrigues N.R. and Rowan A. et al., 1990]. Mutations in the p53 gene were
detected in all cell lines examined (although not all were immunopositive for the p53
protein), therefore suggesting that not all mutations could be detected using
immunohistochemical tests.
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1.4. New Members of the p53 Family Genes
For a long time p53 was believed to be the only member of its family. Recently, two
new members of the p53 family were discovered: p73 [Kaghad M. and Bonnet H. et
al., 1997] in 1997 and p63, one year later [Yang A. and Kaghad M. et al., 1998],
They are structurally related proteins and although share similar functions such as
transcriptional activation, cell-cycle arrest and apoptosis, each of them seem to also
play different roles in normal development.
An important subject in oncology research was to investigate whether the new
members of the p53 family genes have a tumour suppressor role. Following their
discovery, it was believed that they would be involved in tumour suppression,
exactly like p53. But, in contrast to p53, which is mutated or deleted in
approximately 50% of human cancers, it was found that p73 and p63 were not
inactivated in a large number of cancers. Subsequent studies revealed that both p73
and p63 were actually more involved in neurogenesis, natural immunity and
homeostatic control [Yang A. and Kaghad M. et al., 2002] than in tumour
suppression.
However, there is a great structural homology between the three proteins, particularly
in the N-terminal transactivation domain, DNA binding domain and the
oligomerization domain [Chen X., 1999] (Figure 5). p73 and p63 are even capable to
activate some of the p53 target genes, like p21, MDM2, GADD45 [Lee C.W. and La
Thangue N.B., 1999], Moreover, when activated, they are also capable of inducing
apoptosis, in the same way as p53 [Jost C.A. and Marin M.C. et al., 1997], [Yang A.
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Figure 5: Homology among the p53 family ofproteins: p53, p63a andp73a and the
percentage ofp53-similar residuesfound in p73 andp63. The AN isoforms
ofboth p63 andp73 lack the transactivation domain.
Abbreviations: TAD - transactivation domain
DNA-BD — DNA binding domain
OD - oligomerization domain




1.4.1.1. Gene and Protein Structure
p73 protein shares significant homology with p53 in the major functional domains:
transactivation domain (30% identical with p53), DNA binding domain (60%
identical with p53) and C-terminal oligomerization domain [Marin M.C. and Kaelin
W.G., Jr., 2000]. The transactivation domain of p73 interacts with p300 and MDM2
in the same manner as p53. In particular, each of the p53 amino acids implicated in
direct sequence-specific DNA binding is preserved in the p73 protein.
The overall genomic organization of the p73 is similar to that of p53, the only
difference being the larger size ofp73, which contains 14 exons compared with only
11 exons in p53 [Marin M.C. and Kaelin W.G., Jr., 2000]. The p53 gene encodes
only one transcript that yields one protein which is transcriptionally active. In
contrast, p73 produces multiple mRNA transcripts by alternative splicing. p73
generates two proteins expressed under the control of two independent promoters:
the transcriptionally active (TA) p73 generated by the proximal promoter and the N-
terminally truncated (AN) p73 which is generated by the second promoter located in
intron 3 and lacks the transactivation domain [Benard J. and Douc-Rasy S. et al.,
2003] (Figure 6). These proteins have opposite activities. The TAp73 isoforms act as
transcription factors and induce cell-cycle arrest and apoptosis, whereas the AN
forms are incapable of inducing gene expression directly and do not trigger cell-cycle
arrest and apoptosis. Moreover, the N-terminally truncated forms exhibit dominant-





















Figure 6: Gene organization ofthep53 andp73. Exons are shown as numbers in the
boxes and introns as connectors between the exons. p73 generates at least 6
splice variants in contrast top53 which has only two. p73 C-terminal
isoforms are generated by alternative splicing ofexons 10 to 14. p73
N-terminal isoforms are transcribedfrom an alternativepromoter identified
here as 3'. Apartfrom this one, recently otherN-terminal splice variants
have been identified: p73A2 andp73A2/3 that lack either exon 2 or both exon
2 and 3 [Stiewe T. andPutzer B.M., 2002] andp73A3 that lacks exon 3
[Melino G. and DeLaurenzi V. et al„ 2002].
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transactivation activity and therefore limiting their apoptotic function. Furthermore,
the oncogenic variant ANp73 is induced by TAp73 and p53, creating a negative
feedback loop that regulates the functions of p53 and p73 [Benard J. and Douc-Rasy
S. et al., 2003]. Knock out mice for p73 lack both the apoptotic and the oncogenic
form and this may be the reason why they do not develop spontaneous tumours
[Yang A. and Sharpe A. et al., 2000].
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1.4.1.2. Regulation of p73 Activity
Activation of p53 is usually a result of post-translational modifications such as
phosphorylation or acetylation, which are responsible for its stability and activities:
cell cycle arrest and apoptosis. p73 activation occurs through similar mechanisms as
p53 but novel pathways have also been described.
p73 regulation occurs as a result of interaction with DNA damaging agents, tumour
suppressor genes, oncogenes and differentiation signals. Interestingly, even p53 is
an upstream regulator for p73, in the same way as p73 is required by p53 to exert its
apoptotic functions.
Some DNA damaging agents, such as ionizing radiation and cisplatin, but not UV
radiation or actinomycin [Kaghad M. and Bonnet H. et al., 1997], are capable of
activating and induce p73. The activation of p73 in response to DNA damage
involves post-translational modification rather than transcription. The amount of p73
protein increased in cisplatin treated cells [Gong J.G. and Costanzo A. et al., 1999]
and was diminished in cells defective in mismatch repair gene MLH1 or the nuclear
enzyme c-Abl tyrosine kinase, suggesting that the molecular mechanism implicated
in cisplatin p73 activation involves the MLHl-c-Abl-p73 pathway. c-Abl is also
required for p73 phosphorylation in response to ionizing radiation in vivo and in
vitro, as demonstrated by a failure of ionizing radiation to induce apoptosis after
disruption of c-Abl-p73 interaction [Yuan Z.M. and Shioya H. et al., 1999]. Another
mechanism of p73 activation is the acetylation by acetyltransferase p300 on C-
terminal lysine residues [Costanzo A. and Merlo P. et al., 2002], A non-acetylatable
p73 is defective in activating transcription of the p53 gene, but retains the ability to
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regulate p21. p300-mediated acetylation of p73 is also proto-oncogene Abl
dependent . Therefore, DNA damage-induced acetylation potentiates the apoptotic
function of p73 by enhancing the capacity of p73 to selectively activate the
transcription of pro-apoptotic target genes.
p73 is also regulated by oncoproteins like E2F1, c-Myc and MDM2. The E2F1
transcription factor, which is deregulated in many human tumours, has the ability to
activate p73 by binding to E2F-binding sites (at least 3) in the TAp73 promoter and
directly activating p73a and p73p transcription [Irwin M. and Marin M.C. et al.,
2000]. The expression of E2F1 causes accumulation of p73 mRNA, therefore
increasing the levels of p73 protein. Moreover, disruption of p73 function inhibited
E2F-l-induced apoptosis in p53-deficient tumour cells and in p53-/- mouse embryo
fibroblasts.
c-Myc can physically interact with and bind p73, but its protein partner MM1 has the
ability to remove this interaction, therefore mediating the activation of p73
[Watanabe K. and Ozaki T. et al., 2002],
The MDM2 binding site in p53 is well conserved in the structure of p73. MDM2
binds to p73 resulting in inhibition of p73 binding to transcriptional co-activators
p300 and CREB-binding protein [Zeng X. and Li X. et al., ]. This binding leads to
impaired p73-transriptional activation and defective apoptosis. After binding to p73,
MDM2 does not contribute to its ubiquitylation and degradation [Ongkeko W.M. and
Wang X.Q. et al., 1999], as it does when it binds p53, highlighting another difference
between p53 and p73. This interaction between p73 and MDM2 also affects the sub¬
cellular localization of p73 and it seems to contribute to its stability [Wang X. and
Arooz T. et al., 2001],
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Recent studies revealed that hematopoietic and neuronal differentiation influences
the expression of p73. mRNA p73 levels were shown to increase in normal and
cultured peripheral blood lymphocytes following stimulation with
phytohemagglutinin [De Laurenzi V.D. and Catani M.V. et al., 1999], This
stimulation also produced increased p73-dependent apoptosis. Moreover, stimulation
of the T-cell receptor with anti-CD3 also leads to increased levels of the p73 protein
and apoptosis [Lissy N.A. and Davis P.K. et al., 2000], Increased levels of the p73
protein and neuronal differentiation specific cell markers were detected in
neuroblastoma cells treated with retinoic acid [De L., V and Raschella G. et al.,
2000],
Viral oncoproteins have the ability to interact with members of the p53 family,
especially p53 and p73. They also have the ability to discriminate between them. If
the adenovirus E1B55 , human papilloma virus E6 protein, and simian virus (SV40)
T antigen bind to and have the ability to inactivate p53, they do not interact with p73
[Marin M.C. and Jost C.A. et al., 1998]. However, there are viral proteins like the
adenovirus ElA protein [Steegenga W.T. and Shvarts A. et al., 1999] and the human
T-cell leukaemia virus type 1 Tax protein [Kaida A. and Ariumi Y. et al., 2000]
which bind and inactivate both p53 and p73, without any discrimination.
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1.4.1.3. Downstream Targets of p73
p73 has been shown to regulate the expression of several genes, some of which are
also p53 responsive genes. The regulation of similar p53-responsive promoters
causes effects common to those following the activation of p53. For example, p21,
GADD45, cyclin G, IGFBP3, Bax, p53-inducible ribonucleotide reductase 2 genes
are involved in cell-cycle control, DNA repair and apoptosis [Nakano K. and Balint
E. et al., 2000; Yu J. and Zhang L. et al., 1999; Zhu J. and Jiang J. et al., 1998],
Apart from activating some of these genes, p73 seems to contribute to the apoptotic
function of p53, by binding to MDM2 and leading to increased levels of stabilised
p53 and consequently apoptosis. In contrast, the truncated forms of p73 have an anti-
apoptotic function acquired by inhibition ofTAp73 and p53.
Secondly, p73 gene is capable of activating genes that are only weakly induced by
p53, like aquaporin 3 (AQP3) [Zheng X. and Chen X., 2001], a gene important in
maintaining cerebral spinal fluid homeostasis. The same authors assumed that the
lack of regulation of the above gene could be the reason why p73 knockout mice
develop hydrocephalus.
Apart from activating similar p53-responsive genes, p73 has functions that are not
shared by p53 such as down-regulation of the expression of vascular endothelial
growth factor gene (VEGF) [Salimath B. and Marme D. et al., 2000], In addition, it
has a possible role in the control of angiogenesis and possibly in tumour
angiogenesis, as the VEGF production is increased following p73 overexpression
[Vikhanskaya F. and Bani M.R. et al., 2001]. Another example would be the
involvement of p73 in the WNT/p-catenin signalling pathway [Ueda Y. and Hijikata
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M. et al., 2001]. p73 activates this pathway but, unlike p53, not through
accumulation of (3-catenin. The p73 contribution to normal development is made
through the ability of p73(3 to activate the expression of the cyclin-dependent kinase
inhibitor p57(KIP) and KvLQTl genes through mechanisms that again, are not
shared by p53 [Blint E. and Phillips A.C. et al., 2002],
1.4.1.4. Role of p73 in Malignancy
p73 maps to the minimal region of lp36 which is frequently deleted in primary
neuroblastomas [Ichimiya S. and Nimura Y. et al., 2001]. Further studies focused on
demonstrating that p73 is a tumour suppressor in a classic Knudson's manner.
Extensive studies revealed only rare p73 mutations in both cell-lines and primary
tumours, including neuroblastomas with lp36 deletions [Irwin M.S. and Kaelin
W.G., Jr., 2001]. There was, though, a significant incidence of loss of heterozygosity
in neuroblastoma, lung cancer, gastric cancer, esophageal cancer, ovarian cancer and
breast cancer, without a clear confirmation that the remaining allele was silent.
Trying to understand its role in tumourigenesis, researchers were confused about the
fact that p73 encodes two forms with opposite functions: TAp73 tumour suppressor
and ANp73 oncogene. Additionally, as the same exons of the p73 gene contain the
DNA-binding domains of both isoforms, mutations in this region would inactivate
both the tumour suppressor and the putative oncogene, and could explain the lack of
p73 mutations in cancer [Melino G. and De L., V et al., 2002],
Overexpression of p73 was described in few cancer cell-lines (ovarian, breast ,
neuroblastoma), in colon cancer [Sun X.F., 2002] and hepatocellular carcinoma
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[Tannapfel A. and Wasner M. et al., 1999]. p73 overexpression, without
discriminating between its isoforms, was so far associated with poor prognostic
factors. Only one study revealed that poor survival rate was associated with
overexpression of ANp73 in neuroblastoma [Casciano I. and Mazzocco K. et al.,
2002], suggesting that the loss of balance between the TA and AN forms is
important.
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1.5. Sonic Hedgehog Signalling Pathway
It has been long known that Hedgehog (Hh) signalling pathway is crucial for normal
development, but in the past few years there has been an increase in the
understanding of how developmental genes and Hh in particular, could be involved
in tumourigenesis. Recently, it has been hypothesized that tumour suppressor genes
deletions or mutations are late events in carcinogenesis and maybe defects or
mechanisms that trigger cancer in adult life appear and develop early in embryonic
stages. In the past ten years, signalling pathways essential for embryonic
development have been found to be abnormally regulated in cancer [Taipale J. and
Beachy P.A., 2001],
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1.5.1. Sonic Hedgehog in Development and Disease
Few signalling cascades are essential in embryogenesis and one such pathway, Sonic
Hedgehog (Shh), is involved in morphogenesis and patterning of many organs. The
hedgehog gene was first described in the fruit fly Drosophila melanogaster. Unlike
drosophila, which has only one hh gene, mammals have three genes, Sonic hedgehog
(Shh) [Fang L. and Lee S.W. et al., 1999], Indian hedgehog (Ihh) [Yokomizo A. and
Mai M. et al., 1999] and Desert hedgehog (Dhh) [Fang L. and Lee S.W. et al., 1999]
that are homologous to the hh gene. Of the three genes, Shh is the most widely
expressed. The Hh signalling pathway involves other several genes including
patched, dispatched, smoothened, fused, cubitus interruptus, most of which are
highly conserved between insects and vertebrates. In the mammals, there are two
patched (Ptchl and Pthc2) [Hahn H. and Wicking C. et al., 1996; Johnson R.L. and
Rothman A.L. et al., 1996] and one Smoothened gene (Smoh) [Stone D.M. and
Hynes M. et al., 1996], The human equivalent of cubitus interruptus is GLI, which
has three variants, GLI1, GLI2 and GLI3 [Altaba A., 1999]. Moreover, the functional
properties of these genes appear to be highly conserved between species.
The Hh pathway is expressed in the Hensen node, the floorplate of the neural tube,
the early gut endoderm, the posterior of the limb buds and throughout the notochord
[McMahon A.P. and Ingham P.W. et al., 2003]. It has also been implicated as an
important signal in the patterning of the ventral neural tube [Echelard Y. and Epstein
D.J. et al., 1993], the anterior-posterior limb axis [Riddle R.D. and Johnson R.L. et
al., 1993] and the ventral somites [Johnson R.L. and Laufer E. et al., 1994].
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Malformations of several organs have been described in the Shh knockout mice.
Morphologic studies in mice homozygous for a disrupted Shh gene [Chiang C. and
Litingtung Y. et al., 1996] revealed defects in the maintenance ofmid-line structures
such as the notochord and floorplate as well as absence of distal limb structures,
cyclopia, absence of ventral cell types within the neural tube and absence of the
spinal column and most of the ribs. The defects in all tissues extended beyond the
normal sites of Shh transcription, confirming that Shh protein acts as an extracellular
signal that is required for the normal patterning of several systems. Homozygous
Shh null mutant mice were also shown to have foregut defects: oesophageal
atresia/stenosis, tracheo-oesophageal fistula and hypoplastic lungs with a single lobe
[Litingtung Y. and Lei L. et al., 1998]. The same study showed that the lung
mesenchyma displayed increased cell death and decreased cell proliferation,
reiterating that the pathway is indeed essential for normal growth and differentiation
of oesophagus, trachea, and lungs. Mutations in Shh and its signalling components
may be involved in foregut defects in humans. Gastrointestinal defects including gut
malrotation, reduced smooth muscle, intestinal transformation of the stomach,
duodenal stenosis with overgrowth villi, annular pancreas and imperforated anus
were also described in homozygous mice for Shh [Ramalho-Santos M. and Melton
D.A. et al., 2000].
Sporadic and inherited mutations of the human Shh causes holoprosencephaly (HPE)
(OMIM 142945) [Belloni E. and Muenke M. et al., 1996], an autosomal dominant
condition with features like premaxillary aplasia with midline cleft lip and palate,
hypotelorism, sensorineural hearing loss, lack of tooth eruption, single cyclopic eye
and cervical cord compression due to stenosis. Holoprosencephaly is also a cause of
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prenatal death detected in 1 in 250 abortions [Cohen M.M., Jr., 1989]. Loss of one
Shh allele is sufficient to cause HPE in humans, whereas both Shh alleles need to be
lost to produce a similar phenotype in mice [Roessler E. and Belloni E. et al., 1996]
[Chiang C. and Litingtung Y. et al., 1996].
Ptch and Smoh genes are also clinically important. Genetic mutations generating a
truncated or unstable Ptch protein [Stone D.M. and Hynes M. et al., 1996], or
activating mutations of Smoh [Xie J. and Murone M. et al., 1998] are associated with
basal cell carcinoma and medulloblastoma. Ptch functions as a tumour suppressor
and mutant Smoh as an oncogene. Inactivating mutations of Ptch cause the nevoid
basal cell carcinoma syndrome or "Gorlin syndrome", characterized by basal cell
nevi with a high potential of malignant transformation, increased risk of
medulloblastomas and rhabdomyosarcomas, short metacarpals, dental abnormalities
and rib defects.
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1.5.2. Hedeehoe Sienalline Pathway
All hedgehog genes encode molecules that are engaged in short and long range
patterning processes during embryogenesis.
To exert its function, Shh undergoes molecular processing in the endoplasmic
reticulum, which involves autocatalytic cleavage of the precursor hedgehog protein
into two domains: a 19 kDa N-terminal domain (Shh-N) and a 25 kDa C-terminal
domain [Marti E. and Bumcrot D.A. et al., 1995]. The N-terminal domain is
responsible for the protein signalling activity, whilst the C-terminal domain is
required for covalently binding a cholesterol molecule to the N-terminal domain.
This anchors the N-terminal domain to the cell membrane, limiting the Shh diffusion
from the site of secretion [Porter J.A. and Young K.E. et al., 1996].
Shh-N binds to a 12-transmembrane receptor Patched (Ptch), which normally inhibits
the downstream signalling through its binding to a 7-transmembrane receptor,
Smoothened (Smoh). When the pathway is activated, Shh-N binds to Ptch, Smoh
repression is released and the signalling continues via Gli genes (Figure 7). Ptch
further limits the range of Hh action. High levels of Ptch induced by Hh serve to
sequester free Hh, therefore creating a barrier to its further movement [Chen Y. and
Struhl G., 1996], The function of Ptch and other inhibitors is to silence the pathway
in situations when the active Hh ligand is absent. Therefore, the pathway must be
switched off most of the time and active only in situations when its function is
required. It is yet unknown whether the Gli proteins are the only mediators of the Hh
signalling, but they play a central role in mediating the Hh signals.
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1.5.2.1. Targets and mediators of the Gli genes
The Gli family of zinc-finger transcription factors act as important intracellular
mediators of Shh signals. In mammals, there are three Gli factors, Glil, Gli2, Gli3
with Glil and Gli 2 acting as activators ofmany Shh-responsive genes, in contrast to
Gli3 which act as negative regulators and suppress the Shh-target genes ([Kato M.
and Seki N. et al., 2001]).
As Shh has such a wide range of activities, it was of interest to identify some of the
downstream target genes in the pathway. Despite the well-established functions of
the Shh signalling in development and disease, only a few regulatory genes have
been identified as direct targets ofGli regulation.
One of theses targets, HNF3-beta is an early developmental regulator ofnotochord
and floor plate formation and its expression is controlled by Gli2, through a floor-
plate enhancer which has a Gli-binding site [Dufort D. and Schwartz L. et al., 1998]
[Sasaki H. and Hui C. et al., 1997].
Gli proteins can also regulate the expression of differentWnt genes, as it has been
recently demonstrated [Mullor J.L. and Dahmane N. et al., 2001], During ventro-
posterior morphogenesis in frog Gli2 and Gli3 directly activates Wnt 8 and possibly
9+
Wntl 1, which in turn will stimulate the /3-catenin and the Ca /CamKII pathways.
Additional targets of the Shh-Ptch signalling pathway with a particular function in
tumorigenesis include Cyclin D and E, FOXM1 and Igf2 [Altaba A. and Stecca B. et
al., 2004],
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Figure 7: On Shh binding to Ptch, the inhibition Smoh by Ptch is release. Smoh acts
on a complex ofcytoplasmicfactors that includes SFu (Suppressor of
fused), Fu (Fused), PKA (protein kinase A), the Gliproteins and other
possible components notyet identified. The pathway culminates in the
activation ofGli transcription factors and transactivation oftarget genes.
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1.5.3. Sonic Hedseho2 Pathway Genes in Tumourieenesis
With the involvement of the Shh receptor Ptch as a tumour suppressor gene
responsible for the human nevoid basal cell carcinoma syndrome, the Hedgehog
signalling pathway was connected to cancer. It now emerges that constitutive
activation of Hedgehog signalling by inactivating mutations in Ptch or activating
mutations in Smoh, is required and perhaps sufficient for basal cell carcinoma
development.
Indeed, inactivation of Ptch is a major factor in basal cell carcinoma growth with
mutation identified in 12 to 40% of sporadic BCCs [Unden A.B. and Zaphiropoulos
P.G. et al., 1997] [Wolter M. and Reifenberger J. et al., 1997] [Aszterbaum M. and
Rothman A. et al., 1998],
Furthermore, Shh was sufficient to induce BCCs in transgenic mice overexpressing
Shh in the skin [Oro A.E. and Higgins K.M. et al., 1997]. These mice developed
multiple features of the basal cell nevus syndrome. The mouse BCCs appeared
within the first 4 days of skin development, unlike mouse squamous neoplasia where
tumours arise 1 to 12 months after oncogene expression. The rapid and frequent
appearance of Shh-induced tumours in the mice suggested that disruption of the Shh-
Ptch pathway is sufficient to create BCCs. The kinetics of the tumours in these mice
were consistent with previous clinical and epidemiologic data, which suggested that
BCCs, in contrast to melanomas and squamous carcinomas, lack precursor or
intermediate cellular phenotypes.
In addition to its association to BCCs, it seems that the Hh pathway contributes to the
formation of a variety of other tumour types including medulloblastoma [Pietsch T.
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and Waha A. et al., 1997], squamous cell carcinoma of the oesophagus [Maesawa C.
and Tamura G. et al., 1998], transitional cell carcinoma of the bladder [McGarvey
T.W. and Maruta Y. et al., 1998] and benign trichoepitheliomas [Vorechovsky I. and
Unden A.B. et al., 1997], Mice heterozygous for Ptch develop smooth muscle
tumours [Hahn H. and Wojnowski L. et al., 1998], indicating that the pathway may
take part in the pathogenesis of the human rhabdomyosarcoma.
Activating mutations of Smoh have been detected in up to 20% of BCCs [Lam C.W.
and Xie J. et al., 1999] as well as in primitive neuroectodermal tumours
[Reifenberger J. and Wolter M. et al., 1998].
Very recent work implicates sonic hedgehog in the genesis of pancreatic cancer
[Thayer S.P. and Di Magliano M.P. et al., 2003], The same study showed that Shh is
strongly expressed in pancreatic precursor and invasive lesions but is undetectable in
human normal ductal epithelium. Additionally, a wide range of digestive tract
tumours originating in the oesophagus, stomach, biliary tract and pancreas, but not in
the colon, displayed increased hedgehog pathway activity, which was suppressible




In the last two decades there have been constant developments in the understanding
of the genetics of the colorectal cancer. New genes and mechanisms have been
discovered, which have brought us closer to unravelling the complex process of
oncogenesis. And yet, there is no complete understating of the function of the newly
discovered genes and until human based research can be safely undertaken, murine
experimental models will help widening our knowledge.
Consequently, the aims of this thesis are to:
1. Better understand the importance of p53 and related proteins in the regulation
of growth and response to DNA damage following cisplatin injury in primary
murine colonocyte culture.
2. Investigate p53-dependent and independent death pathways in response to
cisplatin DNA damage in primary murine colonocytes.
3. Look at the expression of the Hh signalling pathway at protein and mRNA
levels in normal human colon by immunohistochemistry and RT-PCR from
laser capture microdissected crypts.
4. Examine the distribution patterns of Shh, Ptch and Smoh proteins in colonic
tumourigenesis (hyperplastic polyps, adenomas and colonic
adenocarcinomas).







Wild-type and p53-/- mice [Purdie C.A. and Harrison D.J. et al., 1994] were bred,
genotyped and humanely killed between 50 and 75 days of age, before developing
spontaneous tumours. The colony was maintained in the Medical Faculty Animal
Unit.
BDF-1 mice [Booth C. and Patel S. et al., 1995] were purchased (Charles River-
company) and maintained in the Medical Faculty Animal Unit at The University of
Edinburgh. All the experiments involving animal tissue were performed in
accordance with the animal ethics regulation of the Home Office in the United
Kingdom.
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2.2. Isolation of Colonic Crypts and Culture of Primary Colonocytes from Adult
Wild-Type and p53-/- Mice
The crypt isolation method was successfully adapted from Booth et al. (1995). After
dissection, colons from 3 mice were removed and placed in HBSS (Invitrogen)
supplemented with antibiotics and fungicide to minimise the risk of yeast infections.
(Amphotericin, Sigma). Their contents were flushed with HBSS solution using a
syringe with a pipette tip. They were then placed in a Petri dish and any
mesenchymal tissue was removed using a scalpel. Colons were cut into small pieces
and washed vigorously several times in 50ml of HBSS until free from faecal
material. After all the excess HBSS was removed the tissue was finely minced to a
pulp on a sterile glass dish using two scalpels. The colonic material was then
transferred into 30ml of digestion medium. The enzymatic digestion was carried out
in a water bath at 37°C with occasional shaking every 20 minutes until the single
crypts visible under the microscope were released into the medium. Undigested
material was removed by sieving using sterile meshes size 6. The filtrate was
transferred to universals and topped up with 2% D-sorbitol medium pre-warmed at
37°C. The tubes were centrifuged at 400rpm to remove contaminants and enzymes
and the pellets were washed repeatedly with 2% D-sorbitol medium 4 or 5 times until
the supernatant appeared clear. The crypts were then suspended in culture medium
and plated onto collagen IV (Sigma) coated sonic-seal slides (Invitrogen) at a density
of 800-1000 crypts per ml. The crypts were allowed to settle and attach for 48 hours
and subsequently the medium was changed daily with fresh culture medium. The
crypts were incubated at 37°C in an atmosphere of 5% CO2 in air. Experiments were
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performed between 3 and 5 days of culture when proliferation and viability was
maximal.
2.2.1. Digestion Medium
-DMEM high glucose (4.5g/l) (Invitrogen)
-20/xg/ml dispase type II (Calbiochem)
-75U/ml colagenase type IX (Sigma)
-Antibiotics: lOOU/ml penicillin (Invitrogen); 30/xg/ml streptomycin (Invitrogen) and
25/rg/ml gentamicin (Sigma) and 2.5/ig/ml amphotericin.
-2.5% Serum (14 Foetal Calf Serum & 14 Foetal Bovine Serum) (both purchased from
Invitrogen)
2.2.2. 2% D-sorbitol Medium
- 2mg D-sorbitol powder (Sigma) per 100ml DMEM, sterile filtered
- 2.5% serum (!4 Foetal Calf serum & !4 Foetal Bovine serum)
- Antibiotics: lOOU/ml penicillin (Invitrogen); 30/ig/ml streptomycin (Invitrogen)
and 25/xg/ml gentamycin (Sigma)
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2.2.3. Culture Medium
Medium composition is important for both cell survival and maintenance of murine
colonocytes in-vitro. The present recipe is adapted from Booth et al. (1995). We used
low serum content medium to inhibit the growth of fibroblast in culture, therefore
minimising the fibroblast contamination. The medium was supplemented with
glutamine, insulin/transferrin/selenium, epidermal growth factor important for
epithelial cell survival and antibiotics to reduce the possibility of microbial
contamination especially important in colonic preparation.
Culture Medium Content:
- DMEM supplemented with Glutamax (L-Glutamine) (Invitrogen)
- 2.5% serum ('A Foetal Calf serum & 14 Foetal Bovine serum)
- Antiobiotics: lOOU/ml penicillin (Invitrogen); 30/xg/ml streptomycin (Invitrogen)
and 25/xg/ml gentamycin (Sigma)
- 5ng/ml Epidermal Growth Factor
- Insulin
2.2.4 Collagen Matrix
Primary murine colonocytes were cultured on sonic seal slides (Invitrogen). Cells do
not attach normally to normal plastic surface; therefore we applied a collagen IV
(Sigma) matrix prior to culture. Slides were kept at 4°C, overnight with collagen IV
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(lmg/ml), diluted in acidified DMEM (0.05% acetic acid) and allowed to dry in a
tissue culture cabinet. Coated slides were stored at -20°C wrapped in foil and
defrosted in a tissue culture cabinet prior to use.
2.2.5. Morphology ofPrimary Colonocyte Cultures
Immunocytochemistry with monoclonal pan anti-human keratin antibody (DAKO)
specific for epithelial cells and monoclonal anti-vimentin antibody (clone V9, Sigma,
V6630) specific for fibroblasts, endothelial, lymphoid tissue and melanocytes were
performed using a standard avidin-biotin peroxidase staining technique.
Cells were fixed with ice cold methanol for 5 minutes, air-dried for 10 minutes at
room temperature and then washed in PBS. Endogenous peroxidase was blocked
with 0.5% hydrogen peroxide in methanol. Following Avidin/Biotin block cells were
incubated with the corresponding primary antibody diluted in 20% normal rabbit
serum 2 hours at room temperature.
Anti-keratin antibody was used at a concentration of 1:50 and anti-vimentin antibody
at a concentration of 1:40. Detection was carried out using a rabbit anti-mouse
secondary antibody (DAKO) 1:400 in 20% normal rabbit serum, 30 minutes at room
temperature, and a Steptavidin/Biotin peroxidase Complex kit (DAKO). A positive
signal was detected with diaminobenzidine and haematoxylin was used as nuclear
counterstain.
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2.3. Cisplatin Treatment of Primary Murine Colonocytes
After 3 days in culture, primary murine colonocytes were exposed to cisplatin (David
Bull Laboratories, Warwick, UK). 1ml of the lmg/ml cisplatin (stock) was diluted in
2.334ml PBS to generate a 1000/xM solution that was kept at -20°C and defrosted
prior to use. This solution was then diluted further in culture medium to the desired
concentration. Untreated cells were fed with culture medium containing similar
amounts of PBS as the treated cells. Cells were incubated with the agent for 6, 12
and 24 hours. They were then washed with pre-warmed PBS and fixed as required by
the recommended protocols. For immunocytochemistry cells were fixed in either ice
cold methanol for 5 minutes or 4% paraformaldehyde 10 minutes at room
temperature depending on the recommended method for each antibody. For
quantifying apoptosis cells were fixed in modified Bouin's fixative (85% methanol,
5% acetic acid and 10% formalin) at 4°C overnight.
Cells used for RNA isolation were rinsed with pre-warmed PBS and then RNA
isolated as described (Chapter 2, Materials and Methods, section 2.10.)
Medium containing cisplatin, the PBS used to rinse the cells and all the plasticware
that came into contact with cisplatin were double sealed and disposed by
incineration.
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2.4. Quantification of Apoptosis
Cells were fixed in modified Bouin's fixative (85% methanol, 5% acetic acid and
10% formalin) at 4°C overnight, the DNA denatured in 5M HC1 and the nuclei
stained with Schiff reagent (Merck, Glasgow, UK). We used 0.3% light green as
counterstain. Apoptosis was quantified using morphological criteria [Bellamy C.O.
and Clarke A.R. et al., 1997], with at least 500 cells counted in duplicate and in at
least three separate experiments for each time point.
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2.5. Proliferation Assay
Primary colonocytes cultures were incubated with 0,01mM 5'-bromo-2'-
deoxyuridine (BrdU) (Amersham Pharmacia Biotech) in culture medium for 4 hours
to incorporate the BrdU and then fixed in 80% ethanol overnight. DNA was
denatured incubating cells with 5M hydrochloric acid (HC1) for 45 minutes. Cells
were then washed three times with PBS to remove any acid left on slides. Blocking
was performed using a protein free casein block (DAKO) for 30 minutes and then
cells were incubated with the primary antibody: rat anti-BrdU IgG-direct peroxidase
conjugated (Oxford Biotechnologies) at a concentration of 1:100, diluted in
Background Reducing Antibody Diluent (DAKO). Detection was carried out using
diaminobenzidine (DAB) according to manufacturer's instruction. Slides were
counterstained with haematoxylin, mounted and coversliped. Negative controls
omitted the primary antibody.
BrdU incorporation was estimated by counting the positive nuclei in a total of 500
(sufficient to achieve a stable running mean) in duplicate and from randomly selected
fields. Experiments were performed at least 3 times with comparable results. The
BrdU labelling index is expressed as a percentage.
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2.6. Immunocytochemistrv for p53, p21, PCNA and p73
2.6.1. Immunocytochemistry for Detection of p53, p21 and PCNA Proteins
The monoclonal antibody against p53 (clone pAB421) was purchased from
Calbiochem. This antibody has been previously used in our laboratory to show
expression of p53 in cells of mouse origin following DNA damage (irradiation,
cisplatin). Primary colonocytes derived from p53-/- mice were used as negative
control. Anti-PCNA (clone PC-10) [Al-Nafussi A. and Klys H.S. et al., 1993] and
anti-p21 (clone F-5) [Wong N.A. and Mayer N.J. et al., 2003] were both purchased
from Santa Cruz Biotechnologies (Santa Cruz). The protocols followed were similar.
Immunocytochemistry was carried out on 4% paraformaldehyde fixed cells,
permeated with 0.5% Triton in PBS for 20 minutes at room temperature. Endogenous
peroxidase was quenched exposing the cells to 1% hydrogen peroxide/distilled water
for 20 minutes at room temperature. Slides were then rinsed with distilled water prior
to incubation for 20 minutes with protein serum free blocking solution (casein based,
DAKO). This solution proved useful in reducing non-specific background. Cells
were then incubated with primary antibodies: p53 at a concentration of 1:500, p21 at
1:20 and PCNA at 1:100, all diluted in background reducing antibody diluent
(DAKO). Incubation was carried out at 4°C in a humid chamber, overnight. After
washing away the primary antibody with PBS, biotinylated rabbit anti-mouse F(ab')
(DAKO) 1:400 dilution was applied for 30 minutes. Avidin-biotin peroxidase
complex was used as the final detection step. The slides were washed briefly with
0.5% Triton in PBS before incubating with DAB for 1-5 minutes. Staining was
monitored under the microscope and if further intensification of staining was
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required (usually for the immunodetection of p53), slides were incubated with DAB
for an additional 5-10 minutes. Slides were counterstained with haematoxylin,
mounted with cedar-wood oil and cover-slipped.
Staining was nuclear for all three antibodies and positive nuclei were counted
randomly in at least 500 cells per well, in duplicate and in at least two individual
experiments.
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2.6.2. Immunocytochemistry for p73 Detection in Primary Colonocytes
Two antibodies against p73 were used to identify the protein in the cells. One of
them, rabbit polyclonal anti-p73, clone H-79 (Santa Cruz Biotechnologies)
corresponding to amino acids 1-80 mapping at the N-terminus of p73 of human
origin and reactive with mouse, rat and human proteins and the other Ab-77 (Abeam)
raised in sheep against the first 15 amino-acids of the N-terminus protein. Cells were
grown in sonic seal slides as already reported and fixed in 4% paraformaldehyde for
10 minutes at room temperature. Slides were extensively washed in PBS to eliminate
the fixative and permeated with 0.5% Triton for 20 minutes afterwards. Following
fixation and permeation cells were blocked with 3% PBS-BSA for 1 hour at room
temperature followed by incubation with primary antibody diluted in 1% PBS-BSA
at 4°C overnight. Rabbit anti-73, H-79 was used at a concentration of 1:100 and Ab-
77, raised in sheep at a concentration of 1:300. Next day cells were washed with PBS
and incubated with corresponding secondary antibody, Alexa 488-conjugated goat
anti-rabbit IgG 1:200 (Molecular Probes) and Alexa 488-conjugated donkey anti-
sheep IgG 1:200 (Molecular Probes) for 30 minutes at room temperature in a light
proof immunofluorescence box.
The staining was examined and pictures captured using a fluorescent microscope
Hamammatsu. Staining intensity was quantified measuring the intensity mean using
Image Pro-plus software. Data was transferred to an excel sheet and values plotted
into a histogram.
Auto-fluorescence control slides omitted both the primary and secondary antibodies
and negative controls just the primary antibodies.
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2.6.3. Immunohistochemistry for p73 on Formalin-fixed Paraffin-embedded Mice
Skin and Colon Sections
Tail skin and colon from both wt and p53 deficient mice were fixed in formalin for
24 hours and then processed in paraffin blocks. 3/rni sections were generated and a
peroxidase staining technique used. Sections were de-waxed in xylene and re-
hydrated through alcohol steps (100%, 95%, 70% ethanol) and finally water. Heat
induced epitope retrieval was performed in a microwave at 1000 Watts for 15
minutes using citrate buffer (Vector). Endogenous peroxidase was quenched by
placing slides in 3% hydrogen peroxide diluted in double distilled water. All the
remaining steps were performed as already explained (Chapter 2, section 2.6.1.). The
primary antibodies were used at similar concentration as for immunocytochemistry:
H79 1:100 and Ab77 1:300.
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2.7. Maintenance of Cell-lines and Culture Conditions
Cell lines for culture aliquoted and stored in CryoTube (Nunc) were thawed in a
water bath at 37°C. The cell suspension was then dispersed into 10ml of the
appropriate culture media and spun at lOOOrpm for 5 minutes to remove any DMSO
used in combination with serum as freezing medium. The medium was then aspirated
and cells re-suspended in culture medium and plated out in plasticware, Petri dishes,
multi-well plates, flasks or slides depending on the experiments (Greiner or Nunc).
All cell lines were grown at 37°C temperature and in 5% Carbon Dioxide
atmosphere.
Cells were split when confluent in culture. Media was removed (except for COLO-
320 cells which grow in suspension), cells were washed with pre-warmed PBS and
incubated for few minutes with a small amount (enough to cover the cells) of 0.25%
Trypsin-EDTA at 37°C. The cells were incubated with trypsin solution until
detached completely. Fresh medium was than added to neutralise the trypsin and
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2.8. Reverse Transcriptase-Polymerase Chain Reaction
Total mRNA was extracted using TRIZOL (Invitrogen) and following the company
recommendations. Genomic DNA contamination was removed by treating the total
RNA with DNase I (DNAfree kit, Ambion) following the protocol supplied with the
product. The total mRNA was then denatured at 95°C for 5 minutes to eliminate any
present secondary structures. For cDNA synthesis we used the M-MLV reverse-
transcriptase kit (Invitrogen) and generated cDNA from lOOng of total RNA.
Amplification of the region between:
- p73a exon 11- forward primer: 5 '-ACA CGG TGG TGT CAA CAA ACT -3'
exon 14 - reverse primer: 5'-CGG TAC TGG TCA GGG ACC TTC AG-3'
yields a product of 363bp in the case ofp73o: [Weiss R.H. and Howard L.L., 2001]
and/or a product of 270bp in the case of p73/3. GENEBANK accession no: Y19234.
For the detection of full-length forms, primers annealing to:
- p73a exon 3 - forward primer: 5'-GAG CAC CTG TGG AGT TCT CTA GAG-3'
exon 4 - reverse primer: 5'-GGT ATT GGA AGG GAT GAC AGG CG-3'
were used generating a product of predicted size 297bp as previously reported
[Pozniak C.D. and Radinovic S. et al., 2000], GENEBANK accession no: Y19234.
The primers for AN-forms, annealing to
- ANp73 exon 3'- forward primer:5'-ACC ATG CTT TAC GTC GGT GAC CCC-3'
exon 4- reverse primer: 5'-GAG ACA TGG TGT CGA AGG TGG AGC-3'
generated a product of 187bp [Sayan A.E. and Sayan B.S. et al., 2001],
GENEBANK accession no: Y19235.
- Shh - forward primer: 5'-GTG AGG CTG CGA GTG ACC G-3'
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- reverse primer: 5' -CCT GGT CGT CAG CCG CCA GCA CGC-3'
generated a product of 333bp [Dyer M.A. and Farrington S.M. et al., 2001],
- PTCH - forward primer: 5'-CTG CTG CTA TCC ATC AGC GT-3'
- reverse primer: 5'- AAG AAG GAT AAG AGG ACA GC-3'
generated a product of 452bp [Dyer M.A. and Farrington S.M. et al., 2001].
- PTCH 2 - forward primer: 5'- TGC CTC TCT GGA GGG CTT CC-3'
- reverse primer: 5'-CAG TTC CTC CTG CCA GTG CA-3'
generated a product of 207bp [Dyer M.A. and Farrington S.M. et al., 2001].
- Glil - forward primer: 5'-CAG GGA AGA GAG CAG ACT GA-3'
- reverse primer: 5'- AGC TGA TGC AGC TGA TCC AG-3'
generated a product of 251bp [Dyer M.A. and Farrington S.M. et al., 2001].
- Ihh - forward primer: 5'-ACG TGC ATT GCT CTG TCA AGT-3'
- reverse primer: 5' - CTG GAA AGC TCT CAG CCG GTT-3'
generated a product of 221bp [Farrington S.M. and BelaoussoffM. et al., 1997].
Transcripts levels were normalized to
- GAPDH - forward primer: 5'-CTT CAC CAC CAT GGA GAA GGC-3'
- reverse primer: 5'-GGC ATG GAC TGT GGT CAT GAG-3'
that generate a product of 237bp.
NIH-3T3 cells ofmouse origin were used as species positive control for the RT-PCR
experiments.
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Thermocycling was as follows:






p73aexons 11-14 3 minutes - 94°C 1 minute - 94°C
1 minute - 52°C
1 minute - 72°C
5 minutes - 72°C
p73o:exons 3-4 3 minutes - 94°C 1 minute - 94°C
1 minute - 64°C
1 minute - 72°C
5 minutes - 72°C
ANp73 exons 3'-4 3 minutes - 94°C 1 minute - 94°C
1 minute - 61°C
1 minute - 72°C
5 minutes - 72°C
GAPDH 3 minutes - 94°C 1 minute - 94°C
1 minute - 55°C
1 minute - 72°C
5 minutes - 72°C
Shh, Ptch, Ptch2,
GUI, Ihh
3 minutes - 94°C 1 minute - 94°C
1 minute - 55°C
1 minute - 72°C
5 minutes - 72°C
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PCR products mixed with loading dye were analysed on 2% agarose gel containing
0.5mg/ml ethidium bromide together. 1Kb Plus DNA ladder (Invitrogen) was run
simultaneously and the gel was visualised under ultraviolet light. All RT-PCR results
have been repeated twice from different batches ofRNA.
Agarose Gel Loading Dye (lOx):
1.5g Ficoll
0.02g Bromophenol blue
0.02g Xylene Cyanole FF
dF^O to 10ml
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2.9. Colonic Lesions - Samples and Sections
Normal and abnormal human tissue samples were selected from the archives of the
Division of Pathology, the University of Edinburgh Medical School. 7 hyperplastic
polyps, 20 tubulo-villous adenomas of the colon, 8 adenocarcinomas and 3 normal
colon samples (one formalin-fixed paraffin-embedded and two frozen samples) were
used. All sections were cut at 3-5 fxm except for the frozen sections used for laser
capture microdissection that were cut at 8 fxm.
Histological Diagnosis
H&E sections of the colonic lesions investigated in Chapter 3 were reviewed and
described by Dr. Roger Malcomson and Professor David J. Harrison in the
Department ofPathology.
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2.10. Immunohistochemistry on Colorectal Lesions
2.10.1. Immunohistochemistry for Detection ofShh, Ptch, Smoh, Ki-67 and Cyclin
B1 proteins
For immunohistochemistry we used the following antibodies: goat polyclonal
antibodies against Shh (N-19), Ptch (G-19) and Smoh (C-17) all purchased from
Santa Cruz Biotechnologies and mouse monoclonal Cyclin B1 (clone V-152,) from
DAKO. A mouse monoclonal Ki-67 (clone MEB-1) antibody from DAKO was used
to assess the proliferation status of the tumours examined.
The tissue sections used for immunohistochemistry were de-waxed in xylene and re-
hydrated through a series of graded alcohols followed by incubation for 20 min in
3% hydrogen peroxide to block endogenous peroxidase. A casein serum free block
specific for formalin fixed tissues was then used for 20 minutes as recommended by
supplier (DAKO).




- Cyclin B1 1:250
-Ki-67 1:100
Slides were then washed in PBS 3 x 5 minutes and detection carried out using a
biotinylated rabbit anti-goat IgG (1:400) and rabbit anti-mouse IgG (1 in 400)
secondary antibodies for 30 minutes. Another 30 minutes incubation step was carried
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out using StreptAvidin-Biotin HRP Complex (DAKO) and the staining was
visualised with diaminobenzidine (DAKO). Sections were counterstained with
Mayer's haematoxylin. Negative controls (absence of primary antibody) were run for
each set of antibodies (monoclonal and polyclonal) and for each case analysed.
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2.10.2. Double Fluorescent Stainins for Shh and Ki-67 in a Hyperplastic Polyp
Double immunofluorescence detection for Shh and Ki-67 was performed in a
hyperplastic polyp. Both primary and secondary antibodies were diluted in 1% sterile
filtered PBS-BSA. Following de-waxing, antigen retrieval and blocking the section
was incubated with the first primary antibody mouse anti-Ki-67, 1:100 for 2 hours at
room temperature. The slide was washed in PBS and then incubated for 30 minutes
at room temperature with the first secondary antibody Alexa 488-conjugated rabbit
anti-mouse IgG (Molecular Probes) 1:200. Following extensive washes with PBS,
the section was incubated with the second primary antibody goat anti-Shh 1:100
overnight at 4°C in a light proof immunobox. Secondary detection was performed
using an Alexa 568-conjugated donkey anti-goat IgG (Molecular Probes) 1:200 for 2
hours at room temperature. DAPI was used as nuclear counterstain. The specimen
was examined using a Zeiss laser-scanning confocal microscope.
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2.11. Laser Capture Microdissection, RNA Preparation and RT-PCR
Two separate frozen normal colon samples were used to generate 8 pm cryostat
sections for laser-capture microdissection. Tissue sections were fixed in 70%
alcohol, stained with Mayer's haematoxylin and eosin, de-hydrated in graded
alcohols followed by clearing and dehydration in xylene and air dried for 10-15
minutes. Normal colonic crypts (15-20 crypts) were microdissected onto LCM caps
(CellPix II, Arcturus) and total mRNA isolated using a phenol-chloroform based
method (RNA isolation kit, Ambion). The RNA isolated was DNase I treated (2U per
sample of RNA, usually in 0.5ml thin wall tubes) using the DNA free kit from
Ambion specially designed to DNase I treat small quantities of RNA from any
genomic DNA contamination. The reverse transcriptase reaction was performed
using MMLV reverse transcriptase (Life Technologies), Oligo dTi2-i8 (Life
Technologies), incubated with RNase inhibitor (Life Technologies) at 37°C for 50
minutes. 5pi of cDNA generated in the RT reaction was used for each 25pl PCR
final volume. The oligonucleotides used [Tojo M. and Kiyosawa H. et al., 2002;
Tojo M. and Mori T. et al., 1999] were:
Shh - forward primer 706 - 5'-GAA AGC AGA GAA CTC GGT GG-3'
- reverse primer 875- 5'-GGA AAG TGA GGA AGT CGC TG-3'
Shh product size 170bp - GENBANK accession no. L38518
Ptch - forward primer 1092- 5'-TCC CAA GCA AAT GTA CGA GCA-3'
- reverse primer 1238- 5'TGA GTG GAG TTC TGT GCG ACA C-3'
Ptch product size 144bp - GENEBANK accession no. U59464
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Smoh - forward primer 615 - 5'-CTG GTA CGA GGA CGT GGA GG-3
- reverse primer 756 - 5'- AGG GTG AAG AGC GTG CAG AG-3'
Smoh product size 140bp - GENEBANK accession no. U84401.
P~microglobulin - forward primer - ACC CCC ACT GAA AAA GAT GA
- reverse primer - ATC TTC AAA CCT CCA TGA TG
p-microglobulin product size 120bp
Thermocycling conditions were as follows:






Shh 3 minutes - 94°C 1 minute - 94°C
1 minute - 53°C
1 minute - 72°C
5 minutes - 72°C
Ptch 3 minutes - 94°C 1 minute - 94°C
1 minute - 61.6°C
1 minute - 72°C
5 minutes - 72°C
Smoh 3 minutes - 94°C 1 minute - 94°C
1 minute - 64°C
1 minute - 72°C
5 minutes - 72°C
P-microglobulin 3 minutes - 94°C 1 minute - 94°C
1 minute - 55°C
1 minute - 72°C
5 minutes - 72°C
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The expression of the housekeeping gene (3 microglobulin was used as internal semi¬
quantitative and qualitative control and RNA-cDNA isolated from NIC-H441 cells as
primers positive control. The RT-PCR products were run on 6% TBE gels stained
with ethidium bromide and visualised under ultraviolet light.
PCR products were sequenced and using P Thermosequenase cycle sequencing kits
(Amersham) from primers used for PCR amplification (the sequencing experiment
was performed in collaboration with Dr. Scott Bader).
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2.12. Single-strand Conformation Polymorphism Assay for Shh and Smoh in a
Panel of Colorectal Tumours
This experiment was performed in collaboration with Dr. Roberta M. James, with
excellent technical assistance from Claire Lomas and Audrey Peter.
The entire coding region of the Shh and Smoh genes by single-strand conformation
polymorphism (SSCP) assay in a panel of colon cancer tumours (60 RER-,
microsatellite stable and 20 RER+, microsatellite unstable) was screened as
previously described [Bader S. and Walker M. et al., 2003]. Genomic DNA was
extracted from tumour and matching normal colon tissues by standard techniques and
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amplified using primers at 0.4pM in 10/xl reactions in the presence of [a- PjdATP
(ICN Biomedicals) under standard conditions. PCR products were analysed on a non-
denaturing 0.5x SequaGel MD gels (National Diagnostics) with 10% glycerol and
0.6% TBE for 18 hours at 8W at room temperature. The gels were dried and exposed
to autoradiographic film. A total of 12 primer pairs for Shh (Table 1) and 21 primer
pairs for Smoh were designed from genomic sequence (L38518 and AF114819.1
respectively) and were located just inside introns flanking splice acceptor and donor
sites of smaller exons, or in overlapping segments in larger exons.
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Table 1. Primer pairs used to amplify the 3 exons (including intron/exon boundaries)
of the gene Shh for SSCP analysis.














2.13. Treatment of Primary Colonocytes with Shh Peptide, 5E1 Neutralising
Shh Antibody or Isotype Control IgGl Antibody
Primary murine colonocytes isolated using the method already described (Chapter 2,
Materials and Methods, section 2.2.) were treated with exogenous soluble Shh
peptide, anti-Shh antibody or isotype control antibody. The mouse recombinant Shh
peptide, a 180-residue N-terminal peptide (R&D Systems) was reconstituted in
sterile filtered 0.3% PBS-BSA to a final concentration of 25/xg/ml. This stock
solution was stored at -20°C and added to the culture medium prior to use. The
neutralising anti-Shh antibody (clone 5E1) and the isotype control IgGl antibody
were a gift from Dr. Sarah Howie. 5E1 was raised in mouse against the N-terminal
region of the Shh protein. They were also stored at -20°C and added to the culture
medium before experiments were carried out. The antibodies were both tested by
immunoblotting by Dr. Sarah Howie's group.
After 3 days in culture, primary colonocytes were exposed to various concentrations
of Shh peptide or neutralising antibody as previously described [Lowrey J.A. and
Stewart G.A. et al., 2002], The isotype control antibody was also used as mentioned
[Lowrey J.A. and Stewart G.A. et al., 2002], The recombinant mouse Shh peptide
was added to the cells at a concentration of 0.25/ug/ml, 0.5/xg/ml and 0.75pig/ml. 5E1
antibody was used at 20 and 50/xg/ml and the isotype control antibody at 20/xg/ml.
Cells were exposed to the above concentration of exogenous Shh peptide, 5E1 or
isotype control antibody for 48 or 72 hours in both serum free culture conditions or
2.5 serum culture medium. BrdU was added to the culture medium in concentration
of lOmM for 4 hours and then fixed in 80% ethanol at 4°C overnight.
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Immunodetection was carried out by immunocytochemistry with a rat anti-BrdU
antibody as already detailed in Chapter 2, Materials and Methods, section 2.7.
Positive BrdU cells stained with DAB were counted in a total of 1000 cells and in
three different experiments for all conditions presented.
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2.14. Statistics
Data were analysed using Minitab statistical software version 13. Data are presented
in graphs as the mean ± SEM. Comparison of BrdU results was made using analyse
of variance (ANOVA) test. Comparison of all other results was made using Mann-









Colonic epithelium is a continually regenerating tissue in which a tightly regulated
balance between proliferation and cell death maintains tissue homeostasis. Any
perturbation of a proliferating cell compartment can result in tumourigenesis and
may cause the abnormalities of epithelium seen in inflammatory bowel disease.
Colorectal cancer develops from the pathologic transformation of normal colonic
epithelium to an adenomatous polyp and eventually invasive cancer. Escape from the
induction of apoptosis is believed to be a critical event in colorectal carcinogenesis.
Much of the information on carcinogenesis in the intestine derives from studies
utilising cells from the small intestine, yet the majority of the mutations leading to
cancer in humans occur in the large intestine. Detailed pioneering work by Potten
and others [Booth C. and Potten C.S., 2000; Potten C.S. and Booth C. et al., 1997;
Williams E.D. and Lowes A.P. et al., 1992] has elucidated the kinetics of intestinal
growth in-vivo but primary culture offers a dynamic in-vitro model allowing the
investigation of growth, apoptosis and response to injury [Booth C. and O'Shea J.A.
et al., 1999; Booth C. and Patel S. et al., 1995],
p53 is frequently mutated or deleted in colorectal cancer, particularly in late stage,
acting as a progression step [Carder P.J. and Cripps K.J. et al., 1995]. Approximately
half of all colorectal cancers show p53 gene mutations, with higher frequencies
occurring in distal colon and rectal tumours and lower frequencies in proximal
tumours and those with microsatellite instability or methylator phenotypes [Iacopetta
B., 2003].
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The role of p53 in tumour suppression is linked to its functions in the regulation of
cell-cycle control [Kastan M.B. and Zhan Q. et al., 1992], differentiation [Aloni-
Grinstein R. and Schwartz D. et al., 1995], inhibition of angiogenesis [Dameron
K.M. and Volpert O.V. et al., 1994], senescence [Atadja P. and Wong H. et al.,
1995] and apoptosis following genotoxic stress, nucleotide depletion and oncogene
activation [Ryan K.M. and Phillips A.C. et al., 2001], Following DNA damage, p53
induces expression of p2J(WAFI/CIPI^ whose induction above basal levels results in
binding to cyclin-dependent kinase complexes and their inhibition, thereby blocking
cell proliferation [Xiong Y. and Hannon G.J. et al., 1993]. p21 can also bind to
proliferating cell nuclear antigen (PCNA), a subunit of DNA polymerase 8 [Flores-
Rozas H. and Kelman Z. et al., 1994; Nakanishi M. and Robetorye R.S. et al., 1995;
Waga S. and Hannon G.J. et al., 1994]), blocking PCNA function in DNA
replication but not repair. Consequently, p21 can cause G1 arrest and inhibition of
DNA replication whilst ensuring potential errors are repaired prior to resumption of
cell cycling. p21 appears to be an essential prerequisite for G1 arrest following DNA
damage [El Deiry W.S. and Tokino T. et al., 1993], although there may be other
unknown mediators of this checkpoint. Thus several studies have reported that
homozygous deletion of p21 partially or completely abrogates G1 arrest mediated by
p53 [Brugarolas J. and Chandrasekaran C. et al., 1995; Deng C. and Zhang P. et al.,
1995; Waldman T. and Kinzler K.W. et al., 1995].
Although the significance of p53 in tumour suppression remains undisputed, it has
become apparent that p53-independent mechanisms operate in tandem to ensure
fidelity of replication and elimination of rogue cells from the gene pool. It is now
recognised that p53 is a member of a gene family encompassing its homologues p73
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and p63. p73 shares many similarities with p53, but there are differences in the
upstream regulatory signals leading to p73 activation. In p53-/- cells, oncogene
activation induces endogenous p73 expression engaging on apoptosis pathway that is
p53-independent [Zaika A. and Irwin M. et al., 2001]. Despite the p73 locus (lp36)
being on a chromosome region frequently deleted in human cancers, numerous
studies on human tumours have failed to detect p73 gene deletion or the incidence of
inactivating mutations [Mai M. and Yakomizo a. et al., 1998; Sunahara M. and
Ichimiya S. et al., 1998]. However, the role of p73 in tumourigenesis remains
unclear, as silencing of the p73 gene has been detected in neuroblastoma, squamous
cell carcinoma and lung cancer [Benard J. and Douc-Rasy S. et al., 2003] suggesting
that in the corresponding tissues p73 may assume a tumour suppressor role.
Conversely, overexpression of p73 has been reported in a series of malignancies as
discussed in the general introduction. Finally, p73 null mice do not display an
increased predisposition to spontaneous tumour development [Yang A. and Sharpe
A. et al., 2000] although their response to chemical carcinogenesis has yet to be
reported.
p73 exists as at least six (a, |3, y, 5, e, p) full-length transactivation competent (TA)
forms which differ at the C-terminus and as N-terminally truncated variants (AN)
that are believed to be transactivation deficient [Chen X., 1999]. Overexpression of
the a and [3 forms was shown to cause irreversible growth arrest and apoptosis in
cells lacking functional p53 [Fang L. and Lee S.W. et al., 1999], Recently ANp73
was identified as the predominant form in the developing brain and sympathetic
neurons [Pozniak C.D. and Radinovic S. et al., 2000], This AN-variant assumes a
protective role against apoptosis induced by NGF withdrawal, by directly
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antagonising the apoptotic functions of p53 [Pozniak C.D. and Radinovic S. et al.,
2000] and is capable of suppressing p53 and TAp73-dependent transactivation
[Ishimoto O. and Kawahara C. et al, 2002],
In the present study, the colonic crypt isolation technique developed by Booth et al.
(1995) [Booth C. and Patel S. et al., 1995] was adapted, to obtain primary
colonocytes from adult wt and p53-/- mice. The objectives were to better understand
the importance of p53 and related proteins in the regulation of growth and response
to DNA damage in these cells. In order to investigate both p53 dependent and
independent DNA damage response pathways, primary colonocytes were exposed to
cis-diamminedichloroplatinum(II) (cisplatin), a widely used chemotherapeutic agent
that cross-links DNA, forming intra- and inter-strand adducts [Jordan P. and Carmo-
Fonseca M., 2000],
Why cisplatin?
Cisplatin lesions are detected by components of the mismatch repair machinery
leading to futile repair cycles [Mello J.A. and Acharya S. et al., 1996; Vaisman A.
and Varchenko M. et al., 1998] that culminate in the induction of apoptosis
proceeding via at least two different pathways: one involving p53 and the other
mediated by p73 [Jordan P. and Carmo-Fonseca M., 2000]. These pathways have not
yet been examined in primary colonocyte cultures.
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3.2. Results
3.2.1. In vitro Culture ofPrimary Colonocytes
Colonic crypts isolated from adult mouse colons using a combined dispase and
collagenase enzymatic method attached to a collagen matrix to spread and grow into
colonocytes (Figure 8).
Primary colonocytes survive in culture for a limited period of time (approximately
20-25 days) and have a slow proliferation rate. BrdU positive cells are detected only
in the first few days (up to day 10) in culture. BrdU incorporation in cells after 2, 4,
6, 7, 8 and 9 days in culture shows that primary colonocytes are actively proliferating
in the first 5 or 6 days in culture (Figure 9). After 7 days in culture just a very small
number of cells (roughly 1 or 2 in 10.000 cells) incorporate BrdU, and cells
ultimately die after 20 or 25 days in culture.
Therefore, experiments were performed between 3 and 5 days in culture when
viability is maximal and count of apoptosis, cell-cycle activity and
immunocytochemistry are optimal.
The effect of different culture parameters such as seeding density (densities between
400 and 1000 crypts per well), cell culture plasticware (multi-well slides or plates
purchased from different companies), extra cellular matrix (fibronectin, laminin,
collagen I, collagen IV or their combination) and growth factor supplements (insulin,
EG) were investigated prior to final experiments. These factors had enormous effects
on crypt attachment, spreading and morphology of primary colonocytes in culture.
The Nunc sonic-seal chamber slides coated with collagen IV proved to be the best
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Figure 8: A) Picture offreshly isolated crypts after enzymatic digestion.
B) Crypt settled after I day in culture. Epithelial cells proliferate
by growing outfrom the crypt. The initial crypt and its original
architecture are hardly visible.
C) Cells start to spread out and tend to become a confluent monolayer.
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Figure 9: BrdU incorporation assay demonstratingproliferation in wtprimary
colonocytes over aperiodof9 days in culture. Cells were incubatedwith
BrdU for 4 hours andfixed in 80% ethanol. Positive cells were detected
with DAB and haematoxylin was used as nuclear counterstain.
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combination that favoured the attachment and survival of the adult mouse colonic
crypts. Growth factors like insulin and EGF also proved essential for survival and
growth of epithelial cells in culture. We also used low levels of serum in culture
medium (2.5%) to inhibit the growth of fibroblasts that usually contaminate primary
cultures.
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3.2.2. Confirmation of Epithelial Origin of Colonocyte Preparation by Keratin
Immunocytochemistry and Evaluation ofCulture Purity
The use of a pan-keratin antibody proved that the vast majority of the cells, derived
from adult mouse colons were indeed of epithelial origin (Figure 10). Transmission
electron micrographs studies carried out by Booth et al. (1995) revealed the presence
of desmosomes in cells isolated by a similar method, confirming their epithelial
nature. Vimentin staining, characteristic of fibroblasts, showed that fibroblast
contamination was minimal. Fibroblasts tend to appear in low numbers in culture
after 3 or 5 days, when colonocytes are well settled and spread. They occupy the
empty spaces in the well. The use of low serum concentration in the culture medium
(2.5%) limited their growth.
Ill
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day 3 in culture
Figure 10: Keratin expression in wt andp53 deficientprimary murine colonocytes,
using an anti-pan-keratin antibody. Cells werefixed in coldmethanol
and detection carried out using a peroxidase techinque. Positive staining
is confirmed by brown cytoplasmic staining detectedwith DAB and
haematoxylin was used as nuclear counterstain.
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3.2.3. Cisplatin Treatment ofPrimary Murine Colonocvtes
Colonocytes isolated from wt mice were exposed to different concentrations of
cisplatin: 15pM, 20pM and 25pM to determine the percentage of cell death.
Apoptotic cells were counted on Feulgen stained light green counterstained slides
using a morphological criteria [Bellamy C.O. and Clarke A.R. et al., 1997], Results
are presented in the graph below.
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6 hours 12 hours 24 hours
As some of the cells die and detach by 24 hours, the percentage of death after 25pM
cisplatin is higher in reality. In addition, the cells exposed to high concentrations of
cisplatin suffer a greater damage and are therefore less likely to reflect and express
damage response proteins. Consequently, 15pM cisplatin was the preferred
concentration to be used in the experiments.
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3.2.4. p53 Controls Growth in PrimaryMurine Colonocytes
The percentage of cells in S phase was determined by BrdU incorporation into wt
and p53-/- colonocytes under baseline conditions and at 6 and 12 hours after
exposure to cisplatin (Figure 11). p53-/- colonocytes exhibit a significantly higher
BrdU labelling index, indicating a growth advantage over wt cells under baseline
conditions (see graph below). Following cisplatin treatment BrdU incorporation in wt
cells was reduced by 12 hours (p=0.015, ANOVA) whereas p53-/- colonocytes
continued to engage in DNA synthesis suggesting an essential role for p53 in cell-
cycle arrest following cisplatin damage in murine primary colonocytes.
10
untreated 6 hours 12 hours
time after exposure to cisplatin
■ wt cells □ p53-/- cells
BrdU incorporation in untreated and cisplatin-treated wt and p53-/~ colonocytes.
Results are the average with SEM, and show a higher BrdU incorporation in p53-/~
colonocytes regardless of treatment and time-point (p=0.015, ANOVA).
114
wt untreated wt cisplatin
Figure 11: BrdU incorporation as a marker ofcells in S-phase (cells in culture
were exposed to BrdUjustfor 4 hours). Following cisplatin treatment
the BrdU inrporation decreases in wt cells, whereas p53-/~ cells
continue to incorporate BrdU into theirDNA.
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3.2.5, Cisplatin Kills Colonocvtes by Apoptosis Irrespective ofp53 Status
Apoptosis in colonocyte cultures was monitored at 6, 12 and 24 hours post-cisplatin
exposure (Figure 12). At all time points there was a significant increase in the
incidence of apoptosis (p<0.05, Mann-Whitney U test) between treated cells and
their corresponding controls, irrespective of genotype. There were however reduced
levels of apoptosis in p53-/- colonocytes compared to wt counterparts (see graph
below): whereas 39% ofwt cells were apoptotic 24 hours post exposure to cisplatin,
only 27% of p53-deficient cells had died by this time. The overall levels of apoptosis
at each time point in p53-deficient colonocytes were reduced compared to p53-
proficient cells.
45
6 hours 12 hours 24 hours
□ wt untreated ■ wt cisplatin
□ p53-/- untreated □ p53-/- cisplatin
Apoptosis in wt and p53-/- colonocytes exposed to cisplatin. Apoptotic nuclei in a
total of500 cells were counted in triplicate and in at least 3 experiments. The figure
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Figure 12: Apoptosis in primary murine colonocytes as detected using Feulgen staining.
Light green was used as cytoplasmic counterstain. Increased apoptosis
(indicated by the black arrows) is noticed in cisplatin-treatedwt (B)
andp53-/- (D) cells compared to their untreated couterparts: wt (A) and
P53-/- cells (C).
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3.2.6. p53 Is Unregulated Followins Cisplatin Treatment ofWild-type Colonocvtes
The proportion of cells expressing nuclear p53 was determined by
immunocytochemistry on 4% paraformaldehyde-fixed untreated and cisplatin-treated
colonocytes (Figure 13A and 13B). Although nuclear p53 was detected under
baseline conditions, its expression was significantly upregulated after exposure to
cisplatin at all time points (p<0.05, Mann-Whitney U test) consistent with its
stabilization and transcriptional activity (see graph below).
60
untreated 6 hours 12 hours 24 hours
time after exposure to cisplatin
p53 expression in untreated and cisplatin-damaged colonocytes. p53 is expressed
under baseline conditions but its expression is significantly upregulated after
exposure to cisplatin at all time-points (p<0.05, Mann-Whitney U test). The figure
shows the average percentage ofp53-positive cells in a total of500 ± SEM.
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Figure 13: Expression ofnuclearp53 andp21 in untreated and cisplatin treated
colonocytes detected by immunocytochemistry using an avidin-biotin
peroxidase technique. Positive cells were detectedwith DAB and
haematoxylin was used as nuclear counterstain. p53 expression is
upregulatedfollowing exposure to cisplatin (A andB) whereas p21 levels
do not change significantly in cisplatin treated wt cells (C andD) and
p53-/~ cells (E and F).
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3.2.7, p21 andPCNA Are Expressed in Untreated and Cisplatin-Treated Cells
We also investigated levels of the downstream target gene of p53, p21. Remarkably,
high levels of nuclear p21 were present in both, wt and p53-/- colonocytes under
baseline conditions (Figure 13C, 13E), with no further increase after cisplatin
treatment (Figure 13D, 13F), (see graph below). However, the proportion of cells
expressing p21 was significantly higher in wt cultures compared to p53-/- cells at all
time points (p<0.034, Mann-Whitney U test). PCNA, a binding partner of p21 was
also present in a high proportion of cells regardless of their p53 status or exposure to
cisplatin.
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untreated 6 hours 12 hours 24 hours
time after exposure to cisplatin
■ wt cells □ p63-/- cells
p21 expression in untreated and cisplatin-treated wt and p53-/- colonocytes. The
levels ofp21 expression were significantly higher in wt when compared to p53-/-
cells at all time-points and did not changedfollowing cisplatin treatment. The figure
shows the average percentage ofp21 -positive colonocytes ±SEM.
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3.2.8. p73 is Expressed in Wild-type and p53-/~ Colonocvtes Under Baseline
Conditions and It Is Upresulated Following Treatment with Cisvlatin but
Transcript Levels Remain Unchansed
Some baseline levels of nuclear p73 were detectable by immunofluorescence.
Following treatment with cisplatin for 24 hours, there was an increase in the amount
of p73 protein in the nucleus as evidenced by a 2-3-fold increase in the intensity
signal as measured using Image-Pro Plus software (Figure 14).
The increase is consistent with nuclear translocation of p73. Results were
comparable using two different antibodies against p73 (Figure 15A and 15B). Rabbit
polyclonal H-79 is raised against the N-terminal 80 amino acids of p73 and could
thus not be used to discriminate between full-length forms and AN variants of p73.
Ab77 was raised against a sequence at the extreme N-terminal 15 amino acids and
therefore exclusively identifies full-length p73 and should not cross-react with AN-
p73. To test whether the constitutive levels of nuclear p73 are a consequence of in-
vitro culture or whether they reflect expression levels in the colonic epithelium in
situ, formalin-fixed paraffin-embedded sections were subjected to
immunohistochemistry with the abovementioned p73 antibodies. As staining was
detected in the basal/parabasal cells of murine skin epithelium [Faridoni-Laurens L.
and Bosq J. et al, 2001] the absence of staining in the colonic epithelium is
indicative of the fact that p73 is not normally expressed, at least at levels detectable
by immunohistochemistry, in the murine large intestine in situ.
RT-PCR analysis was employed to investigate the incidence ofmajor p73 forms. We
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Figure 14: p73 is upregulated inprimary colonocytesfollowing treatment with
cisplatin as evidenced by a 2-3-fold increase in the amount of
p73 protein in the nucleus. The intensity signal was measured using
Image-Pro Plus software, in 3 differentfields in at least 80 cells.
Results were comparable using two different antibodies against










Figure 15: Immunofluorescence detection ofnuclear p73 in primary colonocytes
using Alexa-488 conjugated secondary antibody. Similarpattern of
nuclear accumulation after treatment with cisplatin is manifested in both
wt andp53-null cells using two different antibodies: rabbitpolyclonal
H-79 (A) and sheep polyclonal Ab-77 (B). DAPI was used as nuclear
counterstain. The cells shown were exposed to cisplatin for 24 hours.
Images were captured using a Hamamatsu chilled CCD camera and
Zeiss fluorescent microscope.
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for C-terminus, exons 11-14 and N-terminus primers exons 3-4 (Figure 16B). p73a
was detected in both wt and p53-/- colonocytes under baseline conditions and levels
remained unchanged following exposure to cisplatin, consistent with reports in the
literature that p73 stabilization following cisplatin damage docs not involve
transcriptional upregulation. No products corresponding to p73p, AN-p73a (Figure
16C) or AN-p73(3 were detected. The p73 gene encodes two different proteins that
are expressed under the control of two independent promoters, and that have opposite
activities: the transcriptionally active full-length p73 identified already in the cells
and the amino-terminally truncated ANp73. As the truncated protein is induced by
TAp73 and p53, we explored its presence in our cells. No evidence for the truncated
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Figure 16: RT-PCR showingp73 expression in wt andp53-null untreated and
cisplatin treated colonocytes. A - amplification withprimers spanning
exons 11-14 in murineprimary colonocytes. Theprimers couldalso
detect the presence ofC-terminus p73f but no band ofapredicted size
was obtained. B - RT-PCR analysis forN-terminus detection offull-length
p73 using primers for exon 3-4. C - RT-PCR showing the absence of
AN-variants in primary colonocytes. NIH-3T3 cDNA proved that the
primers recognise a product ofa correct size. D - the housekeeping gene
GAPDH was used as internal qualitative and semi-quantitative control.
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3.3. Discussion
In the present study the role of p53 in the regulation of growth and response to
cisplatin injury in primary murine colonocytes was explored. Even though colorectal
cancer is resistant to cisplatin treatment, we chose this chemotherapeutic drug to
allow the investigation of both p53- dependent and independent pathways following
DNA damage.
Under baseline conditions, the proportion of p53-/- colonocytes in S-phase was
significantly greater than wt counterparts, suggesting a role for p53 in regulating
transition through the cell cycle in-vitro. The BrdU incorporation into wt colonocytes
decreases following treatment with cisplatin, indicating that wt cells undergo G1
arrest whereas p53-deficient cells continue unperturbed to engage in DNA synthesis,
despite sustaining damage to their DNA. Thus, as a first line of defence, wt
colonocytes respond to cisplatin damage via a p53-dependent growth arrest.
Both p53-/- and wt cells ultimately died by apoptosis, regardless of the failure of
p53-/- colonocytes to enter growth arrest following cisplatin treatment. The time-
course of cell death was rapid with approximately 40% of wt cells becoming
apoptotic by 24 hours. However, apoptosis levels in p53-deficient cells were
reduced. This may be analogous to the delayed second wave of p53-independent
apoptosis seen in-vivo following irradiation in the small intestine, and to a much
lesser extent in the colon [Clarke A.R. and Howard L.A. et al., 1997], suggesting the
existence of p53-independent mechanisms of eliminating damaged intestinal cells.
Consistent with the proposed role for p53 in mediating the cell cycle arrest and
apoptotic responses to cisplatin, the expression of p53 was significantly upregulated
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in treated wt cells. However, the levels of its downstream target p21 remained
unchanged from the already high baseline. We might predict that these high p21
levels may function to counteract apoptosis. In fact, in the absence of p53, when p21
expression is reduced by 40%, the levels of apoptosis are only reduced. Recently it
was shown that Myc recruitment to the p21 promoter prevents bound p53 from
activating p21 transcription and thus, by inhibiting p21 expression, Myc influences
the decision between life and death favouring induction of apoptosis in colon cancer
cells and highlighting the cytoprotective role of p21 [Seoane J. and Le H.V. et al.,
2002J. Moreover, HCT116 human colon cancer cells exhibit a G1 arrest following
DNA damage by y-irradiation or chemotherapeutic drugs, whereas isogenic cells,
with a targeted inactivation of the p2lWAFI/ciP' gene [Mahyar-Roemer M. and Roemer
K., 2001; Waldman T. and Kinzler K.W. et al., 1995] or cells treated with antisense
[Tian H. and Wittmack E.K. et al., 2000], are sensitised to undergo apoptosis. In
conditions where apoptosis predominates, p21 is cleaved by caspase 3 and re-
localizes to the cytosol enabling apoptosis to proceed [Dotto G.P., 2000], We did not
see a reduction of endogenous p21 or its redistribution to the cytosol preceding the
induction of apoptosis as might be predicted from these studies. Given that apoptosis
was the ultimate fate of damaged colonocytes, there was no apparent cytoprotective
effect ofp21, although only the response ofp21-null cells would resolve this issue.
Levels of nuclear p21 were high regardless of treatment, time point or genotype. This
could be attributed to the stress of in vitro culture. The molecular response to
perceived hypoxia includes amongst others induction of p21, reiterating the
importance of O2 levels during the culture of primary cells isolated from organs [Roy
S. and Khanna S. et al., 2003]. However, elevated amounts of p21 are not
127
inconsistent with reports that its levels are regulated in cultured cells during the
different phases of the cell cycle or indeed with its proposed role in differentiation
[Dotto G.P., 2000],
As already discussed p21 binds to PCNA. The levels of PCNA in primary
colonocytes were persistently high regardless of cell genotype or cisplatin treatment.
One explanation for the high proportion of PCNA positive cells in vitro, in stark
contrast with in vivo, is that it reflects damage or stress to the cells in culture and
corresponds to the reparatory function of PCNA. It is also possible that it simply
represents a population of cells in G1 consistent with the fact that high levels ofKi-
67 nuclear staining were also detected. PCNA is often used as a marker for
proliferation but our findings, taken together with the relatively low levels of BrdU
incorporation, raise questions as to the suitability of using solely PCNA as a reliable
proliferation marker in primary cultures at least.
p53 is not normally implicated in the baseline expression of p21; yet in primary
colonocytes the proportion of cells expressing p21 under the normal conditions of in
vitro culture is halved in the context of p53 deficiency. If we are to accept that
growth in vitro is indeed stressful for the colonocytes, then it is no surprise that p21
levels are high to counteract this effect. This may be also a limitation ofmost of the
primary culture models, as colleagues in our lab have also detected high levels of p21
and PCNA in hepatocytes and Clara cell cultures (pneumocytes).
p53-/- cells are to a certain extent de-sensitised with regard to these stresses. What is
more surprising is the finding that despite high levels of p21, colonocytes are not
protected from entering apoptosis as previous studies have suggested. Nevertheless,
the significance of the high levels of nuclear p21 in primary cultured colonocytes
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remains unclear and cannot be accounted for exclusively by p53-dependent
transactivation. Studies of primary colonocytes lacking p73, both p53 and p73 or
indeed p21 would yield further insight into this question.
As already discussed, although some p53 is detected under baseline conditions this
cannot explain the high percentage of cells expressing p21 nor of course can it
account for expression in p53-/- cells. There are numerous pathways culminating in
the expression of p21 involving TGF|3, BRCA1, ERF1, p73 and others. Recent
reports have placed p73 and p63 as essential downstream mediators of p53-
dependent apoptosis [Flores E.R. and Tsai K.Y. et al., 2002]. Therefore, it seems
plausible that p73 is implicated in at least certain responses to DNA damage and may
indeed act in concert with p53 or, if p53 function is absent, elicit apoptosis by
alternative routes [Chen X. and Zheng Y. et al., 2001], p73 levels are increased and
result in apoptosis in human colorectal carcinoma cells treated with cisplatin in a
manner independent of their p53 status [Gong J.G. and Costanzo A. et al., 1999]. We
therefore hypothesised that p73 may be partly responsible for p21 baseline
expression and also p53-independent apoptosis following cisplatin treatment in
primary colonocytes.
Given the tissue specificity of p73 expression, we employed RT-PCR analysis to
investigate the incidence of major p73 forms in primary colonocytes. RT-PCR
confirmed the presence of full-length p73a in both wt and p53-/- colonocytes under
baseline conditions and following exposure to cisplatin. No evidence was found for
either p73|3 or the anti-apoptotic form AN-p73a/p. By semi-quantitative RT-PCR,
the levels of transcript remained unchanged following cisplatin exposure, consistent
with reports in the literature that p73 stabilisation following cisplatin damage does
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not involve transcriptional upregulation but occurs through post-translational
mechanisms involving c-Abl and other modulators of function [Gong J.G. and
Costanzo A. et al., 1999].
In support of the RT-PCR data, we detected baseline levels of nuclear p73 by
immunofluorescence using two different antibodies raised against p73. Following
treatment with cisplatin for 24hrs, there was an increase in the amount of p73 protein
in the nucleus as evidenced by a 2-3-fold increase in the intensity signal, consistent
with increased nuclear translocation of p73. Therefore it seems possible that p73a
cooperates with p53 in primary wt colonocytes as suggested by Flores et al. (2002)
[Flores E.R. and Tsai K.Y. et al., 2002], Moreover, in the context of p53 deficiency,
p73a activation is highly suggestive of its involvement in the p53-independent
pathway of apoptosis manifested in these cells. Presumably p73 a is a weaker
effector of apoptosis in the absence of p53, or may require interaction with accessory
factors in order that the apoptotic machinery is engaged perhaps accounting for the
temporal delay compared to wt cells.
Nuclear accumulation of p73 is not sufficient to induce apoptosis and post-
translational modification such as acetylation has been shown to potentiate the ability
of p73 to selectively transactivate pro-apoptotic gene targets [Costanzo A. and Merlo
P. et al., 2002]. In the present system, further modulation of p73 at activity level,
through post-translational modifications and/or association with modulators of
function could not be excluded. Given the limited yields of colonocyte extract and
the low levels of endogenous p73, we were unable to pursue further analysis of
endogenous p73 by immunoblotting or immunoprecipitation. Others [Shimodaira H.
and Yoshioka-Yamashita A. et al., 2003] have also reported difficulties in detecting
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endogenous p73 in colorectal cell-lines. However, the power of the approach
described here is that it enables the study of a specific gene alteration and its effects
on the nature of the response elicited compared to normal cells. Several studies have
described the transfection of p73 expression plasmids into cancer cell lines for the
investigation of p73 modification and interaction with regulatory factors. However,
such studies are often confounded by the diversity among cell lines or because they
rely on high levels of exogenous protein whilst ignoring the endogenous. Thus,
whereas these approaches are undoubtedly fruitful and very likely to yield useful
information, we should be reminded of the power of deciphering function in a
physiological setting. In the case of p73 this is of particular importance given the
tissue specificity of the p73 variants, which have demonstrably different functional
consequences. Moreover, the balance of the endogenous full-length and AN forms
may yet determine physiological outcomes and responses in terms of apoptosis,
differentiation and homeostasis.
The emerging evidence of p73 interaction with components of the mismatch repair
signalling pathway [Catani M.V. and Costanzo A. et al., 2002], the high incidence of
mismatch repair deficiencies in colorectal cancer, the role of p73 as a corroborator of
p53 function and also as an independent apoptosis inducer points to a potentially
vital role for p73 in coupling damage repair and death in colonocytes.
In the present study it has been shown that the role of p53 in preventing entry into S-
phase following colonocyte DNA damage appears indispensable whereas its role in
apoptosis seems redundant. Although p53 is indispensable for colonocyte growth
arrest, the process itself is unessential. This does raise questions regarding the
relative importance of growth arrest as a damage response pathway in a tissue such
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as the colon where the ultimate fate of every cell is to die. This strongly suggests that
p53-mediated apoptosis and growth arrest are neither a major nor a unique protector
of colonic epithelial cells against mutation following DNA damage. Furthermore the
nuclear translocation of endogenous p73 a in response to DNA damage in primary
murine colonocytes was demonstrated. This is highly suggestive of a functional pro-
apoptotic role for p73a in these cells, within the framework of p53-independent
apoptosis
One of the major unanswered questions is what governs a cell's choice to undergo
growth arrest or apoptosis in response to p53 activation or indeed in the absence of
functional p53 [Pietenpol J.A. and Stewart Z.A., 2002] [Vousden K.H. and Lu X.,
2002], The results suggest that cisplatin-injured colonocytes enter p53-dependent
growth arrest and apoptosis. In the absence of p53, the failure to enter growth arrest
is probably without long-term consequences as alternative death pathways are
instigated to eliminate cells harbouring mutations.
132
CHAPTER 4
ALTERED EXPRESSION OF HEDGEHOG PATHWAY
GENES IN HUMAN COLONIC TUMOURS
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4.1. Background
The work in the previous chapter suggests that p53-mediated apoptosis and growth
arrest are neither a major nor a unique protector of colonic epithelial cells against
mutation following DNA damage. Moreover, mutations of p53 are common in
colorectal neoplasia but occur late in disease evolution, acting as a progression step.
Cancer represents a deregulation of normal growth in a tissue in which cancer cells
escape from the mechanisms that control normal patterning and growth. This is the
reason why in the last few years scientists have focused more on investigating a
possible role for developmental pathways in carcinogenesis. Hh signalling pathway
is such a pathway important in development which controls growth, cellular
proliferation during embryogenesis and patterning of various organs including brain,
spinal cord, craniofacial structures, lung, teeth, eye, hair and limbs [Wicking C. and
McGlinn E., 2001]. It is also plays a role in haematopoiesis [White E. and Prives C.,
1999] and members of the pathway have been recently linked to tumour formation
(i.e. Ptch and basal carcinoma) [Toftgard R., 2000].
Mutation of the Shh gene in humans has been confirmed as the cause of
holoprosencephaly (OMIM ref. 236100), while over-expression of Shh in transgenic
mouse or transgenic human skin develops BCCs-like tumours within the first few
days of skin development [Takada N. and Ozaki T. et al., 1999]. Genetic mutations
causing truncation or an unstable PTCH protein are associated with familial (Gorlin's
syndrome OMIM ref. 109400) or sporadic basal cell carcinoma [Johnson R.L. and
Rothman A.L. et al., 1996], Medulloblastoma, basal cell carcinoma and meningioma
are all tumours linked to Gorlin's syndrome. In addition, Smoh mutations have been
identified in BCCs and neuroectodermal tumours [Xie J. and Murone M. et al.,
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1998]. Greig syndrome (OMIM ref. 175700) and Pallister-Hall syndrome (OMIM
ref. 146510) result from mutations in GLI3.
Hh signalling proteins interact to maintain equilibrium in the pathway. Repression of
Smoh by Ptch in the absence of Hh culminates in cleavage ofGli to a transcriptional
suppressor. When Shh binds Ptch, Smoh suppression is relieved preventing cleavage
of Gli. This leads to Gli entering the nucleus and activating transcription of the Hh
target genes [Johnson R.L. and Scott M.P., 1998; Kalderon D., 2000; McMahon
A.P., 2000]. Ptch also limits the action of Shh. High levels of Ptch induced by Shh
serve to sequester any free Shh therefore limiting its further diffusion [Chen Y. and
Struhl G., 1996],
These findings suggest that mutations that activate the proto-oncogene Smoh or that
inactivate the tumour suppressor Ptch may lead to disrupted Hh-Ptch-Smoh balance,
the effect being excessive Hedgehog signalling activity that may be important in the
pathogenesis ofmalignant disease.
Shh is important during gastrointestinal tract development. Recent studies have
shown that Shh is important in gastric gland development and gastric epithelial
differentiation in the adult gastrointestinal tract [van den Brink G.R. and Hardwick
J.C. et al., 2002], Therefore, it is important to determine whether the Hh family
genes play a similar role in colonic epithelium.
As the Hh pathway is clearly essential for development of the gut, the aim was to
examine the expression of the Hh family members at the protein and mRNA levels in
normal human colon. Protein expression was also examined in a series of human
colonic lesions that included hyperplastic polyps, adenomas and adenocarcinomas.
Hyperplastic polyps are considered to be groups of elongated and/or thickened
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colonic crypts. Some researchers have regarded them as precursors of colorectal
carcinoma whereas others as non-neoplastic and unrelated to cancer [Achkar E. and
Winawer S.J., 1990]. Consequently, it was of interest to investigate the pattern of
expression of Hh genes in these lesions of the colon as well as in more advanced
neoplastic tumours such as adenomas and adenocarcinomas.
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4.2. Results
4.2.1. Shh Pathway Members Are Expressed in Normal Colon
Shh, Ptch and Smoh stained in the cytoplasm, while the proliferation marker Ki-67
stained the nuclei. The pattern of expression of the proteins was consistent within
each group of cases. No staining was observed when immunodetection was
performed in absence of the primary antibody (Figure 17).
Light positive staining for Shh protein was detected at the top of the normal colonic
crypts within the cytoplasm. Few of the epithelial cells (Figure 18) located at the
base of the crypts also stained positive for Shh. Ganglion cells of the myenteric
plexus found between the circular and longitudinal layers of the muscularis propria
expressed Shh, a pattern similar to that previously reported in the mouse [Ramalho-
Santos M. and Melton D.A. et al., 2000]. Neuroendocrine cells located basally in the
crypts strongly expressed Ptch, consistent with recently published data [Watkins
D.N. and Berman D.M. et al., 2003], whereas the rest of the epithelial cells were
unstained. Smoh expression was found only at the brush border of superficial colonic
epithelium. Ki-67 confirmed that proliferation in normal colon epithelium was
located in the basal compartment of the crypts. Cyclin B1 expression was strong and
present in the cytoplasm of the majority of the cells, throughout the crypts. Total
mRNA isolation, RT-PCR, and sequencing of PCR products from laser
microdissected crypts confirmed that mRNAs encoding Hh signalling pathway





Figure 17: Negative controlsforgoat anti-shh, anti-ptch and anti-smoh antibodies.
No signal was detected when immunodetection omitted theprimary antibody.
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Figure 18: Micrographs ofnormal colon stainedwith SHHPTCH, SMOH andKi-67.
A positive immunohistochemical reaction is indicated by diaminobenzidine
(brown staining) and haematoxylin was used a nuclear counterstain.
Shh stained slightly the superficial epithelial layer ofthe colon andfew cells
located basally, Ptch was detected in the neuroendocrine cells andSmoh




3, 4 - PTCH 144bp
5, 6 - SMO 140bp
7, 8 - p-microglobulin 120bp
Figure 19: Laser microdissected colonic crypts fromfrozen normal human colon.
A) colonic epithelium before laser microdissection; B) the same section
after laser capture microdissection; C) laser microdissected colonic crypts
used to generate mRNA. D) RT-PCR analysis for Shh, Ptch and Smoh
using mRNAfrom laser microdissectednormal crypts (lanes 1, 3, 5 and 7)
andH441 cells (lanes 2, 4, 6 and 8) used as positive control,
beta-microglobulin primers were used as an internal qualitative and
semi-quantitative control. Lanes 1 and 2: Shh-170bp;
Lanes 3 and 4: Ptch-144bp; Lanes 5 and 6: Smoh-140bp;
Lanes 7 and 8: f-microglobulin-!20bp.
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4.2.2. Shh, Ptch and Smoh Are Overexpressed in Hyperplastic Polyps
The pattern of Shh expression in hyperplastic polyps contrasts with that described in
normal colon epithelium. Strong Shh staining was found at the base of the crypts and
became lighter towards the top (Figure 20). Ptch staining was stronger and was
present in most of the cells within the crypt with cells located basally also displaying
intense staining.
Smoh largely maintained the same pattern of expression as found in normal colon,
staining the brush border of superficial epithelium but in addition to that stained the
epithelial cells in the crypts. Ki-67 stained a larger number of the nuclei compared to
normal. The staining was still located in the basal compartment of the crypts and
showed that hyperplastic polyps have a higher proliferation index compared to
normal colonic epithelium as expected.
Double fluorescent staining using Shh and Ki-67 also confirmed the pattern of
staining detected by immunohistochemistry, with cells located basally expressing
both Shh protein and Ki-67 (Figure 21).
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Figure 20: Micrographs ofa hyperplastic polyp stained with Shh, Ptch, Smoh and
Ki-67. A positive immunohistochemical reaction is indicated by
DAB (brown staining) and haematoxylin was used a nuclear counterstain.
The staining was strong with Shh detectedat the base ofthe crypts and





Figure 21: Confocal micrographs (63x) ofa hyperplastic polyps immunojluorescently
labelled with anti-Ki-67 IgG (Alexa-488 green) and anti-Shh IgG
(Alexa-568 red). The overlaid image shows cells located at the base of the
crypts displaying positive signals for both proteins.
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4.2.3. Hh Pathway Members Are Also Overexpressed in Adenoma and
Adenocarcinomas of the Colon
Shh, Ptch and Smoh all showed stronger staining than in normal colon in a large
number ofmalignant crypts. The crypts that stained stronger also displayed multiple
mitoses, showed a higher degree of dysplasia and had lost most of their normal
characteristics (Figure 22 and 23). The cells in the lamina propria, muscularis
mucosa and stroma of invasive carcinoma remained unstained indicating that the
expression of the proteins was genuine and specific. Ki-67 confirmed deregulated
cell proliferation in adenomatous and malignant crypts with a normal pattern of
proliferation within the adjacent, non-neoplastic mucosa. Cyclin B1 expression was
more intense where the glands showed a higher rate of mitosis and grade of
dysplasia. This pattern of staining appears to reflect that cyclin B1 represents a
marker for G2/M phase of the cell-cycle and that most cancer cells actively
proliferate.
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Figure 22: Micrographs ofcolonic adenoma stainedwith Shh, Ptch, Smoh andKi-67.
A positive immunohistochemical reaction is indicated by DAB (brown
staining) and haematoxylin was used a nuclear counterstain. Adenomatous
crypts stained strongfor all threeproteins: Shh, Ptch andSmoh. The
normal crypts found among the adenomatous ones do not stain suggesting
that the expression ofthe studiedproteins is upregulated in colonic adenoma.
SHH Ki-67
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Figure 23: Micrographs ofcolonic adenocarcinoma stained with Shh Ptch, Smoh and
Ki-67. A positive immunohistochemical reaction is indicated by DAB (brown
staining) and haematoxylin was used a nuclear counterstain. Strong staining




Shh, Ptch and Smoh are expressed in normal colon and in colorectal neoplasia.
Moreover, their protein expression is similar to the distribution of their transcripts in
normal human colon.
In the case of hyperplastic polyps, Shh expression was located at the base of the
crypts where proliferation was maximal. Similarly, the pattern of expression of Shh
correlated with increased expression of the proliferation marker Ki-67 in the
adenomatous and malignant crypts of the neoplastic lesions investigated. Ptch and
Smoh were also expressed at high levels in the malignant crypts but not all the
malignant crypts stained positive.
Shh is important in growth and proliferation in the embryo. Shh has also been shown
to promote proliferation when overexpressed in epithelial cells in vitro [Kameda T.
and Hatakeyama S. et al., 2001], Consequently, the hypothesis that Shh has a role in
epithelial proliferation and possibly in the epithelial colon tumour progression in vivo
was addressed. Shh was localised in areas of increased cellular proliferation in
human hyperplastic polyps and it is also increased in areas of worsening dysplasia in
colorectal adenomas as well as in adenocarcinomas.
Therefore, this pattern of expression was suggestive of a role for Shh in epithelial
proliferation and possibly progression of epithelial colon tumours in vivo.
Ptch and Smoh are central to Shh signal transduction and have both been implicated
in human tumourigenesis [Gailani M.R. and Stahle-Backdahl M. et al., 1996; Hahn
H. and Wicking C. et al., 1996; Johnson R.L. and Rothman A.L. et al., 1996; Xie J.
and Murone M. et al., 1998], Basal cell carcinoma, medulloblastoma and
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rhabdomyosarcoma are all associated with mutations that either activate the proto-
oncogene Smoh or inactivate the tumour-suppressor Ptch. In the cases examined,
Ptch and Smoh protein expression was stronger where the lesions displayed a higher
malignant grade. Compared with normal colonic tissue, where Ptch expression was
detected only in the neuroendocrine cells and Smoh at the brush border of the
epithelium, their expression was upregulated in adenoma and carcinoma of the colon.
These findings suggest spatially aberrant Hh signalling or epigenetic activation of the
genes.
A novel interaction between Ptch and Cyclin B1 has been described [Barnes E.A.
and Kong M. et al., ]. DNA damage prevents cyclin B1 from entering the nucleus
and causes cyclin B1 to shuttle rapidly from the nucleus to cytoplasm thereby
delaying mitosis until the damage can be repaired [Toyoshima F. and Moriguchi T.
et al., 1998]. Patched could interact with phosphorylated cyclin B1 derivatives and
thereby be able to alter their subcellular localisation. As Cyclin B1 is a regulatory
subunit of the M-phase proliferating factor (MPF) and Ptch is capable of
sequestering MPF to prevent mitotic progression, Ptch may therefore directly inhibit
cell proliferation. This inhibitory function supports the notion of Ptch as a tumour-
suppressor. Furthermore, overexpression of Shh in transfected cells inhibited the
interaction between Ptch and cyclin B1 [Barnes E.A. and Kong M. et al., ]
strengthening arguments that Shh could have a more direct effect on cell-cycle
progression and be involved in tumour growth. As a result, the distribution patterns
of Cyclin B1 and Ptch were compared by immunohistochemistry but no significant
correlation was found.
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A possible interaction between Ptch and p53 has been recently suggested. Ptch
mutant mice on a p53-null genetic background show a marked increase in the
incidence of medulloblastomas [Wetmore C. and Eberhart D.E. et al., 2001], As
many colorectal carcinomas have mutations or deletion of p53, an additional
mutation or inactivation of Ptch could cause survival and continuous proliferation of
cycling cells carrying damaged DNA. Such cells may give rise to tumours.
A possible explanation for the upregulated expression of the Shh proteins noticed in
this study would be that the increased expression of Shh is the result of gene
mutation or changes in methylation of the Shh promoter as opposed to cell-cycle
dependent alterations in gene transcription. A panel of human colorectal carcinomas
(microsatellite stable and unstable) by single-strand conformation polymorphism for
putative mutations in Shh and Smoh was screened. No mutations were found,
suggesting that mutations of these genes do not play a significant role in
tumourigenesis of the colon.
In summary, the Hh pathway is an important regulator of body plan patterning,
growth and cellular proliferation during embryogenesis, and the results of the present
study show that the pathway is expressed in adult colonic tissues. Altered patterns of
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During embryogenesis, the Hedgehog signalling pathway plays an essential role in
the formation of the gastrointestinal tract. Expression of Shh in the gastrointestinal
embryonic tract has been described in mouse [Bitgood M.J. and McMahon A.P.,
1995], frog [Ryan A.K. and Blumberg B. et al., 1998], chick [Roberts D.J. and Smith
D.M. et al., 1998] and human [Marigo V. and Roberts D.J. et al., 1995]. In the
murine embryonic gut, expression of Shh has been detected in the endoderm from as
early as day 11.5 post coitus, but it changes in the first 3 three postnatal weeks once
the crypts and the glandular structures are formed [Bitgood M.J. and McMahon A.P.,
1995], Shh signalling is important for both antero-posterior and radial patterning in
the developing murine gut [Ramalho-Santos M. and Melton D.A. et al., 2000]
[Sukegawa A. and Narita T. et al., 2000] [Litingtung Y. and Lei L. et al., 1998] but
little is known about its roles in the adult gastrointestinal tract. Recently, van den
Brink et al. [van den Brink G.R. and Hardwick J.C. et al., 2001] reported that Shh is
expressed abundantly in the fundic gastric glands of humans and mice at both protein
and mRNA level. The same group also revealed that mRNA for Shh was detected in
few cells at the base of the crypts in the small and large intestine [van den Brink G.R.
and Hardwick J.C. et al., 2002],
In complete concordance with the above research group, results from the previous
chapter confirmed that Shh is expressed at protein and mRNA levels in adult normal
human colonic epithelium. Moreover, overexpression of the Shh protein and its
receptors Ptch and Smoh was detected in colonic lesions including hyperplastic
polyps, adenoma and adenocarcinoma. The overexpression of the Shh protein
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correlated with increased signal for the proliferation marker Ki-67. Consequently, the
hypothesis that Shh plays a role in epithelial proliferation and possibly in epithelial
colon tumour progression in vivo was addressed. To determine whether Shh may
influence cell proliferation in the colon, we used primary murine colonocytes to
study the effect of exogenous Shh peptide (Shh-Np) and Shh neutralising antibody
(5E1) in vitro.
Several studies focused on a possible effect of Shh on cell growth and proliferation.
Human blood cells responded to exogenous Shh-N treatment by increased
proliferative capacity. Alternatively, cells treated with anti-Shh resulted in
maintenance of progenitors and stem cells in an undifferentiated state, reducing the
proliferative ability these cells [Bhardwaj G. and Murdoch B. et al., 2001],
In a similar experiment, activated CD4+ T lymphocytes responded with
increased/decreased proliferation to external treatment with Shh-N peptide or anti-
Shh blocking antibody [Lowrey J.A. and Stewart G.A. et al., 2002], reaffirming that
Shh sustains cell proliferation and controls growth.
It appears that the ability of Shh to promote growth is achieved by promoting
expression of the cell-cycle regulators Cyclin D and Cyclin E in Drosophila
[Duman-Scheel M. and Weng L. et al., 2002], Furthermore, upregulation ofmurine
cyclin Dl, D2 and E in response to Hh signalling has also been described in
mammalian neuronal precursors [Kenney A.M. and Rowitch D.H., 2000].
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5.2. Results
5.2.1. Hh pathway senes are expressed at mRNA levels in primary murine
colonocvtes
The expression of Hh pathway genes was assessed by RT-PCR analysis using RNA
isolated from primary murine colonocytes after 3 days in culture (Figure 24).
All members of the pathway: Shh, Ptch, Ptch2, Gli 1 and Ihh were expressed at
mRNA level in actively growing colonocytes.
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1 2 3 4 5 6 7
Figure 24: RT-PCR analysis showing expression ofmurine Shh, Plchl, Ptchl, Ihh and
GUI using RNA isolatedfromprimary colonocytes after 3 days in culture.
DNA ladder: 1Kb Plus (bands every 100 bp up to SOObp)
Lane I - negative control
Lane 2 - Shh: 333bp
Lane 3 - Ptchl: 452bp
Lane 4 - Ptch2: 207bp
Lane 5 - Ihh: 221bp
Lane 6 - Glil: 251bp
Lane 7 - GAPDH: 237hp
5.2.2. Exogenous Soluble Mouse Shh Peptide Has a Proliferative Effect on
PrimaryMurine Colonocytes
To investigate the possibility that Shh promotes cellular growth primary murine
colonocytes were exposed to recombinant 180 amino-acids N-terminus peptide.
Colonic crypts were isolated using the method described in Chapter 2, section 2.2.
After 3 days in culture, cells treated with 0.25/rg/ml, 0.5/xg/ml and 0.75/xg/ml of Shh
peptide for 72 hours were incubated with BrdU. The percentage of cells in S-phase
was quantified by counting the BrdU positive cells. The mouse Shh peptide was
reconstituted in 0.3% PBS-BSA, carrier for the soluble protein. Control cells were
treated with the same solution. Cells treated with 0.75/rg/ml Shh-Np show a
statistically significant increase in BrdU incorporation compared to control cells






Graph of the percentage cells in S-phase detected by BrdU incorporation in primary
murine colonocytes after exposure to exogenous mouse Shh-N recombinant peptide
(Shh-Np) for 72 hours in the presence of2.5% serum.
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Cells treated with 0.75 pg/ml Shh-Np in the absence of serum show a similar trend in
BrdU incorporation compared to control cells (3.4% vs. 1.6% respectively),
demonstrating that the proliferative effect of Shh-Np is not due to interaction with










Graph of the percentage cells in S-phase detected by BrdU incorporation in primary
murine colonocytes after exposure to exogenous mouse Shh-N recombinant peptide
(Shh-Np) for 72 hours in serum free medium.
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5.2.3. Blocking Endogenous Shh Protein with Mouse Neutralisms Anti-Shh
Antibody Decreases the Proportion ofCells in S-vhase
The mitogenic effect of exogenous Shh in primary colonocytes was similar to that of
the anti-Shh treated cells. Colonocytes were exposed to 20pg/ml or 50pg/ml of 5E1
neutralising antibody for 48 and 72 hours. Compared to untreated cells, the mean
percentage of BrdU staining cells was significantly reduced after 48 hours in the
presence of 20pg/ml (5.35% vs. 2.90% respectively, p=0.0398, Mann-Whitney U
test) and 50pg/ml (5.35% vs. 2.25%, p=0.0147, Mann-Whitney U test) of 5E1 (see
graph below). After 72 hours a statistically significant difference is seen between
untreated cells and cells cultured in the presence of 50pg/ml (3.90% vs. 1.8%,
p=0.0152, Mann-Whitney U test).
7
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Graph of the percentage cells in S-phase detected by BrdU incorporation in primary
murine colonocytes after exposure for 48 and 72 hours to exogenous anti-Shh
antibody (5E1)
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No inhibition of S-phase was observed in the presence of the isotype control
antibody at previously reported concentrations (see graph below).
Graph of the percentage cells in S-phase detected by BrdU incorporation in primary
murine colonocytes after exposure for 48 and 72 hours to the 5E1- isotype control
antibody (IgGj) for 48 and 72 hours.
159
5.3. Discussion
To investigate whether Shh influences cell proliferation in the colon, primary
colonocytes were exposed to the agonist Shh peptide (Shh-Np) and neutralising
antibody (5E1). The human colorectal cell-lines SW480 and Colo-320 showed no
response to either Shh-Np or 5E1, when analysed by flow cytometry (this experiment
was performed in collaboration with Dr. Roberta M. James) (data not shown) Since
these cell-lines are transformed to allow clonogenic survival, it is not surprising that
they are refractory to external stimuli. Furthermore, Watkins et al. [Watkins D.N.
and Berman D.M. et al., 2003] reported that a colorectal cell-line, HCT116, showed
no growth reduction in response to the drug cyclopamine, which inhibits Hh
signalling by binding to Smoh. This suggests that the pathway may not be active in
some colorectal cell-lines. Therefore, the use primary murine colonocytes derived
from normal adult murine colon was preferred. These cells offer the advantage of
being untransformed epithelial cells and more likely to reflect the in vivo situation.
Furthermore, both exogenous Shh-N peptide and 5E1 blocking antibody have been
reactive with human and mouse as reported by several groups [Bhardwaj G. and
Murdoch B. et al., 2001] [Lowrey J.A. and Stewart G.A. et al., 2002] [Watkins D.N.
and Berman D.M. et al., 2003],
In conclusion, the results in this chapter show that exogenous Shh has a mitogenic
effect on primary murine colonocytes. Moreover, uninterrupted blocking of
endogenous Shh inhibited proliferation in these cells, suggesting that Shh is required
for epithelial cell proliferation in vitro.
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Cell-cycle is dependent on key components of the cell-cycle including the cyclins
and cyclin-dependent kinases (cdk). Shh expression has been reported to associate
with increased activity of cdk2 and cdk4 in normal keratinocytes [Fan H. and
Khavari P.A., 1999], Both these kinases have important roles in the Gl-S transition
of the cell-cycle. Another study showed that Shh exerts his proliferative effects
through regulation of the G1 -phase cyclins like cyclins Dl, D2 and E [Altaba A. and
Stecca B. et al., 2004]. Moreover, Shh is capable to promote cell proliferation by
activating the M-phase promoting factor. Cyclin B1 is a regulatory subunit of the M-
phase proliferating factor as mentioned earlier and could interact with Ptch to prevent
cell-cycle progression. Maybe the exogenous Shh-N peptide could disrupt the
interaction between Ptch and Cyclin B1 facilitating cell-cycle progression.
Consequently, it would be of interest as a future line of research to investigate
possible mechanisms that could be responsible for the ability that Shh has to increase
proliferation in primary murine colonocytes.
Two years ago, it has been revealed that cyclopamine, a small steroidal alkaloid, has
the capacity to bind Smoothened, therefore inhibiting Hedgehog signalling [Chen
J.K. and Taipale J. et al., 2002], The same study revealed that cyclopamine could
reverse the retention of spatially missfolded Smoh in the endoplasmic reticulum,
mechanism responsible for the teratogenic and anti-tumour effects of this small
molecule.
Inhibition of Hh signalling by cyclopamine induced apoptosis and blocked
proliferation in a wide variety of cancer cell-lines in vitro (originating in the brain,
oesophagus, stomach, biliary tract, pancreas and lung) [Berman D.M. and Karhadkar
S.S. et al., 2003] [Thayer S.P. and Di Magliano M.P. et al., 2003] [Altaba A. and
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Stecca B. et al., 2004]. Subsequently, Berman et al. [Berman D.M. and Karhadkar
S.S. et al., 2003] showed that cyclopamine inhibits the growth of medulloblastoma
mouse allografts. These findings provide a sound basis for therapeutic approach and
open a new way ofviewing tumorigenesis.
These studies open the way for further investigations using the primary colonocytes





The investigations undertaken in this thesis focused on two areas:
1. the importance of p53 and related proteins in the regulation of growth and
responses to DNA damage caused by cisplatin.
2. the investigation of expression of developmental Hh signalling proteins in
normal colon and colonic neoplastic lesions including hyperplastic polyps,
adenomas and adenocarcinomas.
p53 mutations or deletions are common events in colorectal cancer. One might
anticipate that the loss of p53 would have an early role in tumourigenesis by
allowing mutation to occur through avoidance of normal DNA damage-induced cell
cycle arrest, DNA repair or induction of apoptosis mediated by p53. In fact, studies
of human disease indicated that p53 loss or mutation is a late stage phenomenon
associated with disease progression and a likelihood of invasion leading to
metastases. Furthermore, crossing p53 deficient mice with Min mice, which are
heterozygous for mutant APC, does not result in an increase in intestinal
tumourigenesis in either small or large intestine. Finally, in p53 deficient mice, as in
humans with Li Fraumeni syndrome, there is no increase in susceptibility to
colorectal cancer. If p53 is the only gene responsible for deletion of damaged cells
following damage by apoptosis, then clear differences in frequency of apoptosis after
ionizing radiation in p53 wild-type and null epithelium would be expected. In fact, in
colon there is little apoptosis in either genotypes and after 24 hours there is a second
wave of apoptosis in both genotypes. This strongly suggests that p53 mediated
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apoptosis is neither a unique nor a major protector of colonic epithelial cells against
mutations following DNA damage.
As much of the information in carcinogenesis in the intestine derives from studies in
the small intestine and the majority of the mutations leading to cancer occur in the
large intestine, the use of a large bowel model and in particular the primary murine
colonocytes system was considered to overcome some of these issues. Primary
murine colonocytes isolated from wt and p53 null mice were exposed to cisplatin to
better understand the importance of p53 and related proteins in the regulation of
growth and responses to DNA damage. The results of the first project in this thesis
showed that the role of p53 in preventing entry into S-phase following colonocytes
DNA damage appears crucial whereas its role in apoptosis seems redundant. This
strongly confirms that p53-mediated apoptosis and growth arrest are indeed neither a
major nor a unique protector of colonic epithelial cells against mutation following
DNA damage. The baseline expression p21, p53 and p73 could be attributed to the
stress of the in vitro conditions, as hypoxia is known to activate both p53 and p73
and this seems to be a limitation of this in vitro model.
Furthermore, the nuclear translocation of endogenous p73a in response to DNA
damage in primary colonocytes is highly suggestive of a functional pro-apoptotic
role for p73a in these cells, within the context of p53-independent apoptosis. It
seems that the effects of p53 are not solely determined by p53 itself but by
interaction with its family members, with p73 in particular. It also appears that
whereas loss of p53, as a late event in colorectal carcinogenesis, is important in
progression, p53 may still have a modulatory role in early tumourigenesis in
partnership or competition with variants of p73. As a future research direction, an
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investigation of a possible role played by p63, another p53 family member, following
treatment with cisplatin in primary murine colonocytes, would be interesting to see if
it shares the pro-apoptotic roles with the other members of the family.
The second part of this thesis investigated the roles of developmental Hh genes in
colonic tumourigenesis. The expression of Shh, Ptch and Smoh at protein and mRNA
levels was examined using immunohistochemistry and RT-PCR from laser captured
microdissected colonic crypts.
The novel findings of this study were to show:
1. expression of Sonic Hedgehog developmental genes in normal adult colonic
epithelium
2. over-expression of these genes in "pre" and "early" neoplasia as well as in
colonic adenocarcinoma.
Previously it was demonstrated that hedgehog genes are important in gut
development and function, but they were never shown to be present in adult normal
colonic epithelium. These findings suggest that Shh dysregulation may be important
in tumourigenesis or allowing early changes that facilitate tumourigenesis in colon
cancer.
To address whether the Hh signalling pathway is functional in the gut, the effect of
Shh on epithelial cells in vitro was explored by treating primary murine colonocytes
isolated from adult mouse colons, with either Shh peptide or neutralizing anti-Shh
antibody. Exogenous Shh promotes cell proliferation in colonocytes while anti-Shh
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inhibits proliferation, confirming that Shh is required during proliferation ofmurine
epithelial cells in vitro.
These findings indicate that Hh developmental genes play a role in the epithelial
proliferation of the colon and possibly in the colon tumour progression in vivo. These
genes were not found mutated in a set of primary human colorectal tumours but it is
possible that it is not mutation of these genes but other events such as methylation
and protein overexpression play a role in colon carcinogenesis.
Consequently, more experiments would be necessary to establish a possible role and
mechanism by which these genes, or their interconnection with other factors, alter




Achkar E. and Winawer S. J. (1990). Controversies, dilemmas, and dialogues. A
hyperplastic polyp is discovered on flexible sigmoidoscopy. Is a full
colonoscopy indicated? AmJ.Gastroenterol. 85: 367-370.
Al-Nafussi A.; Klys H.S.; Rebello G.; Kelly C.; Kerr G. and Cowie V. (1993).
The assessment ofproliferating cell nuclear antigen (PCNA)
immunostaining in the uterine cervix and cervix squamous neoplasia.
Int. J. Gynecol. Cancer 3: 154-158.
Aloni-Grinstein R.; Schwartz D. and Rotter V. (1995). Accumulation ofwild-type
p53 protein upon gamma-irradiation induces a G2 arrest-dependent
immunoglobulin kappa light chain gene expression. EMBO J. 14:
1392-1401.
Altaba A. (1999). Gli proteins and Hedgehog signaling: development and cancer.
Trends Genet. 15: 418-425.
Altaba A.; Stecca B. and Sanchez P. (2004). Hedgehog—Gli signaling in brain
tumors: stem cells and paradevelopmental programs in cancer. Cancer
Lett. 20;204: 145-157.
An W. G.; Kanekal M.; Simon M. C.; Maltepe E.; Blagosklonny M. V. and
Neckers L. M. (1998). Stabilization ofwild-type p53 by hypoxia-
inducible factor-1 alpha. Nature 392: 405-408.
ASTLER V. B. and COLLER F. A. (1954). The prognostic significance of direct
extension of carcinoma of the colon and rectum. Ann.Surg. 139: 846-
852.
Aszterbaum M.; Rothman A.; Johnson R. L.; Fisher M.; Xie J.; Bonifas J. M.;
Zhang X.; Scott M. P. and Epstein E. H., Jr. (1998). Identification
169
ofmutations in the human PATCHED gene in sporadic basal cell
carcinomas and in patients with the basal cell nevus syndrome. J
Invest Dermatol. 110: 885-888.
Atadja P.; Wong H.; Garkavtsev I.; Veillette C. and Riabowol K. (1995).
Increased activity of p53 in senescing fibroblasts.
Proc.Natl.Acad.Sci.U.S.A 92: 8348-8352.
Bader S.; Walker M.; McQueen H. A.; Sellar R.; Oei E.; Wopereis S.; Zhu Y.;
Peter A.; Bird A. P. and Harrison D. J. (2003). MBD1, MBD2 and
CGBP genes at chromosome 18q21 are infrequently mutated in
human colon and lung cancers. Oncogene 22: 3506-3510.
Baker S. J.; Fearon E. R.; Nigro J. M.; Hamilton S. R.; Preisinger A. C.; Jessup
J. M.; vanTuinen P.; Ledbetter D. H.; Barker D. F.; Nakamura Y.
(1989). Chromosome 17 deletions and p53 gene mutations in
colorectal carcinomas. Science 244: 217-221.
Baker S. J.; Markowitz S.; Fearon E. R.; Willson J. K. and Vogelstein B. (1990).
Suppression of human colorectal carcinoma cell growth by wild-type
p53. Science 249: 912-915.
Barlow C.; Brown K. D.; Deng C. X.; Tagle D. A. and Wynshaw-Boris A.
(1997). Atm selectively regulates distinct p53-dependent cell-cycle
checkpoint and apoptotic pathways. Nat.Genet. 17: 453-456.
Barnes E. A.; Kong M.; Ollendorff V. and Donoghue D. J. (2001) Patchedl
interacts with cyclin B1 to regulate cell cycle progression. EMBO J.
20: 2214-23.
170
Beahrs O. H. (1984). The American Joint Committee on Cancer. Bull.Am
Coll.Surg. 69: 16-17.
Bellamy C. O.; Clarke A. R.; Wyllie A. H. and Harrison D. J. (1997). p53
Deficiency in liver reduces local control of survival and proliferation,
but does not affect apoptosis after DNA damage. FASEB J. 11: 591 -
599.
Belloni E.; Muenke M.; Roessler E.; Traverso G.; Siegel-Bartelt J.; Frumkin A.;
Mitchell H. F.; Donis-Keller H.; Helms C.; Hing A. V.; Heng H.
H.; Koop B.; Martindale D.; Rommens J. M.; Tsui L. C. and
Scherer S. W. (1996). Identification of Sonic hedgehog as a
candidate gene responsible for holoprosencephaly. Nat.Genet. 14:
353-356.
Benard J.; Douc-Rasy S. and Ahomadegbe J. C. (2003). TP53 family members
and human cancers. Hum.Mutat. 21: 182-191.
Berman D. M.; Karhadkar S. S.; Maitra A.; Montes De O.; Gerstenblith M. R.;
Briggs K.; Parker A. R.; Shimada Y.; Eshleman J. R.; Watkins D,
N. and Beachy P. A. (2003). Widespread requirement for Hedgehog
ligand stimulation in growth of digestive tract tumours. Nature 425:
846-851.
Bhardwaj G.; Murdoch B.; Wu D.; Baker D. P.; Williams K. P.; Chadwick K.;
Ling L. E.; Karanu F. N. and Bhatia M. (2001). Sonic hedgehog
induces the proliferation ofprimitive human hematopoietic cells via
BMP regulation. Nat.Immunol. 2: 172-180.
171
Bitgood M. J. and McMahon A. P. (1995). Hedgehog and Bmp genes are
coexpressed at many diverse sites of cell-cell interaction in the mouse
embryo. Dev.Biol. 172: 126-138.
Blint E.; Phillips A. C.; Kozlov S.; Stewart C. L. and Vousden K. H. (2002).
Induction ofp57(KIP2) expression by p73beta.
Proc.Natl.Acad.Sci.U.S.A 19; 99: 3529-3534.
Booth C.; O'Shea J. A. and Potten C. S. (1999). Maintenance of functional stem
cells in isolated and cultured adult intestinal epithelium. Exp.Cell Res.
249: 359-366.
Booth C.; Patel S.; Bennion G. R. and Potten C. S. (1995). The isolation and
culture of adult mouse colonic epithelium. Epithelial Cell Biol. 4: 76-
86.
Booth C. and Potten C. S. (2000). Gut instincts: thoughts on intestinal epithelial
stem cells. J.Clin.Invest 105: 1493-1499.
Brugarolas J.; Chandrasekaran C.; Gordon J. I.; Beach D.; Jacks T. and
Hannon G. J. (1995). Radiation induced cell cycle arrest
compromised by p21 deficiency. Nature 377: 552-557.
Bunz F.; Dutriaux A.; Lengauer C.; waldman t.; Zhou S.; Brown J. P.; Sedivy J.
M.; Kinzler K. W. and Vogelstein B. (1998). Requirement for p53
and p21 to sustain G2 arrest after DNA damage. Science 20;282:
1497-1501.
Cannon-Albright L. A.; Skolnick M. H.; Bishop D. T.; Lee R. G. and Burt R. W.
(1988). Common inheritance of susceptibility to colonic adenomatous
172
polyps and associated colorectal cancers. N.Engl.J Med. 319: 533-
537.
Carder P. J.; Cripps K. J.; Morris R.; Collins S.; White S.; Bird C. C. and
Wyllie A. H. (1995). Mutation of the p53 gene precedes aneuploid
clonal divergence in colorectal carcinoma. Br.J.Cancer 71: 215-218.
Casciano 1.; Mazzocco K.; Boni L.; Pagnan G.; Banelli B.; Allemanni G.;
Ponzoni M.; Tonini G. P. and Romani M. (2002). Expression of
DeltaNp73 is a molecular marker for adverse outcome in
neuroblastoma patients. Cell Death.Differ. 9: 246-251.
Catani M. V.; Costanzo A.; Savini I.; Levrero M.; De Laurenzi, V; Wang J. Y.;
Melino G. and Avigliano L. (2002). Ascorbate up-regulates MLH1
(Mut L homologue-1) and p73: implications for the cellular response
to DNA damage. Biochem.J. 364: 441-447.
Chen J. K.; Taipale J.; Cooper M. K. and Beachy P. A. (2002). Inhibition of
Hedgehog signaling by direct binding of cyclopamine to Smoothened.
Genes Dev. 16: 2743-2748.
Chen X. (1999). The p53 family: same response, different signals? Mol.Med.Today
5: 387-392.
Chen X.; Zheng Y.; Zhu J.; Jiang J. and Wang J. (2001). p73 is transcriptionally
regulated by DNA damage, p53, and p73. Oncogene 20: 769-774.
Chen Y. and Struhl G. (1996). Dual roles for patched in sequestering and
transducing Hedgehog. Cell 87: 553-563.
173
Chiang C.; Litingtung Y.; Lee E.; Young K. E.; Corden J. L.; Westphal H. and
Beachy P. A. (1996). Cyclopia and defective axial patterning in mice
lacking Sonic hedgehog gene function. Nature 383: 407-413.
Cho Y.; Gorina S.; Jeffrey P. D. and Pavletich N. P. (1994). Crystal structure of a
p53 tumor suppressor-DNA complex: understanding tumorigenic
mutations. Science 265: 346-355.
Chung D. C. and Rustgi A. K. (2003). The hereditary nonpolyposis colorectal
cancer syndrome: genetics and clinical implications. Ann.Intern.Med.
138: 560-570.
Clarke A. R.; Howard L. A.; Harrison D. J. and Winton D. J. (1997). p53,
mutation frequency and apoptosis in the murine small intestine.
Oncogene 14: 2015-2018.
Clarke A. R.; Purdie C. A.; Harrison D. J.; Morris R. G.; Bird C. C.; Hooper
M. L. and Wyllie A. H. (1993). Thymocyte apoptosis induced by
p53-dependent and independent pathways. Nature 362: 849-852.
Cohen M. M., Jr. (1989). Perspectives on holoprosencephaly: Part I. Epidemiology,
genetics, and syndromology. Teratology 40: 211-235.
Costanzo A.; Merlo P.; Pediconi N.; Fulco M.; Sartorelli V.; Cole P. A.;
Fontemaggi G.; Fanciulli M.; Schiltz L.; Blandino G.; Balsano C.
and Levrero M. (2002). DNA damage-dependent acetylation ofp73
dictates the selective activation of apoptotic target genes. Mol.Cell 9:
175-186.
Coulier F.; Imbert J.; Albert J.; Jeunet E.; Lawrence J. J.; Crawford L. and
Birg F. (1985). Permanent expression of p53 in FR 3T3 rat cells but
174
cell cycle-dependent association with large-T antigen in simian virus
40 transformants. EMBO J 4: 3413-3418.
Cunningham J.; Lust J. A.; Schaid D. J.; Bren G. D.; Carpenter H. A.; Rizza E.;
Kovach J. S. and Thibodeau S. N. (1992). Expression ofp53 and
17p allelic loss in colorectal carcinoma. Cancer Res. 52: 1974-1980.
Dameron K. M.; Volpert O. V.; Tainsky M. A. and Bouck N. (1994). Control of
angiogenesis in fibroblasts by p53 regulation of thrombospondin-1.
Science 265: 1582-1584.
De Laurenzi V. D.; Catani M. V.; Terrinoni A.; Corazzari M.; Melino G.;
Costanzo A.; Levrero M. and Knight R. A. (1999). Additional
complexity in p73: induction by mitogens in lymphoid cells and
identification of two new splicing variants epsilon and zeta. Cell
Death.Differ. 6: 389-390.
De Laurenzi, V; Raschella G.; Barcaroli D.; Annicchiarico-Petruzzelli M.;
Ranalli M.; Catani M. V.; Tanno B.; Costanzo A.; Levrero M.
and Melino G. (2000). Induction of neuronal differentiation by p73 in
a neuroblastoma cell line. J Biol.Chem. 19; 275: 15226-15231.
Deans G. T.; Heatley M.; Anderson N.; Patterson C. C.; Rowlands B. J.; Parks
T. G. and Spence R. A. (1994). Jass' classification revisited. J Am
Coll.Surg. 179: 11-17.
Deng C; Zhang P.; Harper J. W.; Elledge S. J. and Leder P. (1995). Mice lacking
p21CIPl/WAFl undergo normal develoment, but are defective in G1
checkpoint control. Cell 82: 675-684.
175
Denoix P. F. (1954). Importance of a classification common to the various forms of
cancer. Acta Radiol. 116:122-9: 122-129.
Di Leonardo A.; Linke S. P.; Clarkin K. and Wahl G. M. (1994). DNA damage
triggers a prolonged p53-dependent G1 arrest and long-term induction
ofCipl in normal human fibroblasts. Genes Dev. 8: 2540-2551.
Donehower L. A.; Harvey M.; Slagle B. L.; McArthur M. J.; Montgomery C. A.,
Jr.; Butel J. S. and Bradley A. (1992). Mice deficient for p53 are
developmentally normal but susceptible to spontaneous tumours.
Nature 19;356: 215-221.
Dotto G. P. (2000). p21(WAFl/Cipl): more than a break to the cell cycle?
Biochim.Biophys.Acta 1471: M43-M56.
Dufort D.; Schwartz L.; Harpal K. and Rossant J. (1998). The transcription factor
HNF3beta is required in visceral endoderm for normal primitive
streak morphogenesis. Development 125: 3015-3025.
Dukes C. E. (1932). The clasification of cancer of the rectum. Journal ofPathology
and Bacteriology 616: 323-332.
Duman-Scheel M.; Weng L.; Xin S. and Du W. (2002). Hedgehog regulates cell
growth and proliferation by inducing Cyclin D and Cyclin E. Nature
417: 299-304.
Dyer M. A.; Farrington S. M.; Mohn D.; Munday J. R. and Baron M. H. (2001).
Indian hedgehog activates hematopoiesis and vasculogenesis and can
respecify prospective neurectodermal cell fate in the mouse embryo.
Development 128: 1717-1730.
176
Eastwood G. L. (1977). Gastrointestinal epithelial renewal. Gastroenterology 72:
962-975.
Echelard Y.; Epstein D. J.; St Jacques B.; Shen L.; Mohler J.; McMahon J. A.
and McMahon A. P. (1993). Sonic hedgehog, a member of a family
of putative signaling molecules, is implicated in the regulation of CNS
polarity. Cell 75: 1417-1430.
Eizenberg O.; Faber-Elman A.; Gottlieb E.; Oren M.; Rotter V. and Schwartz
M. (1996). p53 plays a regulatory role in differentiation and apoptosis
of central nervous system-associated cells. Mol.Cell Biol. 16: 5178-
5185.
El Deiry W. S.; Tokino T.; Velculescu V. E.; Levy D. B.; Parsons R.; Trent J.
M.; Lin D.; Mercer W. E.; Kinzler K. W. and Vogelstein B.
(1993). WAF1, a potential mediator ofp53 tumor suppression, cell
75: 817-825.
Eliyahu D.; Michalovitz D. and Oren M. (1985). Overproduction ofp53 antigen
makes established cells highly tumorigenic. Nature 316: 158-160.
Fagin J. A.; Tang S. H.; Zeki K.; Di Lauro R.; Fusco A. and Gonsky R. (1996).
Reexpression of thyroid peroxidase in a derivative of an
undifferentiated thyroid carcinoma cell line by introduction ofwild-
type p53. Cancer Res. 56: 765-771.
Fan H. and Khavari P. A. (1999). Sonic hedgehog opposes epithelial cell cycle
arrest. J Cell Biol. 147: 71-76.
Fang L.; Lee S. W. and Aaronson S. A (1999).Comparative analysis ofp73 and
p53 regulation and effector functions. J Cell Biol. 15; 147: 823-830.
177
Faridoni-Laurens L.; Bosq J.; Janot F.; Vayssade M.; Le Bihan M. L.; Kaghad
M.; Caput D.; Benard J. and Ahomadegbe J. C. (2001). P73
expression in basal layers of head and neck squamous epithelium: a
role in differentiation and carcinogenesis in concert with p53 and
p63? Oncogene 20: 5302-5312.
Farrington S. M.; Belaoussoff M. and Baron M. H. (1997). Winged-helix,
Hedgehog and Bmp genes are differentially expressed in distinct cell
layers of the murine yolk sac. Mech.Dev. 62: 197-211.
Fearon E. R.; Hamilton S. R. and Vogelstein B. (1987). Clonal analysis of human
colorectal tumors. Science 238: 193-197.
Flood Andrew; Velie Ellen M.; Chaterjee Nilanjan; Subar Amy F.; Thompson
Frances E.; Lacey James V., Jr.; Schairer Catherine; Troisi
Rebecca and Schatzkin Arthur (2002). Fruit and vegetable intakes
and the risk of colorectal cancer in the Breast Cancer Detection
Demonstration Project follow-up cohort. American Journal ofClinical
Nutrition 75: 936-943.
Flores-Rozas H.; Kelman Z.; Dean F. B.; Pan Z. Q.; Harper J. W.; Elledge S. J.;
O'Donnell M. and Hurwitz J. (1994). Cdk-interacting protein 1
directly binds with proliferating cell nuclear antigen and inhibits DNA
replication catalyzed by the DNA polymerase delta holoenzyme.
Proc.Natl.Acad.Sci.U.S.A 91: 8655-8659.
Flores E. R.; Tsai K. Y.; Crowley D.; Sengupta S.; Yang A.; McKeon F. and
Jacks T. (2002). p63 and p73 are required for p53-dependent
apoptosis in response to DNA damage. Nature 416: 560-564.
178
Fodde R.; Edelmann W.; Yang K.; van Leeuwen C.; Carlson C.; Renault B.;
Breukel C.; Alt E.; Lipkin M.; Khan P. M. and . (1994). A targeted
chain-termination mutation in the mouse Ape gene results in multiple
intestinal tumors. Proc.Natl.Acad.Sci.U.S.A 91: 8969-8973.
Gailani M. R.; Stahle-Backdahl M.; Leffell D. J.; Glynn M.; Zaphiropoulos P.
G.; Pressman C.; Unden A. B.; Dean M.; Brash D. E.; Bale A. E.
and Toftgard R. (1996). The role of the human homologue of
Drosophila patched in sporadic basal cell carcinomas. Nat.Genet. 14:
78-81.
Giaccia A. J. and Kastan M. B. (1998). The complexity ofp53 modulation:
emerging patterns from divergent signals. Genes Dev. 12: 2973-2983.
Giovannucci E.; Rimm E. B.; Stampfer M. J.; Colditz G. A.; Ascherio A. and
WillettW. C. (1994). Intake of fat, meat, and fiber in relation to risk
of colon cancer in men. Cancer Res. 54: 2390-2397.
Gong J. G.; Costanzo A.; Yang H. Q.; Melino G.; Kaelin W. G., Jr.; Levrero M.
andWang J. Y. (1999). The tyrosine kinase c-Abl regulates p73 in
apoptotic response to cisplatin-induced DNA damage. Nature 399:
806-809.
Gottlieb E.; Haffner R.; King A.; Asher G.; Gruss P.; Lonai P. and Oren M.
(1997). Transgenic mouse model for studying the transcriptional
activity of the p53 protein: age- and tissue-dependent changes in
radiation-induced activation during embryogenesis. EMBO J 16:
1381-1390.
Gottlieb T. M. and Oren M. (1998). p53 and apoptosis. Semin.Cancer Biol. 8: 359-
368.
179
Hahn H.; Wicking C.; Zaphiropoulous P. G.; Gailani M. R.; Shanley S.;
Chidambaram A.; Vorechovsky I.; Holmberg E.; Unden A. B.;
Gillies S.; Negus K.; Smyth I.; Pressman C.; Leffell D. J.; Gerrard
B.; Goldstein A. M.; Dean M.; Toftgard R.; Chenevix-Trench G.;
Wainwright B. and Bale A. E. (1996). Mutations of the human
homolog ofDrosophila patched in the nevoid basal cell carcinoma
syndrome. Cell 85: 841-851.
Hahn H.; Wojnowski L.; Zimmer A. M.; Hall J.; Miller G. and Zimmer A.
(1998). Rhabdomyosarcomas and radiation hypersensitivity in a
mouse model of Gorlin syndrome. Nat.Med. 4: 619-622.
Harvey M.; McArthur M. J.; Montgomery C. A., Jr.; Butel J. S.; Bradley A.
and Donehower L. A. (1993). Spontaneous and carcinogen-induced
tumorigenesis in p53-deficient mice. Nat.Genet. 5: 225-229.
Hedrick L.; Cho K. R.; Fearon E. R.; Wu T. C.; Kinzler K. W. and Vogelstein
B. (1994). The DCC gene product in cellular differentiation and
colorectal tumorigenesis. Genes Dev. 8: 1174-1183.
Herman J. G.; Merlo A.; Mao L.; Lapidus R. G.; Issa J. P.; Davidson N. E.;
Sidransky D. and Baylin S. B. (1995). Inactivation of the
CDKN2/pl6/MTSl gene is frequently associated with aberrant DNA
methylation in all common human cancers. Cancer Res. 55: 4525-
4530.
Hollstein M.; Sidransky D.; Vogelstein B. and Harris C. C. (1991). p53 mutations
in human cancers. Science 253: 49-53.
Houlston R. S.; Collins A.; Slack J. and Morton N. E. (1992). Dominant genes for
colorectal cancer are not rare. Ann.Hum.Genet. 56: 99-103.
180
Iacopetta B. (2003). TP53 mutation in colorectal cancer. Hum.Mutat. 21: 271-276.
Ichimiya S.; Nimura Y.; Kageyama H.; Takada N.; Sunahara M.; Shishikura
T.; Nakamura Y.; Sakiyama S.; Seki N.; Ohira M.; Kaneko Y.;
McKeon F.; Caput D. and Nakagawara A. (2001). Genetic analysis
ofp73 localized at chromosome lp36.3 in primary neuroblastomas.
Med.Pediatr.Oncol. 36: 42-44.
Irwin M.; Marin M. C.; Phillips A. C.; Seelan R. S.; Smith D. I.; Liu W.; Flores
E. R.; Tsai K. Y.; Jacks T.; Vousden K. H. and Kaelin W. G., Jr.
(2000). Role for the p53 homologue p73 in E2F-1-induced apoptosis.
Nature 407: 645-648.
Irwin M. S. and Kaelin W. G., Jr. (2001). Role of the newer p53 family proteins in
malignancy. Apoptosis. 6: 17-29.
Ishimoto O.; Kawahara C.; Enjo K.; Obinata M.; Nukiwa T. and Ikawa S.
(2002). Possible oncogenic potential ofDeltaNp73: a newly identified
isoform of human p73. Cancer Res. 62: 636-641.
Issa J. P. (1999). Aging, DNA methylation and cancer. Crit Rev.Oncol.Hematol. 32:
31-43.
Issa J. P. (2000). The epigenetics of colorectal cancer. Ann.N.Y.Acad.Sci. 910: MO¬
SS.
Jacks T.; Remington L.; Williams B. O.; Schmitt E. M.; Halachmi S.; Bronson
R. T. and Weinberg R. A. (1994). Tumor spectrum analysis in p53-
mutantmice. Curr.Biol. 4: 1-7.
181
Johnson R. L.; Laufer E.; Riddle R. D. and Tabin C. (1994). Ectopic expression
of Sonic hedgehog alters dorsal-ventral patterning of somites. Cell 79:
1165-1173.
Johnson R. L.; Rothman A. L.; Xie J.; Goodrich L. V.; Bare J. W.; Bonifas J.
M.; Quinn A. G.; Myers R. M.; Cox D. R.; Epstein E. H., Jr. and
Scott M. P. (1996). Human homolog of patched, a candidate gene for
the basal cell nevus syndrome. Science 272: 1668-1671.
Johnson R. L. and Scott M. P. (1998). New players and puzzles in the Hedgehog
signaling pathway. Curr.Opin.Genet.Dev. 8: 450-456.
Jordan P. and Carmo-Fonseca M. (2000). Molecular mechanisms involved in
cisplatin cytotoxicity. Cell Mol.Life Sci. 57: 1229-1235.
Jost C. A.; Marin M. C. and Kaelin W. G., Jr. (1997). p73 is a simian p53-related
protein that can induce apoptosis. Nature 389: 191-194.
Kaghad M.; Bonnet H.; Yang A.; Creancier L.; Biscan J. C.; Valent A.; Minty
A.; Chalon P.; Leiias J. M.; Dumont X.; Ferrara P.; McKeon F.
and Caput D. (1997). Monoallelically expressed gene related to p53
at lp36, a region frequently deleted in neuroblastoma and other
human cancers. Cell 90: 809-819.
Kaida A.; Ariumi Y.; Ueda Y.; Lin J. Y.; Hijikata M.; Ikawa S. and Shimotohno
K. (2000). Functional impairment of p73 and p51, the p53-related
proteins, by the human T-cell leukemia virus type 1 Tax oncoprotein.
Oncogene 19: 827-830.
Kalderon D. (2000). Transducing the hedgehog signal, cell 103: 371-374.
182
Kameda T.; Hatakeyama S.; Terada K. and Sugiyama T. (2001). Acceleration of
the formation of cultured epithelium using the sonic hedgehog
expressing feeder cells. Tissue Eng 7: 545-555.
Kastan M. B.; Zhan Q.; El-Deiry W. S.; Carrier F.; Jacks T.; Walsh w. V.;
Plunkett B. S.; Vogelstein B. and Fornace A. jr. (1992). A
mammalian cell cycle checkpoint pathway utilizing p53 and GADD45
is defective in ataxia-telangiectasia. Cell 71: 587-597.
Kato M.; Seki N.; Sugano S.; Hashimoto K.; Masuho Y.; Muramatsu M.;
Kaibuchi K. and Nakafuku M. (2001). Identification of sonic
hedgehog-responsive genes using cDNA microarray.
Biochem.Biophys.Res Commun. 289: 472-478.
Kaye G. I.; Fenoglio C. M.; Pascal R. R. and Lane N. (1973). Comparative
electron microscopic features of normal, hyperplastic, and
adenomatous human colonic epithelium. Variations in cellular
structure relative to the process of epithelial differentiation.
Gastroenterology 64: 926-945.
Kenney A. M. and Rowitch D. H. (2000). Sonic hedgehog promotes G(l) cyclin
expression and sustained cell cycle progression in mammalian
neuronal precursors. Mol.Cell Biol. 20: 9055-9067.
Knudson C. M.; Tung K. S.; Tourtellotte W. G.; Brown G. A. and Korsmeyer S.
J. (1995). Bax-deficient mice with lymphoid hyperplasia and male
germ cell death. Science 270: 96-99.
Lam C. W.; Xie J.; To K. F.; Ng H. K.; Lee K. C.; Yuen N. W.; Lim P. L.; Chan
L. Y.; Tong S. F. and McCormick F. (1999). A frequent activated
183
smoothened mutation in sporadic basal cell carcinomas. Oncogene 18:
833-836.
Lane D. P. (1992). Cancer. p53, guardian of the genome. Nature 358: 15-16.
Le Marchand L.; Wilkens L. R.; Kolonel L. N.; Hankin J. H. and Lyu L. C.
(1997). Associations of sedentary lifestyle, obesity, smoking, alcohol
use, and diabetes with the risk of colorectal cancer. Cancer Res. 57:
4787.4794.
Lee C. W. and La Thangue N. B. (1999). Promoter specificity and stability control
ofthe p53-related protein p73. Oncogene 18: 4171-4181.
Lee J. M.; Abrahamson J. L.; Kandel R.; Donehower L. A. and Bernstein A.
(1994). Susceptibility to radiation-carcinogenesis and accumulation of
chromosomal breakage in p53 deficient mice. Oncogene 9: 3731-
3736.
Levy D. B.; Smith K. J.; Beazer-Barclay Y.; Hamilton S. R.; Vogelstein B. and
Kinzler K. W. (1994). Inactivation ofboth APC alleles in human and
mouse tumors. Cancer Res. 54: 5953-5958.
Li, F. P. and Fraumeni, J. F (1969). Rhabdomyosarcoma in children: an
epidemiologic study and identification of a familial cancer syndrome.
J. Nat. Cancer Inst. 43: 1364-1373.
Lissy N. A.; Davis P. K.; Irwin M.; Kaelin W. G. and Dowdy S. F. (2000). A
common E2F-1 and p73 pathway mediates cell death induced by TCR
activation. Nature 407: 642-645.
184
Litingtung Y.; Lei L.; Westphal H. and Chiang C. (1998). Sonic hedgehog is
essential to foregut development. Nat.Genet. 20: 58-61.
Lothe R. A.; Fossli T.; Danielsen H. E.; Stenwig A. E.; Nesland J. M.; Gallie B.
and Borresen A. L. (1992). Molecular genetic studies of tumor
suppressor gene regions on chromosomes 13 and 17 in colorectal
tumors. JNCI Cancer Spectrum 84: 1100-1108.
Lowe S. W.; Schmitt E. M.; Smith S. W.; Osborne B. A. and Jacks T. (1993).
p53 is required for radiation-induced apoptosis in mouse thymocytes.
Nature 362: 847-849.
Lowrey J. A.; Stewart G. A.; Lindey S.; Hoyne G. F.; Dallman M. J.; Howie
S.Ee. and Lamb J. R. (2002). Sonic hedgehog promotes cell cycle
progression in activated peripheral CD4(+) T lymphocytes.
J.Immunol. 169: 1869-1875.
Lu H.; Taya Y.; Ikeda M. and Levine A. J. (1998). Ultraviolet radiation, but not
gamma radiation or etoposide-induced DNA damage, results in the
phosphorylation of the murine p53 protein at serine-389. Proc.Natl
Acad.Sci.U.S.A 95: 6399-6402.
Lutzker S. G. and Levine A. J. (1996). A functionally inactive p53 protein in
teratocarcinoma cells is activated by either DNA damage or cellular
differentiation. Nat.Med. 2: 804-810.
Maesawa C.; Tamura G.; Iwaya T.; Ogasawara S.; Ishida K.; Sato N.;
Nishizuka S.; Suzuki Y.; Ikeda K.; Aoki K.; Saito K. and Satodate
R. (1998). Mutations in the human homologue of the Drosophila
patched gene in esophageal squamous cell carcinoma. Genes
Chromosomes.Cancer 21: 276-279.
185
Mahyar-Roemer M. and Roemer K. (2001). p21 Wafl/Cipl can protect human
colon carcinoma cells against p53- dependent and p53-independent
apoptosis induced by natural chemopreventive and therapeutic agents.
Oncogene 20: 3387-3398.
Mai M.; Yakomizo A.; Qian C. P.; Yang P.; Tindall D. J.; Smith D. I. and Liu
W. (1998). Activation ofp73 silent allele in lung cancer. Cancer Res.
2347-2349.
Marigo V.; Roberts D. J.; Lee S. M.; Tsukurov O.; Levi T.; Gastier J. M.;
Epstein D. J.; Gilbert D. J.; Copeland N. G.; Seidman C. E. and .
(1995). Cloning, expression, and chromosomal location of SHH and
EHH: two human homologues of the Drosophila segment polarity gene
hedgehog. Genomics 28: 44-51.
Marin M. C.; Jost C. A.; Irwin M. S.; DeCaprio J. A.; Caput D. and Kaelin W.
G., Jr. (1998). Viral oncoproteins discriminate between p53 and the
p53 homologp73. Mol.Cell Biol. 18: 6316-6324.
Marin M. C. and Kaelin W. G., Jr. (2000). p63 and p73: old members of a new
family. Biochim.Biophys.Acta 1470: M93-M100.
Marti E.; Bumcrot D. A.; Takada R. and McMahon A. P. (1995). Requirement of
19K form of Sonic hedgehog for induction of distinct ventral cell
types in CNS explants. Nature 375: 322-325.
Matlashewski G.; Lamb P.; Pirn D.; Peacock J.; Crawford L. and Benchimol S.
(1984). Isolation and characterization of a human p53 cDNA clone:
expression of the human p53 gene. EMBO J 20; 3: 3257-3262.
186
McBride O. W.; Merry D. and Givol D. (1986). The gene for human p53 cellular
tumor antigen is located on chromosome 17 short arm (17pl3).
Proc.Natl.Acad.Sci.U.S.A 83: 130-134.
McGarvey T. W.; Maruta Y.; Tomaszewski J. E.; Linnenbach A. J. and
Malkowicz S. B. (1998). PTCH gene mutations in invasive
transitional cell carcinoma of the bladder. Oncogene 17: 1167-1172.
McMahon A. P. (2000). More surprises in the Hedgehog signaling pathway. Cell
100: 185-188.
McMahon A. P.; Ingham P. W. and Tabin C. J. (2003). Developmental roles and
clinical significance ofhedgehog signaling. Curr.Top.Dev.Biol. 53:1-
114: 1-114.
Melino G.; De Laurenzi, V and Vousden K. H. (2002). p73: Friend or foe in
tumorigenesis. Nat.Rev.Cancer 2: 605-615.
Mello J. A.; Acharya S.; Fishel R. and Essigmann J. M. (1996). The mismatch-
repair protein hMSH2 binds selectively to DNA adducts of the
anticancer drug cisplatin. Chem.Biol. 3: 579-589.
Miyoshi Y.; Nagase H.; Ando H.; Horii A.; Ichii S.; Nakatsuru S.; Aoki T.; Miki
Y.; Mori T. and Nakamura Y. (1992). Somatic mutations of the
APC gene in colorectal tumors: mutation cluster region in the APC
gene. Hum.Mol.Genet. 1: 229-233.
Monpezat J. P.; Delattre O.; Bernard A.; Grunwald D.; Remvikos Y.; Muleris
M.; Salmon R. J.; Frelat G.; Dutrillaux B. and Thomas G. (1988).
Loss of alleles on chromosome 18 and on the short arm of
187
chromosome 17 in polyploid colorectal carcinomas. Int.J Cancer 41:
404-408.
Mora P. T.; Chandrasekaran K. and McFarland V. W. (1980). An embryo
protein induced by SV40 virus transformation ofmouse cells. Nature
288: 722-724.
Morin P. J.; Vogelstein B. and Kinzler K. W. (1996). Apoptosis and APC in
colorectal tumorigenesis. Proc.Natl.Acad.Sci.U.S.A 93: 7950-7954.
Mullor J. L.; Dahmane N.; Sun T. and Altaba A. (2001). Wnt signals are targets
and mediators ofGli function. Curr.Biol. 11: 769-773.
Nagata S. (1997). Apoptosis by death factor. Cell 88: 355-365.
Nakanishi M.; Robetorye R. S.; Pereira-Smith O. M. and Smith J. R. (1995).
The C-terminal region ofp21SDIl/WAFl/CIPl is involved in
proliferating cell nuclear antigen binding but does not appear to be
required for growth inhibition. J.Biol.Chem. 270: 17060-17063.
Nakano K.; Balint E.; Ashcroft M. and Vousden K. H. (2000). A ribonucleotide
reductase gene is a transcriptional target ofp53 and p73. Oncogene
19: 4283-4289.
Nishisho I.; Nakamura Y.; Miyoshi Y.; Miki Y.; Ando H.; Horii A.; Koyama K.;
Utsunomiya J.; Baba S. and Hedge P. (1991). Mutations of
chromosome 5q21 genes in FAP and colorectal cancer patients.
Science 253: 665-669.
Ohue M.; Tomita N.; Monden T.; Fujita M.; Fukunaga M.; Takami K.; Yana
I.; Ohnishi T.; Enomoto T.; Inoue M. and . (1994). A frequent
188
alteration ofp53 gene in carcinoma in adenoma of colon. Cancer Res.
54: 4798-4804.
Oliner J. D.; Kinzler K. W.; Meltzer P. S.; George D. L. and Vogelstein B.
(1992). Amplification of a gene encoding a p53-associated protein in
human sarcomas. Nature 358: 80-83.
Ongkeko W. M.; Wang X. Q.; Siu W. Y.; Lau A. W.; Yamashita K.; Harris A.
L.; Cox L. S. and Poon R. Y. (1999). MDM2 and MDMX bind and
stabilize the p53-related protein p73. Curr.Biol. 9: 829-832.
Oren M. and Levine A. J. (1983). Molecular cloning of a cDNA specific for the
murine p53 cellular tumor antigen. Proc.Natl Acad.Sci.U.S.A 80: 56-
59.
Oro A. E.; Higgins K. M.; Hu Z.; Bonifas J. M.; Epstein E. H., Jr. and Scott M.
P. (1997). Basal cell carcinomas in mice overexpressing sonic
hedgehog. Science 276: 817-821.
Parker S. L.; Tong T.; Bolden S. and Wingo P. A. (1997). Cancer statistics, 1997.
CA: A Cancer Journal for Clinicians 47: 5-27.
Piard F.; Martin L.; Chapusot C.; Ponnelle T. and Faivre J. (2002). Genetic
pathways in colorectal cancer: interest for the pathologist. Ann.Pathol
22: 277-288.
Pietenpol J. A. and Stewart Z. A. (2002). Cell cycle checkpoint signaling: cell
cycle arrest versus apoptosis. Toxicology 181-182: 475-481.
Pietsch T.; Waha A.; Koch A.; Kraus J.; Albrecht S.; Tonn J.; Sorensen N.;
Berthold F.; Henk B.; Schmandt N.; WolfH. K.; von Deimling A.;
189
Wainwright B.; Chenevix-Trench G.; Wiestler O. D. and Wicking
C. (1997). Medulloblastomas of the desmoplastic variant carry
mutations of the human homologue ofDrosophila patched. Cancer
Res. 57: 2085-2088.
Polyak K.; Xia Y.; Zweier J. L.; Kinzler K. W. and Vogelstein B. (1997). A
model for p53-induced apoptosis. Nature 389: 300-305.
Porter J. A.; Young K. E. and Beachy P. A. (1996). Cholesterol modification of
hedgehog signaling proteins in animal development. Science 274:
255-259.
Potten C. S.; Booth C. and Pritchard D. M. (1997). The intestinal epithelial stem
cell: hte mucosal governor. Int. Journal of Exp. Pathology 78: 219-
243.
Potter John D. (1999). Colorectal Cancer: Molecules and Populations. JNCI Cancer
Spectrum 91: 916-932.
Pozniak C. D.; Radinovic S.; Yang A.; McKeon F.; Kaplan D. R. and Miller F.
D. (2000). An anti-apoptotic role for the p53 family member, p73,
during developmental neuron death. Science 289: 304-306.
Purdie C. A.; Harrison D. J.; Peter A; Dobbie L.; White S.; Howie S. E.; Salter
D. M.; Bird C. C.; Wyllie A. H. and Hooper M. L. (1994). Tumour
incidence, spectrum and ploidy in mice with a large deletion ofp53
gene. Oncogene 603-609.
158. Ramalho-Santos M.; Melton D. A. and McMahon A. P. (2000). Hedgehog
signals regulate multiple aspects of gastrointestinal development.
Development 127: 2763-2772.
190
Reifenberger J.; Wolter M.; Weber R. G.; Megahed M.; Ruzicka T.; Lichter P.
and Reifenberger G. (1998). Missense mutations in SMOH in
sporadic basal cell carcinomas of the skin and primitive
neuroectodermal tumors of the central nervous system. Cancer Res.
58: 1798-1803.
Riddell R. H. (1992). Flat adenomas and carcinomas: seeking the invisible?
Gastrointest.Endosc. 38: 721-723.
Riddle R. D.; Johnson R. L.; Laufer E. and Tabin C. (1993). Sonic hedgehog
mediates the polarizing activity of the ZPA. Cell 75: 1401-1416.
Rigaudy P. and EckhartW. (1989). Nucleotide sequence of a cDNA encoding the
monkey cellular phosphoprotein p53. Nucleic Acids Res 17: 8375.
Riggins G. J.; Thiagalingam S.; Rozenblum E.; Weinstein C. L.; Kern S. E.;
Hamilton S. R.; Willson J. K.; Markowitz S. D.; Kinzler K. W.
and Vogelstein B. (1996). Mad-related genes in the human.
Nat.Genet. 13: 347-349.
Roberts D. J.; Smith D. M.; Goff D. J. and Tabin C. J. (1998). Epithelial-
mesenchymal signaling during the regionalization of the chick gut.
Development 125: 2791-2801.
Rodrigues N. R.; Rowan A.; Smith M. E.; Kerr I. B.; Bodmer W. F.; Gannon J.
V. and Lane D. P. (1990). p53 mutations in colorectal cancer.
Proc.Natl.Acad.Sci.U.S.A 87: 7555-7559.
Roessler E.; Belloni E.; Gaudenz K.; Jay P.; Berta P.; Scherer S. W.; Tsui L. C.
and Muenke M. (1996). Mutations in the human Sonic Hedgehog
gene cause holoprosencephaly. Nat.Genet. 14: 357-360.
191
Rommel C. and Hafen E. (1998). Ras - a versatile cellular switch.
Curr.Opin.Genet.Dev. 8: 412-418.
Rosenberg Steven A.; DeVita Vincent T. and Hellman Samuel (2001). Cancer
principles & practice of oncology. 6th ed.
Roy S.; Khanna S.; BickerstaffA. A.; Subramanian S. V.; Atalay M.; Bierl M.;
Pendyala S.; Levy D.; Sharma N.; Venojarvi M.; Strauch A.;
Orosz C. G. and Sen C. K. (2003). Oxygen sensing by primary
cardiac fibroblasts: a key role ofp21(Wafl/Cipl/Sdil). Circ.Res. 92:
264-271.
Ryan A. K.; Blumberg B.; Rodriguez-Esteban C.; Yonei-Tamura S.; Tamura
K.; Tsukui T.; de la Pena J.; Sabbagh W.; Greenwald J.; Choe S.;
Norris D. P.; Robertson E. J.; Evans R. M.; Rosenfeld M. G. and
Izpisua Belmonte J. C. (1998). Pitx2 determines left-right
asymmetry of internal organs in vertebrates. Nature 394: 545-551.
Ryan K. M.; Phillips A. C. and Vousden K. H. (2001). Regulation and function of
the p53 tumor suppressor protein. Curr.Opin.Cell Biol. 13: 332-337.
Sakaguchi K.; Herrera J. E.; Saito S.; Miki T.; Bustin M.; Vassilev A.;
Anderson C. W. and Appella E. (1998). DNA damage activates p53
through a phosphorylation-acetylation cascade. Genes Dev. 12: 2831-
2841.
Salimath B.; Marme D. and Finkenzeller G. (2000). Expression of the vascular
endothelial growth factor gene is inhibited by p73. Oncogene 20;19:
3470-3476.
192
Sasaki H.; Hui C.; Nakafuku M. and Kondoh H. (1997). A binding site for Gli
proteins is essential for HNF-3beta floor plate enhancer activity in
transgenics and can respond to Shh in vitro. Development 124: 1313-
1322.
Sayan A. E.; Sayan B. S.; Findikli N. and Ozturk M. (2001). Acquired expression
of transcriptionally active p73 in hepatocellular carcinoma cells.
Oncogene 20: 5111-5117.
Selivanova G.; Iotsova V.; Okan I.; Fritsche M.; Strom M.; Groner B.;
Grafstrom R. C. and Wiman K. G. (1997). Restoration of the
growth suppression function ofmutant p53 by a synthetic peptide
derived from the p53 C-terminal domain. Nat.Med. 3: 632-638.
Seoane J.; Le H. V. and Massague J. (2002). Myc suppression of the p21(Cipl)
Cdk inhibitor influences the outcome of the p53 response to DNA
damage. Nature 419: 729-734.
Shaulsky G.; Goldflnger N.; Peled A. and Rotter V. (1991). Involvement ofwild-
type p53 in pre-B-cell differentiation in vitro.
Proc.Natl.Acad.Sci.U.S.A 88: 8982-8986.
Shaw P.; Tardy S.; Benito E.; Obrador A. and Costa J. (1991). Occurrence ofKi-
ras and p53 mutations in primary colorectal tumors. Oncogene 6:
2121-2128.
Shieh S. Y.; Ikeda M.; Taya Y. and Prives C. (1997). DNA damage-induced
phosphorylation ofp53 alleviates inhibition byMDM2. Cell 91: 325-
334.
193
Shimodaira H.; Yoshioka-Yamashita A.; Kolodner R. D. and Wang J. Y. (2003).
Interaction ofmismatch repair protein PMS2 and the p53-related
transcription factor p73 in apoptosis response to cisplatin.
Proc.Natl.Acad.Sci.U.S.A 100: 2420-2425.
Soussi T.; Caron de F.; Mechali M.; May P. and Kress M. (1987). Cloning and
characterization of a cDNA from Xenopus laevis coding for a protein
homologous to human and murine p53. Oncogene 1: 71-78.
Soussi T.; Dehouche K. and Beroud C. (2000). p53 website and analysis ofp53
gene mutations in human cancer: forging a link between epidemiology
and carcinogenesis. Hum.Mutat. 15: 105-113.
Spandau D. F. (1994). Distinct conformations ofp53 are observed at different stages
of keratinocyte differentiation. Oncogene 9: 1861-1868.
Steegenga W. T.; Shvarts A.; Riteco N.; Bos J. L. and Jochemsen A. G. (1999).
Distinct regulation ofp53 and p73 activity by adenovirus ElA, E1B,
and E4orf6 proteins. Mol.Cell Biol. 19: 3885-3894.
Stone D. M.; Hynes M.; Armanini M.; Swanson T. A.; Gu Q.; Johnson R. L.;
Scott M. P.; Pennica D.; Goddard A.; Phillips H.; Noll M.;
Hooper J. E.; de Sauvage F. and Rosenthal A. (1996). The tumour-
suppressor gene patched encodes a candidate receptor for Sonic
hedgehog. Nature 384: 129-134.
Su L. K.; Kinzler K. W.; Vogelstein B.; Preisinger A. C.; Moser A. R.; Luongo
C.; Gould K. A. and Dove W. F. (1992). Multiple intestinal
neoplasia caused by a mutation in the murine homolog of the APC
gene. Science 256: 668-670.
194
Sukegawa A.; Narita T.; Kameda T.; Saitoh K.; Nohno T.; Iba H.; Yasugi S.
and Fukuda K. (2000). The concentric structure of the developing
gut is regulated by Sonic hedgehog derived from endodermal
epithelium. Development 127: 1971-1980.
Sun X. F. (2002). p73 overexpression is a prognostic factor in patients with
colorectal adenocarcinoma. Clin.Cancer Res. 8: 165-170.
Sunahara M.; Ichimiya S.; Nimura Y.; Takada N.; Sakiyama S.; Sato Y.; Todo
S.; Adachi W.; Amano J. and Nakagawara A. (1998). Mutational
analysis of the p73 gene localized at chromosome lp36.3 in colorectal
carcinomas. Int.J.Oncol. 13: 319-323.
Taipale J. and Beachy P. A. (2001). The Hedgehog and Wnt signalling pathways in
cancer. Nature 411: 349-354.
Takada N.; Ozaki T.; Ichimiya S.; Todo S. and Nakagawara A. (1999).
Identification of a transactivation activity in the COOH-terminal
region ofp73 which is impaired in the naturally occurring mutants
found in human neuroblastomas. Cancer Res. 59: 2810-2814.
Tanaka K.; Oshimura M.; Kikuchi R.; Seki M.; Hayashi T. and Miyaki M.
(1991). Suppression of tumorigenicity in human colon carcinoma cells
by introduction of normal chromosome 5 or 18. Nature 349: 340-342.
Tannapfel A.; Wasner M.; Krause K.; Geissler F.; Katalinic A.; Hauss J.;
Mossner J.; Engeland K. and Wittekind C. (1999). Expression of
p73 and its relation to histopathology and prognosis in hepatocellular
carcinoma. J Natl.Cancer Inst. 91: 1154-1158.
195
Thayer S. P.; Di Magliano M. P.; Heiser P. W.; Nielsen C. M.; Roberts D. J.;
Lauwers G. Y.; Qi Y. P.; Gysin S.; Fernandez-Del Castillo C.;
Yajnik V.; Antoniu B.; McMahon M.; Warshaw A. L. and
Hebrok M. (2003). Hedgehog is an early and late mediator of
pancreatic cancer tumorigenesis. Nature 425: 851-856.
Thiagalingam S.; Lengauer C.; Leach F. S.; Schutte M.; Hahn S. A.;
Overhauser J.; Willson J. K.; Markowitz S.; Hamilton S. R.;
Kern S. E.; Kinzler K. W. and Vogelstein B. (1996). Evaluation of
candidate tumour suppressor genes on chromosome 18 in colorectal
cancers. Nat.Genet. 13: 343-346.
Thomas R.; Kaplan L.; Reich N.; Lane D. P. and Levine A. J. (1983).
Characterization ofhuman p53 antigens employing primate specific
monoclonal antibodies. Virology 131: 502-517.
Tian H.; Wittmack E. K. and Jorgensen T. J. (2000). p21WAFl/CIPl antisense
therapy radiosensitizes human colon cancer by converting growth
arrest to apoptosis. Cancer Res. 60: 679-684.
Toftgard R. (2000). Hedgehog signalling in cancer. Cell Mol.Life Sci. 57: 1720-
1731.
Tojo M.; Kiyosawa H.; Iwatsuki K. and Kaneko F. (2002). Expression of a sonic
hedgehog signal transducer, hedgehog-interacting protein, by human
basal cell carcinoma. Br.J.Dermatol. 146: 69-73.
Tojo M.; Mori T.; Kiyosawa H.; Honma Y.; Tanno Y.; Kanazawa K. Y.;
Yokoya S.; Kaneko F. and Wanaka A. (1999). Expression of sonic
hedgehog signal transducers, patched and smoothened, in human
basal cell carcinoma. Pathol.Int. 49: 687-694.
196
Toyoshima F.; Moriguchi T.; Wada A.; Fukuda M. and Nishida E. (1998).
Nuclear export of cyclin B1 and its possible role in the DNA damage-
induced G2 checkpoint. EMBO J. 17: 2728-2735.
Toyota M.; Ahuja N.; Ohe-Toyota M.; Herman J. G.; Baylin S. B. and Issa J. P.
(1999). CpG island methylator phenotype in colorectal cancer.
Proc.Natl.Acad.Sci.U.S.A 20; 96: 8681-8686.
Ueda Y.; Hijikata M.; Takagi S.; Takada R.; Takada S.; Chiba T. and
Shimotohno K. (2001). p73beta, a variant of p73, enhances Wnt/beta-
catenin signaling in Saos-2 cells. Biochem.Biophys.Res.Commun.
283: 327-333.
Unden A. B.; Zaphiropoulos P. G.; Bruce K.; Toftgard R. and Stahle-Backdahl
M. (1997). Human patched (PTCH) mRNA is overexpressed
consistently in tumor cells ofboth familial and sporadic basal cell
carcinoma. Cancer Res. 57: 2336-2340.
Vaisman A.; Varchenko M.; Umar A.; Kunkel T. A.; Risinger J. I.; Barrett J.
C.; Hamilton T. C. and Chaney S. G. (1998). The role ofhMLHl,
hMSH3, and hMSH6 defects in cisplatin and oxaliplatin resistance:
correlation with replicative bypass ofplatinum- DNA adducts. Cancer
Res. 58: 3579-3585.
van den Brink G. R.; Hardwick J. C.; Nielsen C.; Xu C.; ten Kate F. J.;
Glickman J.; van Deventer S. J.; Roberts D. J. and Peppelenbosch
M. P. (2002). Sonic hedgehog expression correlates with fundic gland
differentiation in the adult gastrointestinal tract. Gut 51: 628-633.
van den Brink G. R.; Hardwick J. C.; Tytgat G. N.; Brink M. A.; ten Kate F. J.;
van Deventer S. J. and Peppelenbosch M. P. (2001). Sonic
197
hedgehog regulates gastric gland morphogenesis in man and mouse.
Gastroenterology 121: 317-328.
Varley, J. M.; Evans, D. G. R. and Birch, J. M. (1997). Li-Fraumeni syndrome: a
molecular and clinical review. Brit. J. Cancer 76: 1-14.
Varley, J. M. (2003). Germline TP53 mutations and Li-Fraumeni syndrome. Hum.
Mutat. 21: 313-320.
Vikhanskaya F.; Bani M. R.; Borsotti P.; Ghilardi C.; Ceruti R.; Ghisleni G.;
Marabese M.; Giavazzi R.; Broggini M. and Taraboletti G.
(2001). p73 Overexpression increases VEGF and reduces
thrombospondin-1 production: implications for tumor angiogenesis.
Oncogene 20: 7293-7300.
Vogelstein B.; Fearon E. R.; Hamilton S. R. and Feinberg A. P. (1985). Use of
restriction fragment length polymorphisms to determine the clonal
origin of human tumors. Science 227: 642-645.
Vogelstein B.; Fearon E. R.; Hamilton S. R.; Kern S. E.; Preisinger A. C.;
Leppert M.; Nakamura Y.; White R.; Smits A. M. and Bos J. L.
(1988). Genetic alterations during colorectal-tumor development.
N.Engl.J Med. 319: 525-532.
Vogelstein B. and Kinzler K. W. (1992). p53 function and dysfunction. Cell 70:
523-526.
Vorechovsky I.; Unden A. B.; Sandstedt B.; Toftgard R. and Stahle-Backdahl
M. (1997). Trichoepitheliomas contain somatic mutations in the
overexpressed PTCH gene: support for a gatekeeper mechanism in
skin tumorigenesis. Cancer Res. 57: 4677-4681.
198
Vousden K. H. and Lu X. (2002). Live or let die: the cell's response to p53.
Nat.Rev.Cancer 2: 594-604.
Waga S.; Hannon G. J.; Beach D. and Stillman B. (1994). The p21 inhibitor of
cyclin-dependent kinases controls DNA replication by interaction
with PCNA. Nature 369: 574-578.
Waldman T.; Kinzler K. W. and Vogelstein B. (1995). p21 is necessary for the
p53-mediated G1 arrest in human cancer cells. Cancer Res. 55: 5187-
5190.
Walker K. K. and Levine A. J. (1996). Identification of a novel p53 functional
domain that is necessary for efficient growth suppression.
Proc.Natl.Acad.Sci.U.S.A 93: 15335-15340.
Wang X.; Arooz T.; Siu W. Y.; Chiu C. H.; Lau A.; Yamashita K. and Poon R.
Y. (2001). MDM2 andMDMX can interact differently with ARF and
members of the p53 family. FEBS Lett. 490: 202-208.
Watanabe K.; Ozaki T.; Nakagawa T.; Miyazaki K.; Takahashi M.; Hosoda M.;
Hayashi S.; Todo S. and Nakagawara A. (2002). Physical
interaction ofp73 with c-Myc and MM1, a c-Myc-binding protein,
and modulation of the p73 function. J Biol.Chem. 277: 15113-15123.
Watkins D. N.; Berman D. M.; Burkholder S. G.; Wang B.; Beachy P. A. and
Baylin S. B, (2003). Hedgehog signalling within airway epithelial
progenitors and in small- cell lung cancer. Nature 422: 313-317.
Weiss R. H. and Howard L. L. (2001). p73 is a growth-regulated protein in
vascular smooth muscle cells and is present at high levels in human
atherosclerotic plaque. Cell Signal. 13: 727-733.
199
Wetmore C.; Eberhart D. E. and Curran T. (2001). Loss ofp53 but not ARF
accelerates medulloblastoma in mice heterozygous for patched.
Cancer Res. 61: 513-516.
White E. and Prives C. (1999). DNA damage enables p73. Nature 399: 734-5, 737.
Wicking C. and McGlinn E. (2001). The role of hedgehog signalling in
tumorigenesis. Cancer Lett. 173: 1-7.
Williams E. D.; Lowes A. P.; Williams D. and Williams G. T. (1992). A stem cell
niche theory of intestinal crypt maintenance based on a study of
somatic mutation in colonic mucosa. American Journal ofPathology
141: 773-776.
Wolter M.; Reifenberger J.; Sommer C.; Ruzicka T. and Reifenberger G.
(1997). Mutations in the human homologue of the Drosophila
segment polarity gene patched (PTCH) in sporadic basal cell
carcinomas of the skin and primitive neuroectodermal tumors of the
central nervous system. Cancer Res. 57: 2581-2585.
Wong N.A.; Mayer N.J.; Anderson C.E.; McKenzie H.C.; Morris R.G.; Diebold
J.; Mayr D.; Brock I.W.; Royds J. A.; Gilmour H.M. and
Harrison D.J. (2003). Cyclin D1 and p21 in ulcerative colitis -related
inflammation and epithelial neoplasia: a study of aberrant expression
and underlying mechanisms. Hum. Pathol. 34: 580-588.
Xie J.; Murone M.; Luoh S. M.; Ryan A.; Gu Q.; Zhang C.; Bonifas J. M.; Lam
C. W.; Hynes M.; Goddard A.; Rosenthal A.; Epstein E. H., Jr.
and de Sauvage F. J. (1998). Activating Smoothened mutations in
sporadic basal-cell carcinoma. Nature 391: 90-92.
200
Xiong Y.; Hannon G. J.; Zhang H.; Casso D.; Kobayashi R. and Beach D.
(1993). p21 is a universal inhibitor of cyclin kinases. Nature 366: 701 -
704.
Yang A.; Kaghad M.; Caput D. and McKeon F. (2002). On the shoulders of
giants: p63, p73 and the rise ofp53. Trends Genet. 18: 90-95.
Yang A.; Kaghad M.; Wang Y.; Gillett E.; Fleming M. D.; Dotsch V.; Andrews
N. C.; Caput D. and McKeon F. (1998). p63, a p53 homolog at
3q27-29, encodes multiple products with transactivating, death-
inducing, and dominant-negative activities. Mol.Cell 2: 305-316.
Yang A.; Sharpe A.; McKeon F. and Caput D. (2000). p73-deficient mice have
neurological, pheromonal and inflammatory defects but lack
spontaneous tumours. Nature 404: 99-103.
Yashiro M.; Carethers J. M.; Laghi L.; Saito K.; Slezak P.; Jaramillo E.; Rubio
C.; Koizumi K.; Hirakawa K. and Boland C. R. (2001). Genetic
pathways in the evolution ofmorphologically distinct colorectal
neoplasms. Cancer Res. 61: 2676-2683.
Yokomizo A.; Mai M.; Tindall D. J.; Cheng L.; Bostwick D. G.; Naito S.; Smith
D. I. and Liu W. (1999). Overexpression of the wild type p73 gene in
human bladder cancer. Oncogene 18: 1629-1633.
Yu J.; Zhang L.; Hwang P. M.; Rago C.; Kinzler K. W. and Vogelstein B.
(1999). Identification and classification ofp53-regulated genes.
Proc.Natl.Acad.Sci.U.S.A 96: 14517-14522.
Yuan Z. M.; Shioya H.; Ishiko T.; Sun X.; Gu J.; Huang Y. Y.; Lu H.;
Kharbanda S.; Weichselbaum R. and Kufe D. (1999). p73 is
201
regulated by tyrosine kinase c-Abl in the apoptotic response to DNA
damage. Nature 399: 814-817.
Zaika A.; Irwin M.; Sansome C. and Moll U. M. (2001). Oncogenes induce and
activate endogenous p73 protein. J.Biol.Chem. 276: 11310-11316.
Zeng X.; Li X.; Miller A.; Yuan Z.; Yuan W.; Kwok R. P.; Goodman R. and Lu
H. (2000) The N-terminal domain ofp73 interacts with the CHI
domain ofp300/CREB binding protein and mediates transcriptional
activation and apoptosis. Mol Cell Biol. 20: 1299-310.
Zhan Q.; Antinore M. J.; Wang X. W.; Carrier F.; Smith M. L.; Harris C. C.
and Fornace A. J., Jr. (1999). Association with Cdc2 and inhibition
ofCdc2/Cyclin B1 kinase activity by the p53-regulated protein
Gadd45. Oncogene 18: 2892-2900.
Zheng X. and Chen X. (2001). Aquaporin 3, a glycerol and water transporter, is
regulated by p73 of the p53 family. FEBS Lett. 489: 4-7.
Zhu J.; Jiang J.; Zhou W. and Chen X. (1998). The potential tumor suppressor






1. p53-Dependent and Independent DNA Damage Responses in PrimaryMurine
Colonocytes: a Possible Functional Role for p73a (see page 206).
Pathological Society ofGreat Britain and Ireland, lst-4th July 2003, section:
Molecular and Cellular Pathology
2. Altered Expression of Sonic Hedgehog Pathway Genes in Human Colon
Tumours (see page 207).
Pathological Society ofGreat Britain and Ireland, lst-4th July 2003, Bristol,
UK, section: Gastrointestinal Pathology
3. Expression of Sonic Hedgehog Pathway Genes is Altered in Human Colonic
Tumors (see page 208-209).
American Society of Clinical Pathology, 18th-22nd September 2003, New
Orleans, US.
PUBLICATIONS
1. p73a is a candidate effector in the p53-independent apoptosis pathway of
cisplatin-damaged primary murine colonocytes.
Anca Oniscu, Nathalie Sphyris, Robert G. Morris, Scott Bader and David J.
Harrison
Journal ofClinical Pathology 2004, 57:492-498
204
2. Expression of Sonic Hedgehog Pathway Genes is Altered in Colonic
Neoplasia.
Anca Oniscu, Roberta M. James, Robert G. Morris, Scott Bader, Roger D.G.
Malcomson and David J. Harrison
Journal of Pathology 2004, 203(4): 909-917
3. p53-Dependent and Independent DNA Damage Responses in Primary Murine
Colonocytes: a Possible Functional Role for p73a.
Anca Oniscu, Nathalie Sphyris, Robert G. Morris, Scott Bader and David J.
Harrison
Journal of Pathology, September Supplement, Vol. 201.
4. Altered Expression of Sonic Hedgehog Pathway Genes in Human Colon
Tumours.
Anca Oniscu, Roger D.G. Malcomson, Roberta M. James, Scott Bader,
Robert G. Morris and David J. Harrison
Journal of Pathology, September Supplement, Vol. 201.
5. Expression of Sonic Hedgehog Pathway Genes is Altered in Human Colonic
Tumors.
Anca Oniscu, Roger D.G. Malcomson, Roberta M. James, Scott Bader,
Robert G. Morris and David J. Harrison
American Journal of Clinical Pathology, September 2003, Vol. 120 (3):
459-460.
205
p53-Dependent and Independent DNA Damage Responses in Primary Murine
Colonocytes: a Possible Functional Role for p73a
Anca Oniscu, Nathalie Sphyris, Robert G. Morris, Scott Bader and David J. Harrison
Division of Pathology, School of Molecular and Clinical Medicine, The University
ofEdinburgh, Teviot Place, Edinburgh, EH8 9AG
p53 is a tumour suppressor gene important in growth regulation, differentiation and
apoptosis which is frequently mutated or deleted in colorectal cancer.
We derived primary colonocytes from wild-type (wt) and p53-deficient mice to
investigate the effect of p53 status on growth and the p53-dependent and independent
pathways following cisplatin-induced DNA damage. Apoptosis, S-phase DNA
synthesis and the induction of p53, p21 and p73 expression were monitored over a
24-hour period. As measured by 5'-bromo-2'-deoxyuridine incorporation, p53-null
colonocytes displayed a significant growth advantage over wt cells and continued to
enter DNA synthesis following cisplatin exposure, suggesting a critical role for p53
in cell-cycle arrest following damage. There was a distinct delayed apoptosis in p53-
null cells. Nuclear p21 expression was identified in 87% wt cells compared with 52%
in p53-null colonocytes (p<0.05). As p73 has been implicated in the transcriptional
activation of p21 and the p53-independent apoptosis after cisplatin damage, we
investigated its expression. RT-PCR confirmed the presence of full-length p73a. p73
transcript levels remained unchanged whereas the endogenous p73 protein
accumulated in the nucleus of cisplatin treated cells.
We therefore propose a pro-apoptotic role for full-length p73a in the absence of
p53, and collaboration with p53 in the wt cisplatin-damaged colonocytes.
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Altered Expression of Sonic Hedgehog Pathway Genes in Human Colon
Tumours
Anca Oniscu, Roger D.G. Malcomson, Roberta M. James, Scott Bader, Robert G.
Morris and David J. Harrison
Division of Pathology, School of Molecular and Clinical Medicine, The University
ofEdinburgh, Teviot Place, Edinburgh, EH8 9AG
The Hedgehog signalling pathway is crucial for normal development and patterning
of various organs in humans including the gut. Hedgehog proteins are also important
in gastric gland development and gastric epithelial differentiation in adults.
This work investigates the presence of the Hedgehog signalling pathway at
protein and mRNA level in normal colon and compares the distribution patterns of
these genes in a series of colonic lesions: hyperplastic polyps, adenomas and colonic
adenocarcinoma.
We report that Hedgehog pathway members are expressed in normal colonic
epithelium with sonic hedgehog (SHH) expressed at the top of the crypts, patched
(PTCH) in the neuroendocrine cells and smoothened (SMOH) at the brush border of
the epithelium. RT-PCR analysis of laser-microdissected crypts from normal human
colon confirmed that mRNAs encoding these signalling molecules were expressed in
colonic epithelium. Expression of SHH, PTCH and SMOH was upregulated in
hyperplastic polyps, adenoma and adenocarcinoma of the colon as detected by
immunohistochemistry, suggesting a role for these molecules in human
tumorigenesis. SHH expression correlated with an increased expression of the
proliferation marker Ki-67 in all lesions examined.
Therefore, we suggest a role for SHH in epithelial proliferation in the colon and
possibly in epithelial colon tumour progression in-vivo.
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Expression of Sonic Hedgehog Pathway Genes is Altered in Human Colonic
Tumours
Anca Oniscu, Roger D.G. Malcomson, Roberta M. James, Scott Bader, Robert G.
Morris and David J. Harrison
Sir Alastair Currie Cancer Research UK Laboratories, Division of Pathology,
Molecular Medicine Centre, The University of Edinburgh, Crewe Road, Edinburgh,
EH42XU
Introduction The Hedgehog signalling pathway is crucial for normal development
and patterning of various organs in humans including the gut. Hedgehog proteins are
also important in gastric gland development and gastric epithelial differentiation in
adults. The present work investigates the presence of the Hedgehog signalling
pathway at protein and mRNA level in normal colon and compares the distribution
patterns of these genes in a series of colonic lesions: hyperplastic polyps, adenomas
and colonic adenocarcinoma.
Materials and Methods 7 hyperplastic polyps, 20 tubulo-villous adenomas, 8
adenocarcinomas and 3 normal colon samples were used in the study. Normal
colonic crypts were microdissected from 70% ethanol-fixed cryostat sections onto
laser-capture microdissection caps and total mRNA isolated using a phenol-
chloroform based method. RNA analysis was performed by RT-PCR. For
immunohistochemistry we used antibodies against sonic hedgehog (Shh), patched
(Ptch), smoothened (Smoh), Cyclin B1 and Ki-67.
Results We report that Hedgehog pathway members are expressed in normal colonic
epithelium with Shh expressed at the top of the crypts, Ptch in the neuroendocrine
cells and Smoh at the brush border of the epithelium. RT-PCR analysis of laser-
microdissected crypts from normal human colon confirmed that mRNAs encoding
these signalling molecules were expressed in colonic epithelium. Expression of Shh,
Ptch and Smoh was upregulated in hyperplastic polyps, adenoma and
adenocarcinoma of the colon as detected by immunohistochemistry, suggesting a role
for these genes in human tumorigenesis. Shh expression correlated with an increased
expression of the proliferation marker Ki-67 in all lesions examined.
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Conclusion We suggest a role for Shh in epithelial proliferation in the colon and
possibly in epithelial colon tumour progression in-vivo. Further work is underway to
determine whether the increased expression of Shh is a result of gene mutation or
changes in methylation of the Shh promoter as opposed to cell-cycle dependent




p73a is a candidate effector in the p53 independent
apoptosis pathway of cisplatin damaged primary murine
colonocytes
A Oniscu, N Sphyris, R G Morris, S Bader, D J Harrison
J Clin Pathol 2004;57:492-498. doi: 10.1136/jcp.2003.0l 2559
Aims: Colonocytes were derived from wild-type (wt) and p53 deficient mice to investigate p53 dependent
and independent death pathways after cisplatin treatment, and the role of p53 in growth regulation of
primary, untransformed epithelial cells.
Methods: Wtand p53 null colonocytes were exposed to cisplatin and DNA synthesis, apoptosis, and p53,
p21, and p73 expression were investigated alter six, 12, and 24 hours. Major p73 isoforms were
identified by reverse transcription polymerase chain reaction (RT-PCR).
Results: Cisplatin treated wt cells exhibited cell cycle arrest, whereas p53 null cells continued to synlhesise
DNA, although both cell types died. Apoptosis was significantly higher in cisplatin treated wt and p53 null
colonocytes than in controls at all timepoints, although apoptosis was lower in cisplatin treated p53 null
colonocytes than in wt cells. p53 expression was upregulated in cisplatin treated wt colonocytes. p21
expression was high and remained unchanged in cisplatin treated wt cells, although if was reduced in the
absence of p53. p73 was investigated because it could account for p53 independent p21 expression and
p53 independent death. RT-PCR detected lull length p73a. p73 transcript levels remained unchanged,
whereas p73 protein accumulated in the nucleus of cisplatin treated cells, irrespective of genotype.
Conclusions: p53 is essential for cell cycle arrest, but not apoptosis in primary murine colonocytes.
Apoptosis is reduced in cisplatin treated p53 null cells. Nuclear accumulation of endogenous p73 after
cisplatin treatment suggests a proapoptofic role for p73a in the absence of p53 and collaboration with
p53 in wt colonocytes.
See end of article for
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Escape from the induction of apoptosis is believed to be acrucial event in colorectal carcinogenesis. Mutations ofp53 are common in colorectal neoplasia but occur late In
disease evolution, acting as a progression step.1
Approximately half of all colorectal cancers show p53 gene
mutations.2
The role of p53 in tumour suppression is linked to its
functions in the regulation of cell cycle control1 differentia¬
tion/ inhibition of angiogenesis,' senescence/ and apoptosis
after genotoxic stress, nucleotide depletion, and oncogene
activation.7 After DNA damage, p53 induces the expression of
p21(WAF,/c'pl). a cyclin dependent kinase inhibitor that
causes cell cycle arrest when overexpressed.* p21 can also
bind to proliferating cell nuclear antigen (PCNA),9 blocking
its function in DNA replication but not repair.10
Consequently, p21 can cause G1 arrest and inhibition of
DNA replication, ensuring that potential errors are repaired
before the resumption of cell cycling.
Although the importance of p53 in tumour suppression
remains undisputed, it has become apparent that p53
independent mechanisms operate in tandem to ensure the
fidelity of replication and the elimination of rogue cells.
Recendy, p73 was identified as a p53 homologue, and
exhibits considerable sequence and structural similarities.
Similar to p53, p73 can transactivate p21. and Induce cell
cycle arrest and apoptosis when overexpressed." Moreover, in
p53 null cells, oncogene activation induces endogenous p73
expression, engaging an apoptosis pathway that Is p53
independent.12 Despite the p73 locus (lp36) being on a
chromosome region frequently deleted in human cancers,
studies on human tumours have failed to detect p73 gene
deletion or inactivating mutations." 14 The role of p73 in
tumorigenesis remains unclear, because silencing of the p73
gene has been detected in neuroblastoma, squamous cell
carcinoma, and lung cancer," suggesting that p73 may
assume a tumour suppressor role. Conversely, overexpression
of p73 has been reported in haemopoietic malignancies,"
ovarian," bladder,1* and breast cancer." Moreover, p73 null
mice do not display an increased predisposition to sponta¬
neous tumour development.20
p73 exists as at least six (a, p. y, 8, e, and q) full length
transactlvation competent (TA) forms, which differ at the C-
terminus, and as N-terminally truncated variants (AN).21
Overexpression of the TA isoforms was shown to cause
irreversible growth arrest and apoptosis in cells lacking
functional p53.22 In contrast, the AN variants assume a
protective role against apoptosis by directly antagonising the
apoptotic functions of p5323 and by suppressing p53 and
TAp73 dependent transactivation.24
"Similar to p53, p73 can fransactivate p21, and induce
cell cycle arrest and apoptosis when overexpressed"
Much of the information on carcinogenesis in the intestine
derives from studies in the small intestine or cell lines, yet
most of the mutations leading to cancer occur in the large
intestine. Pioneering work by Potten and others27-27 has
elucidated the kinetics of intestinal growth in vivo but
primary culture offers a dynamic in vitro model that allows
Abbreviations: BrdU, 5'-bromo-2'-deoxyuridine; AN, N-terminaly
truncated variant; GAPDH, ajyceroldehyde 3-phosphate
dehydrogenase; PCNA, prolilWating eel nuclear antigen; RT-PCR,
reverse transcription polymerase chain reaction; TA, transacfivation
competent; wt, wild-type
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the investigation of growth, apoptosis. and responses to
injury." "
Therefore, we adapted the colonic crypt isolation technique
developed by Booth and colleagues2* to obtain primary
colonocytes from adult wt and p53 null mice. Our objectives
were to gain a better understanding of the importance of p53
and related proteins in the regulation of growth and response
to cisplatin in these cells. Cisplatin crosslinks DNA, forming
intrastrand and interstrand adducts. This damage culminates
in the induction of apoptosis via at least two different
pathways: one involving p53 and the other mediated by p73.M
These pathways have not yet been examined in primary
colonocyte cultures.
MATERIALS AND METHODS
Isolation of colonic crypts and culture of primary
colonocytes from adult wt and p53 null mice
Wt and p53 null mice11 were humanely killed between 50 and
75 days of age. The crypt isolation technique was successfully
adapted from Booth et at.2" NIH-3T3 cells were cultured in
double modified eagle medium supplemented with 10% fetal
bovine serum.
Cisplatin treatment
After three days in culture, cells were exposed to 15pM
cisplatin (David Bull Laboratories, Warwick, UK) for six, 12,
or 24 hours.
Proliferation assay
Primary colonocyte cultures were incubated with 0.01 mM
(BrdU) (Amersham Pharmacia Biotech, Little Chalfont,
Buckinghamshire, UK) in culture medium for four hours
and fixed in 80% ethanol overnight. Immunodetection of
BrdU incorporation was performed using rat anti-BrdU
antibody (1/100 dilution) (Oxford Biotechnologies, Oxford,
UK) and positive cells were detected using diaminobenzidine.
Slides were counterstained with haematoxylin. BrdU incor¬
poration was measured by counting the positive nuclei in a
total of 500 cells in duplicate. Experiments were performed at
least three times with comparable results.
Measurement of apoptosis
For the determination of apoptosis, cells were fixed in
modified Bouin's fixative (85% methanol, 5% acetic acid,
and 10% formalin) at 4t overnight, the DNA denatured in
5M hydrochloric acid, and the nuclei stained with Schiff
reagent (Merck, Darnstadt, Germany). We used 0.3% light
green as a cytoplasmic counterstain. Apoptosis was measured
using morphological criteria,12 with 500 cells counted in
duplicate for each timepoint in three separate experiments.
Immunocytochemistry for p53, p21, and p73
The monoclonal antibody against p53 (clone pAB421) was
purchased from Calbiochem and mouse anti-p21 (F-5) and
rabbit anti-p73 (H-79) from Santa-Cruz Biotechnologies
(Santa Cruz, California, USA). Immunocytochemistry was
carried out on 4% paraformaldehyde fixed cells, permeated
with 0.5% Triton using an avidin-biotin peroxidase techni¬
que, except for p73, which was detected by immunofluores¬
cence using an Alexa-488, conjugated secondary antibody
(Molecular Probes, Eugene, Oregon, USA). Negative control
samples omitted the primary antibody. In addition, p53 null
colonocytes were used as a negative control for immunocy¬
tochemistry with anti-p53 antibody. For p21 and p53 we
counted at least 500 cells for each individual timepoint in
three separate experiments.
p73 immunohistochemistry was also performed on for¬
malin fixed paraffin wax embedded mouse colon and skin
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Figure 1 5'-Bromo-2'-deoxyuridine (BrdU) incorporation into
untreated and a'spiatin treated wild-type (wt) and p53 nul colonocytes.
Cellswere incubated with BrdU for lour hours and immunodetection was
performed using rat anti-BrdJ antibody. Positive ceUs were detected by
immunocytochemistry and a total of 500 cells counted in triplicate in at
least three different experiments. Results are mean (SEM), and show a
higher BrdU incorporation in p53 null colonocytes, regardless of
treatment and timepoint (p «■ 0.015, ANOVA).
Statistics
Data were analysed usingMinitab statistical software version
13. Data are presented as the mean (SEM). Comparison of
BrdU results was made using ANOVA. Comparison of all
other results was made using the Mann-Whitney U test. A p
value of < 0.05 was considered significant.
Reverse transcriptase polymerase chain reaction
Total RNA was extracted using TRIZOL (Invitrogen, Breda,
the Netherlands). Contaminating genomic DNA was removed
by treating the total RNA with DNase I (DNAfree kit;
Ambion, Huntingdon, Cambridgeshire, UK) according to the
protocol supplied by the manufacturer. For cDNA synthesis
we used the M-MLV reverse transcriptase kit (Invitrogen)
and generated cDNA from 100 ng of total RNA. Amplification
of the region between exons 11 and 14" yields a product of
363 bp in the case of p73a and/or a product of 270 bp in the
case of p730. For the detection of full length forms, primers
annealing to exons 3-421 were used, generating a product of
predicted size 297 bp. The primers for AN forms, annealing to
exons 3-4,M generate a product of 187 bp. Transcript values
were normalised to glyceraldehyde 3-phosphate dehydrogen¬
ase (GAPDH) expression (237 bp)." NIH-3T3 cells of mouse
origin were used as positive controls for the reverse tran¬
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Figure 2 Apoptosis in wild-type {wt) and p53 null colonocytes exposed
to cisplatin. The Feulgen stain and a 0.3% light green counterstain were
used to assess apoptosis in cisplatin treated oels and their corresponding
untreated controls. Apoptotic nudei in o total of 500 cells were counted
in triplicate, in at least three experiments. The mean percentages of
apoptotic cells (SEM) are shown.
www.jdinpath.com
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Figure 3 Expression of nuclear p53
and p21 in untreated and cisplatin* treated colonocytes detected by
4 immunocytocbemistry using an avidin-
biotin peroxidase technique. Positive
cells were detected with
♦ diaminobenzidine and haematoxylin
was used as nuclear counterslain. p53
expression is upregubted after
t exposure to cisplatin (A and B),
whereas p21 levels do not change
significantly in cisplatin treated wt cells
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Thermocycling was as follows: three minutes at 931,
followed by 40 cycles of one minute at 93°C, one ruinute at
52°C (p73a exons 11-14), 64t (p73a exons 3-4), 61t
(ANp73 exons 3-4), or 55t (GAPDH), and one minute at
72t, with a final elongation step of five minutes at 72°C.
All RT-PCRs were repeated twice using different batches of
RNA.
RESULTS
Confirmation of epithelial origin of colonocyte
preparation by keratin immunocytochemistry and
evaluation of culture purity
Cells derived from colonic crypts by the method cited were of
epithelial origin. These cells were cytokeratin positive.
Staining for vimentin, characteristic of fibroblasts, proved
that fibroblast contamination was minimal (data not
shown). Experiments were performed after three days in
culture when viability and counts of apoptosis, cell cycle
activity, and immunocytochemistry are optimal.
p53 controls growth in primary murine colonocytes
The proportion of cells in S phase was determined by BrdU
incorporation into wt and p53 null colonocytes under
baseline conditions and after six and 12 hours of exposure
to cisplatin. p53 null colonocytes have a growth advantage
over wt cells under baseline conditions, exhibiting a
significantly higher BrdU labelling index. After cisplatin
treatment, BrdU incorporation into wt cells was reduced by
12 hours (p = 0.015, ANOVA), whereas p53 null colonocytes
continued to synthesise DNA (fig 1).
Cisplatin kills colonocytes by apoptosis irrespective of
p53 status
Apoptosis in colonocyte cultures was monitored six, 12, and
24 hours after exposure to cisplatin. At all timepoints there
was a significant increase in the incidence of apoptosis
(P < 0.05, Mann-Whitney U test) between treated cells and
their corresponding controls, irrespective of genotype.
However, apoptosis was lower in p53 null colonocytes than
in wt cells (fig 2): whereas 39% of wt cells were apoptotic
24 hours after exposure to cisplatin, only 27% of p53 null
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Time after exposure to cisplatin
Figure 4 p53 expression in untreated and cispbtin damaged
colonocytes. p53 is expressed under baseline conditions but its
expression is significantly upregulated after exposure to cispbtin at all
timepoints (p<0.05, Mann-Whitney U test). The figure shows the mean
(SEM) percentage of p53 positive eels in a total of 500.
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Figure 5 Immunofluorescent detection of nuclear p73 in primary colonocytes using Alexa-488 conjugated secondary antibody. Nudeor accumulationofp73 is seen after treatment with cisplatin in bom wild-type (wt) and p53 null cells using the rabbit polyclonal H-79 antibody. DAP! was used as a
nuclear counlerstain. The cells shown were exposed to cisplatin for 24 hours. Images were captured using a Hamomatsu chilled CCD camera and Zeiss
fluorescent microscope.
test). The overall degree of apoptosis was reduced at each
timepoint in p53 deficient colonocytes compared with wt
cells.
p53 is induced after cisplatin treatment of wt
colonocytes
The proportion of cells expressing nuclear p53 was deter¬
mined by immunocytochemistry on paraformaldehyde
fixed, untreated and cisplatin treated colonocytes. Although
nuclear p53 was detected under baseline conditions, its
expression was significantly increased after exposure to
cisplatin (figs 3 and 4) at all timepoints (p < 0.05, Mann-
Whitney U test), consistent with its stabilisation and
transcriptional activity.
p21 is expressed in both untreated and cisplatin
treated colonocytes
We also investigated the expression of the p53 target gene,
p21. High amounts of nuclear p21 were present in both wt
and p53 null colonocytes under baseline conditions, with no
further increase after cisplatin treatment (fig 3).
Interestingly, in the absence of p53, p21 was still expressed
but in significantly lower amounts at all timepoints
(p = 0.034, Mann-Whitney U test; data not shown).
p73 is expressed in wt and p53 null colonocytes
Low baseline expression of nuclear p73 were detectable by
immunofluorescence. However, the intensity of the fluores¬
cent signal increased 24 hours after cisplatin treatment, as




Figure 6 Immunofluorescent detection of nuclear p73 in primary colonocytes using Alexa-488 conjugated secondary antibody. Nuclear accumulation
of p73 is seen after treatment with cisplatin in bom wild-type (wt) and p53 null cells using the sheep polyclonal Ab77 antibody. DAPI was used as a
nuclear counterstain. The cells shown were exposed to cisplatin for 24 hours. Images were captured using a Hamamatsu chilled CCD camera and Zeiss
fluorescent microscope.
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Figure 7 Reverse transcription polymerase chain reaction (RT-PCR)
showing p73 expression in wild-type (wt) and p53 null untreated (UNT)
and cispfafin (cis) treated colonocytes. (A) Amplification with primers
spanning exons 11-14 in murine primary colonocytes. The primers
could also detect the presence of the C-terminus of p73p, but no band of
the predicted size was obtained. (B) RT-PCR analysis for N-terminus
detection of full length p73 using primers for exon 3-4. (C) RT-PCR
showing the absence of AN variants in primary colonocytes. NIH-3T3
cDNA proved that the primers recognise a product of the correct size.
(D) The housekeeping gene glyceralaehyde 3-phosphate dehydrogenase
(GAPDH) was used as an internal qualitative and semiquantitative
control.
with translocation of p73 to the nucleus. Results were
comparable using two different antibodies against p73.
Rabbit polyclonal H-79 (fig 5) recognises the N-terminal 80
amino acids of p73, and cannot be used to discriminate
between full length forms and AN variants of p73. Ab77
(fig 6) recognises a sequence at the extreme N-terminal 15
amino acids and therefore exclusively identifies full length
p73 and should not crossreact with ANp73. To test whether
constitutive expression of nuclear p73 is a consequence of in
vitro culture or whether it reflects expression in colonic
epithelium in situ, formalin fixed, paraffin wax embedded
sections were subjected to immunohistochemistry with both
of the anti-p73 antibodies. Staining was present in the basal/
parabasal cells of murine skin epithelium,* but not in the
colonic epithelium, indicating that p73 is not normally
expressed, at least in amounts detectable by immunohisto¬
chemistry, in the murine large intestine in situ.
We also investigated the nature of p73 isoforms in primary
colonocytes by RT-PCR and identified the predominant form
as full length p73ot, present in both wt and p53 null
colonocytes with no change during cisplatin treatment
(fig 7). No products corresponding to p73P, ANp73a, or
ANp73|J were detected.
DISCUSSION
In our study, we investigated the role of p53 in the regulation
of growth and the response to cisplatin injury in freshly
isolated, non-transformed primary murine colonocytes and
found that whereas p53 seemed to regulate cell cycle arrest
after cisplatin induced DNA damage, perhaps its role in
apoptosis was less important.
Under baseline conditions, the proportion of p53 null
colonocytes in S phase was significantly greater than in the
wt counterparts, suggesting a role for p53 in regulating the
cell cycle in vitro in primary colonocytes. The decreased BrdU
incorporation after treatmentwith cisplatin inwt colonocytes
indicates that wt cells undergo G1 arrest, whereas p53
deficient cells continue to enter the phase of DNA synthesis,
despite sustaining damage to their DNA. Thus, as a first line
of defence, wt colonocytes respond to cisplatin damage via a
p53 dependent growth arrest.
Ultimately, many p53 null and wt cisplatin treated cells
died by apoptosis. The time course of cell death was rapid,
with approximately 40% ofwt cells becoming apoptotic by 24
hours. However, cell death in p53 deficient cells was reduced
compared with wt colonocytes. This may be analogous to the
delayed p53 independent apoptosis seen in vivo after
irradiation in the small intestine, and to a much lesser
extent in the colon," suggesting the existence of p53
independent mechanisms of eliminating damaged intestinal
cells. Consistent with the proposed role for p53 in mediating
cell cycle arrest and apoptosis in response to cisplatin, the
expression of p53 was significantly upregulated in treated wt
cells. Nonetheless, the expression of its downstream target
p21 remained unchanged from the already high baseline. We
might predict that these high amounts of p21 function to
counteract apoptosis.1" In fact, in the absence of p53, when
baseline p21 values are 40% lower, apoptosis is reduced.
Expression of nuclear p21 was high regardless of treatment,
timepoint, or genotype. This could be attributed to the stress
of in vitro culture, which seems to be a limitation of the
primary murine colonocyte model. p53 is not normally
implicated in the baseline expression of p21, yet in primary
colonocytes, the proportion of cells expressing p21 under the
normal conditions of in vitro culture is halved in the context
of p53 deficiency. If growth in vitro is indeed stressful for
colonocytes, then it is not surprising that p21 values are high
to counteract this, and that perhaps p53 null cells are to a
certain extent desensitised with regard to these stresses.
www.jdinpath.com
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Take home messages
• p53 is essential for primary oolonocytes to undergo cell
cycle arrest but not apoptosis after cispiatin induced
damage, suggesting that p53 mediated apoptosis and
growth arrest are not the only means by which colonic
murine epithelial cells guard against mutation after
DNA damage
• In the absence of p53, the failure of colonocytes to
enter growth arrest probably has no longterm con¬
sequences because alternative death pathways are
instigated to eliminate cells harbouring mutations
• Endogenous p73a was translocated to the nucleus in
response to DNA damage in primary murine colono¬
cytes, suggesting a functional proapoptotic role for
p73a in p53 deficient cells
Studies of primary colonocytes lacking p21, both p53 and
p21, or p53 and p73 would yield further insight into this
question.
"After treatment with cisplatin for 24 hours, there was an
increase in the amount of p73 protein in the nucleus as
demonstrated by an increase in signal intensity, consistent
with increased nuclear translocation of p73"
We detected constitutive expression of p73 in the nucleus
of wt and p53 null cells, and increased translocation of p73 to
the nucleus after exposure to cisplatin. This suggests that p73
is responsive to cisplatin induced damage of colonocytes and
could contribute to the p53 independent expression of p21
and to apoptosis after DNA damage. We used RT-PCR
analysis to investigate the incidence of major p73 isoforms
in primary colonocytes and confirmed the presence of full
length p73a in both wt and p53 null cells under baseline
conditions. Amounts of the transcripts remained unchanged
after exposure to cisplatin, consistent with reports in the
literature that p73 stabilisation after cisplatin induced
damage does not involve transcriptional upregulation."
Nuclear expression of p73 detected by means of immuno¬
fluorescence was demonstrated using two different antibo¬
dies raised against p73. After treatment with cisplatin for 24
hours, there was an increase in the amount of p73 protein in
the nucleus as demonstrated by an increase in signal
intensity, consistent with increased nuclear translocation of
p73. This is in accord with the possibility that p73a
cooperates with p53 in wt colonocytes, as has recently been
shown in other systems,40 and that p73a may be a p53
independent pathway of apoptosis in p53 deficient cells.
Given the limited yields of colonocyte extract and the low
amounts of endogenous p73, we were unable to analyse
endogenous p73 by immunoblotting or immunoprecipitation.
Several studies have described the transfection of p73
expression plasmids into cancer cell lines for the investiga¬
tion of p73 modification and interaction with regulatory
factors. However, such studies are often confounded by the
diversity among cell lines or because they rely on high
amounts of exogenous protein and ignore the endogenous
protein. Thus, although these approaches are undoubtedly
fruitful and very likely to yield useful information, we should
be reminded of the power of deciphering function in a
physiological setting, such as our primary colonocyte system.
The emerging evidence of the interaction of p73 with
components of the mismatch repair signalling pathway,*' *!
the high incidence of mismatch repair deficiencies in color¬
ectal cancer, the role of p73 as a corroborator of p53 function
and also as an independent apoptosis inducer point to a
potentially vital role for p73 in coupling damage repair and
death in colonocytes.
in our study we have shown that p53 is essential for
primary colonocytes to undergo cell cycle arrest but not
apoptosis after cisplatin induced damage. This suggests that
p53 mediated apoptosis and growth arrest are neither a major
nor a unique protector of colonic murine epithelial cells
against mutation after DNA damage. In the absence of p53,
the failure of colonocytes to enter growth arrest probably has
no longterm consequences because alternative death path¬
ways are instigated to eliminate cells harbouring mutations.
Furthermore, we demonstrated the nuclear translocation of
endogenous p73a in response to DNA damage in primary
murine colonocytes, which, within the context of p53
independent apoptosis, is highly suggestive of a functional
proapoptotic role for p73a in these ceils.
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Abstract
The Hedgehog (Hh) signalling pathway is crucial for normal development and patterning
of numerous human organs including the gut Hh proteins are also expressed during gastric
gland development and gastric epithelial differentiation in adults. Recently, dysregulation
of these developmentally important genes has been implicated in cancer, leading to the
present study of the expression of Hh signalling proteins in colon cancer. In this study,
normal colon and colonic lesions (hyperplastic polyp, adenoma, and colonic adenocarcinoma)
were examined by immunohistochemistry using antibodies against Hh signalling molecules;
the secreted protein Sonic hedgehog (SHH), its receptor Patched (PTCH), and the PTCH-
associated transmembrane protein Smoothened (SMOH). The study shows that Hh signalling
pathway members are expressed in normal colonic epithelium. SHH was expressed at the
top of the crypts and in a few basally located cells, while PTCH was detected in the
neuroendocrine ceils and SMOH at the brush border of superficial epithelium. RT-PCR
analysis of lascr-microdissected crypts from normal human colon confirmed that mRNAs
encoding these proteins were expressed in colonic epithelium. Expression of SHH, PTCH,
and SMOH was up-regulated in hyperplastic polyps, adenomas, and adenocarcinomas of
the colon, and SHH expression correlated with increased expression of the proliferation
marker Ki-67 in all lesions examined. To address whether the Hh signalling pathway is
functional in the gut, the effect of Shh on epithelial cells in vitro was explored by treating
primary murine colonocytes with either Shh peptide or neutralizing anti-Shh antibody. The
proportion of ceils in the S-phase was assessed by bromodeoxyuridine (BrdU) incorporation.
It was found that exogenous Shh promotes cell proliferation in colonocytes, while anti-Shh
inhibits proliferation, suggesting that Shh is required during proliferation of epithelial cells
in vitro. It is suggested that SHH is required during epithelial proliferation in the colon and
that there is a possible role for Hh signalling in epithelial colon tumour progression in vivo.
Copyright © 2004 Pathological Society of Great Britain and Ireland. Published by John
Wiley & Sons, Ltd.
Keywords: SHH; PTCH; SMOH; colonic epithelium; primary murine colonocytes; laser
capture microdissection
Introduction
The hedgehog (hh) gene was first identified in a screen
for genes implicated in the embryonic development of
the fruit fly, Drosophila melanogaster [1 ]. Hh encodes
a secreted protein important in regulating proliferation
and establishing cell fate in Drosophila [2]. There
are three mammalian hedgehog homologues, Sonic
hedgehog (Shh) [2], Indian hedgehog (Ihh) [3], and
Desert hedgehog (Dhh) [2], whose functional proper¬
ties appear to be highly conserved between organisms.
Repression of the transmembrane protein Smoothened
(Smoh) [4] by the Hh receptor Patched (Ptch) [5,6] in
the absence of Hh culminates in cleavage of Gli [7]
to a transcriptional suppressor. When Shh binds Ptch,
Smoh suppression is relieved, preventing cleavage of
Gli. This leads to Gli entering the nucleus and activat¬
ing transcription of Hh target genes [8-10]. Ptch also
limits the action of Shh, as high levels of Ptch induced
by Shh serve to sequester free Shh, therefore limiting
its further diffusion [11].
In humans, the Hh signalling pathway is crucial for
normal development and patterning of various organs
including the brain, spinal cord, craniofacial structures,
lung, teeth, eye, hair, and limbs [12]. It also plays a
role in haematopoiesis [13] and in tumour formation
[14].
Inactivation of the SHH gene has been con¬
firmed as the cause of holoprosencephaly (OMIM
ref 236 100), while overexpression of Shh in trans¬
genic mice resulted in the appearance of basal cell
carcinoma (BCC)-like tumours within the first few
days of skin development [15]. The latter was mir¬
rored in transgenic human skin [11], Genetic mutations
causing truncation or an unstable PTCH protein are
associated with familial (Gorlin's syndrome, OMIM
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ref 109400) or sporadic BCC [6]. Medulloblastoma,
BCC, and meningioma are all tumours linked to Gor-
lin's syndrome. In addition, SMOH mutations have
been identified in BCCs and neuroectodermal tumours
[16]. In summary, mutations that activate the proto-
oncogene SMOH or inactivate the tumour suppressor
PTCH may lead to activation of the signalling pathway
in the absence of Hh, allowing inappropriate transcrip¬
tion of target genes, a factor that may be important in
the pathogenesis of malignant disease.
Shh is crucial for gastrointestinal tract develop¬
ment. Homozygous Shh knockout (Shh~f~) mice
show oesophageal atresia/stenosis, tracheoesophageal
fistula, and tracheal and lung anomalies, features sim¬
ilar to those observed in humans with foregut defects
[17], Inactivation of the Shh gene in mice leads
to annular pancreas (OMIM ref 167750) [18], and
gut malrotations and imperforate anus (OMIM ref
301 800), often associated with annular pancreas in
humans, are also a phenotype of Shh~'~ mice. In
addition, Shh~'~ mice also display intestinal transfor¬
mation of the stomach with overgrowth of the gastric
epithelium, and duodenal stenosis caused by hyper¬
plastic villi [18], Recent studies have shown that Shh
is involved in gastric gland development and gastric
epithelial differentiation in adults [19]. These data led
us to address whether the Hh signalling genes play a
similar role in colonic epithelium.
As the Hh pathway is clearly essential for devel¬
opment of the gut, our aim was to examine expres¬
sion of the Hh signalling molecules in normal human
colon. Protein expression was also examined in a
series of human colonic lesions that included hyper¬
plastic polyps, adenomas, and adenocarcinomas. Some
researchers have regarded hyperplastic polyps as pre¬
cursors of colorectal carcinoma, whereas others view
them to be non-neoplastic and unrelated to cancer [20].
Consequently, it was of interest to investigate these
lesions as well as more advanced neoplastic tumours
such as adenomas and adenocarcinomas.
Materials and methods
All of the samples used in this study were obtained
from the archives of the Department of Pathology, the
University of Edinburgh. We studied only anonymized
tissues, in accordance with the guidance of the local
ethics research committee. The investigation did not
extend to examination of the individual case records.
All animal experiments were carried out in compliance
with UK Home Office regulations.
Immunohistochemistry
Tissue samples were selected from the archives of the
Division of Pathology, the University of Edinburgh
Medical School. Seven hyperplastic polyps, 20 tubulo-
villous adenomas of the colon, eight adenocarcino¬
mas, and three normal colon samples (formalin-fixed.
paraffin-embedded and frozen samples) were used in 61
the study. Sections were serially cut at 3-5 gm. 62
For immunohistochemistry, we used the following 63
antibodies and dilutions: goat polyclonal antibodies 64
raised against Shh (N-19), 1:100; Ptch (G-19), 1:80; 65
and Smoh (C-17), 1:100 (Santa Cruz Biotechnologies, 66
Inc); and mouse monoclonal Ki-67, 1; 100 (clone 67
MlB-1) (DAKO). 68
Unless otherwise stated, all reagents were from 69
DAKO. Sections were dewaxed in xylene and rehy- 70
drated through graded alcohols, followed by incuba- 71
tion for 20 min in 3% hydrogen peroxide to block 72
endogenous peroxidase. A casein serum-free blocking 73
solution specific for formalin-fixed tissues was applied 74
for 20 min and sections were incubated overnight 75
at 4°C with primary antibodies. Slides were given 76
three 5-min washes in PBS and incubated with 77
either biotinylated rabbit anti-goat IgG (1:400) or 78
rabbit anti-mouse IgG (1:400) secondary antibodies 79
for 30 min before incubating for 30 min in Strep- 80
tAvidin-Biotin HRP Complex. The antibody com- 81
plex was visualized with diaminobenzidine. Sections 82
were counterstained with Mayer's haematoxylin. Neg- 83
ative controls (absence of primary antibody) were 84
included for each antibody and for each case anal- 85
ysed. 86
87
Laser capture microdissection, RNA preparation, ^
RT-PCR, and sequencing 90
Eight-micrometre cryostat sections were used for laser 91
capture microdissection. Tissue sections were fixed 92
in 70% alcohol, stained with Mayer's haematoxylin 93
and eosin, dehydrated in graded alcohols, cleared and 94
dehydrated in xylene, and air-dried for .15 min. Nor- 95
mal colonic crypts were microdissected onto LCM 96
caps (CellPix II, Arcturus) and RNA was prepared 97
using an RNA isolation kit (Ambion). cDNA was 98
synthesized from DNase I-treated (2 U; DNA free 99
kit, Ambion) RNA using MMLV reverse transcriptase 100
(Life Technologies) and Oligo dTi2-i8 primer (Life 101
Technologies) in the presence of RNase inhibitor (Life 102
Technologies). Five microlitres of cDNA was ampli-103
fied in 25 gl PCRs. The primer pairs used [21,22] were 104
SHH, forward 706 — 5'-GAA AGC AGA GAA CTC 105
GGT GG-3' and reverse 875 — 5'-GGA AAG TGA 106
GGA AGT CGC TG-3', yielding a 170 bp product 107
(GENBANK accession No L38518); PTCH, forward 108
1092 — 5'-TCC CAA GCA AAT GTA CGA GCA-3' 109
and reverse 1238 — 5'-TGA GTG GAG TTC TGT 110
GCG ACA C-3\ 144 bp (GENBANK accession No 111
U59464); and SMOH, forward 615 — 5'-CTG GTA 112
CGA GGA CGT GGA GG-3 and reverse 756 — 5'- 113
AGG GTG AAG AGC GTG CAG AG-3', 140 bp 114
(GENBANK accession No U84401). The housekeep-115
ing gene (i-microglobulin (120 bp) was used as an 116
internal semi-quantitative and qualitative control, and 117
cDNA isolated from H441 cells (human pneumocytes 118
type II cell line) as a positive control. RT-PCR prod- 119
ucts were run on 6% polyacrylamide gels stained 120
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with ethidium bromide and visualized under ultraviolet
light. PCR products were sequenced using 33P Ther-
mosequenase cycle sequencing kits (Amersham) from
primers used for PCR amplification.
Primary murine colonocyte cultures
Primary mouse colonocytes were used as an in vitro
assay to address whether the Hh signalling pathway
was functional in the gut. BDF-1 mice (Charles River
Laboratories) were used to derive primary murine
colonocytes as previously described [23]. Recombi¬
nant mouse Shh, a 180-residue N-terminal peptide
(Shh-Np, R&D Systems), was reconstituted in sterile
PBS with 0.3% BSA. The neutralizing mouse anti-
Shh antibody (clone 5E1) and the isotype control IgGl
antibody were a gift from Dr Sarah Howie, University
of Edinburgh. After 3 days in culture in high glu¬
cose, L-glutamine-containing DMEM culture medium
(Invitrogen), supplemented with antibiotics [100 U/ml
penicillin (Invitrogen), 30 pg/ml streptomycin (Invit¬
rogen), and 25 pg/ml gentamycin (Sigma)], 0.25 U/ml
insulin (Calbiochem), and 5 ng/ml EGF (Sigma),
colonocytes were incubated for 72 h either with the
addition of 2.5% serum or with no serum, in the
presence of 0.25, 0.5 or 0.75 pg/ml Shh N-terminal
peptide. Control cells were treated with PBS-0.3%
BSA. Colonocytes were also grown in the presence of
20 or 50 pg/ml 5E1, or 20 gg/ml IgGl isotype control
antibody as previously reported [24] for 48 and 72 h.
Proliferation assay
After culturing for 48 or 72 h in the presence or
absence of exogenous Shh or 5E1, primary murine
colonocytes were assayed by BrdU incorporation to
determine the proportion of cells in the S-phase.
The study was designed having, as models, previ¬
ously published methods [24-26]. Cells were incu¬
bated in the presence of BrdU for 4 h and then
fixed in cold 80% ethanol overnight. The incorpo¬
rated BrdU was detected by immunocytochemistry as
previously described [27] using a rat anti-BrdU anti¬
body (1:100 dilution) (Immunologicals Direct). Posi¬
tive nuclei were counted in no less than 500 cells and
the experiments were performed in triplicate.
Results
Shh pathway members are expressed in normal
colon
SHH, PTCH, and SMOH stained the cytoplasm, while
the proliferation marker Ki-67 stained the nuclei.
Expression patterns of the proteins were consistent
within each group of cases. No staining was observed
when secondary detection was performed in the
absence of primary antibody. Light positive staining
for SHH protein was detected within the cytoplasm at
the top of normal colonic crypts (Figure 1A — SHH).
A few cells located basally in the crypts stained pos¬
itive for SHH, as recently reported [19]. Ganglion
cells of the myenteric plexus, found between the circu¬
lar and longitudinal layers of the muscularis propria,
expressed SHH, in a pattern •similar to that previ¬
ously reported in the mouse [18]. Neuroendocrine cells
located basally in the crypts expressed PTCH strongly
(Figure 1A — PTCH), also consistent with recently
published studies in the lung [25], whereas the rest
of the epithelial cells were unstained. SMOH expres¬
sion was found only at the brush border of superfi¬
cial colonic epithelium (Figure 1A — SMOH). Ki-67
confirmed that proliferation in normal colon epithe¬
lium was located in the basal compartment of the
crypts (Figure 1A — Ki-67). Total mRNA isolation,
RT-PCR, and sequencing of PCR products (data not
shown) from laser microdissected crypts confirmed
that mRNAs encoding Hh signalling pathway mem¬
bers are expressed in the epithelium of colonic crypts
(Figure 2).
SHH, PTCH, and SMOH are expressed in
hyperplastic polyps
The pattern of SHH expression in hyperplastic polyps
contrasts with that described in normal colon epithe¬
lium. Strong SHH staining was found at the base
of the crypts and became lighter towards the top
(Figure IB — SHH). The intensity of PTCH staining
was strong and present in most of the cells within
the crypt, with cells located basally also displaying
intense staining (Figure IB — PTCH). The pattern of
SMOH expression was largely maintained compared
with normal colon, with SMOH# staining the brush
border of superficial epithelium, but in addition the
epithelial cells of the crypts were moderately stained
(Figure IB — SMOH). Ki-67 expression remained in
the basal compartment of the crypts, although a greater
number of nuclei were stained compared with nor¬
mal colon (Figure IB — Ki-67), showing that, as
expected, hyperplastic polyps have a higher prolifera¬
tion index than normal colonic epithelium,
Hh pathway members are also expressed in
colonic adenoma and adenocarcinoma
SHH, PTCH, and SMOH all showed stronger staining
than in normal colon in a large number of adenoma¬
tous (Figure 1C) and malignant crypts (Figure ID).
The crypts that stained more strongly also displayed
multiple mitoses, showed a higher degree of dyspla¬
sia, and had lost most of their normal characteristics.
The staining was heterogeneous as not all malignant
crypts stained positive for the discussed antibodies.
The cells in the lamina propria, muscularis mucosae,
and stroma of invasive carcinoma remained unstained,
indicating that the expression of the proteins was gen¬
uine and specific. Ki-67 confirmed dysregulated cell
proliferation at the superficial surface of adenomatous
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Figure I. Micrographs of normal colon (A), hyperplastic polyp (B), colonic adenoma (C), and colonic adenocarcinoma (D) stained
with SHH, PTCH, SMOH, and Ki-67. A positive immunohistochemical reaction is indicated by diaminobenzidine (brown staining)
and haematoxylin was used a nuclear counterstain. In normal colon, SHH stained lightly the superficial epithelial layer of the
colon and few cells located basally; PTCH was detected in the neuroendocrine cells; and SMOH stained the brush border of the
epithelium. In hyperplastic polyps, strong staining was detected for SHH at the base of the crypts, and for PTCH and SMOH,
the staining was moderate and in most of the epithelial cells within the crypts. Adenomatous crypts stained strongly for all three
proteins: SHH, PTCH, and SMOH. Staining was strong and heterogeneous for SHH, PTCH, and SMOH proteins in the majority of
the malignant crypts of colonic adenocarcinomas. Ki-67 showed a few positive nuclei at the base of the crypts in normal colonic
epithelium; an increased number of positive nuclei, but still located at the base of the crypts in hyperplastic polyps; and a high
number of positive cells at the luminal surface of the adenomatous glands. Numerous neoplastic cells stained positive for Ki-67 in
the adenocarcinomas examined
1 the majority of the malignant crypts in adenocarcino-
2 mas (Figure ID), with a normal pattern of proliferation
3 within the adjacent, non-neoplastic mucosa.
4
^ Exogenous soluble mouse Shh peptide has a
-j proliferative effect on primary murine colonocytes
8 To investigate the possibility that Shh may promote
9 proliferation in the gut, primary murine colonocytes
J Pathol 2004; 203: 000-000
were exposed to exogenous mouse Shh recombinant 10
peptide (Shh-Np) for 72 n. The percentage of cells 11
in the S-phase was detected by BrdU incorpora- 12
tion. Cells treated with 0.75 gg/ml Shh-Np showed 13
a statistically significant increase in BrdU incor- 14
poration compared with control cells (6.5% ver- 15
sus 3.0%, respectively; p = 0.0383, Mann-Whitney 16
U-test) (Figure 3). Cells treated with 0.75 gg/ml '7
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in BrdU incorporation compared with control cells
(3.4% versus 1.6%, respectively), demonstrating that
the proliferative effect of Shh-Np was not due to inter¬
action with the serum in culture medium (Figure 4).
Blocking endogenous Shh protein with mouse
neutralizing anti-Shh antibody decreases the
proportion of cells in the S-phase
To determine whether the Hh signalling pathway is
functional in the gut, primary mouse colonocytes were
exposed to 20 or 50 pg/ml 5E1 neutralizing antibody
for 48 and 72 h. Compared with untreated cells, the
mean percentage of BrdU staining cells was signifi¬
cantly reduced after 48 h in the presence of 20 pg/ml
5E1 (5.35% versus 2.90%, respectively; p — 0.0398,
Mann-Whitney U -test) and 50 pg/ml 5E1 (5.35%
versus 2.25%, p — 0.0147, Mann-Whitney U-test)
(Figure 5). After 72 h, a statistically significant dif¬
ference was seen between untreated cells and cells
cultured in the presence of 50 pg/ml (3.90% versus
1.8%, p = 0.0152, Mann-Whitney U - test). No inhi¬
bition of the S-phase was observed in the presence of
20 jig/ml isotype control antibody (Figure 5).














































SHH, PTCH, and SMOH are expressed in normal
colon and in colorectal neoplasia. Moreover, their
protein expression is similar to the distribution of their
transcripts in normal human colon. In hyperplastic
polyps, wild-type SHH protein expression was located
at the base of the crypts where proliferation was max¬
imal. SHH is crucial for growth and proliferation in
the embryo and has been shown to promote prolif¬
eration when overexpressed in epithelial cells in vitro
[28]. We found that SHH protein localized to areas
of increased cellular proliferation in human hyper¬
plastic polyps and that staining was more intense in
J Pathol 2004; 203: 000-000
areas of increased dysplasia in colorectal adenomas
and adenocarcinomas. Similarly, expression of SHH
correlated with increased expression of the prolifer¬
ation marker Ki-67 in adenomatous and malignant
crypts in the neoplastic lesions. PTCH and SMOH
wild-type proteins were also overexpressed in malig¬
nant crypts, although not all malignant crypts stained
positive for these antibodies, their expression being
heterogeneous but of comparable intensity, as can be
seen from the figures. A similar observation could
also be reflected by our findings regarding expres¬
sion of Hh pathway genes in colorectal cancer cell
lines [29]. Consequently, we addressed the hypothe¬
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and possibly in epithelial colon tumour progression
in vivo.
We wished to investigate whether Shh •influences
cell proliferation in the colon using the agonist Shh
peptide (Shh-Np) and neutralizing antibody (5E1)
in vitro. The human colorectal cell lines SW480 and
Colo-320 showed no response to either Shh-Np or 5E1
when analysed by flow cytometry (data not shown).
Since these cell lines are transformed to allow clono-
genic survival, it is not surprising that they are refrac¬
tory to external stimuli. Furthermore, Watkins et al
[25] reported that several cell lines, including one
colorectal (HCT116), showed no growth reduction in
response to the drug cyclopamine, which inhibits Hh
signalling by binding to Smoh, suggesting that the
pathway may not be active in these cell lines. We
therefore chose to use primary murine colonocytes,
which offer the advantage of being untransformed
epithelial cells derived from normal adult tissue and
which are more likely to reflect the in vivo situation.
Our results show that exogenous Shh has a mitogenic
effect on primary murine colonocytes and that unin¬
terrupted blocking of endogenous Shh inhibits prolif¬
eration, suggesting that Shh is required for epithelial
cell proliferation in vitro.
PTCH and SMOH are central to Hh signal trans¬
duction and are implicated in human tumourigenesis
[5,6,16,30]. Basal cell carcinoma, medulloblastoma,
I Pathol 2004; 203: 000-000
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3, 4 - PTCH 144bp
5, 6 - SMOH 140bp
7, 8 - p-microglobulin 120bp
Figure 2. RT-PCR analysis for SHH, PTCH, and SMOH using
mRNA from laser microdissected normal crypts (lanes I, 3,
5, and 7) and H44I cells (lanes 2, 4, 6, and 8) used as a
positive control. /? 2-microglobulin primers were used as an
internal qualitative and semi-quantitative control. Lanes I and
2: Shh — 170 bp;* lanes 3 and 4: Ptch — 144 bp; lanes 5 and 6:
Smoh — 140 bp; lanes 7 and 8: /8-microglobulin - 120 bp
lL
ei control
o 20 pg/ml 5E1




Figure 3. Graph of the percentage of ceils in the S-phase
detected by BrdU incorporation in primary murine colonocytes
after exposure to exogenous mouse Shh-N recombinant
peptide (Shh-Np) for 72 h in the presence of 2.5% serum
concentration of Shh-Np
Figure 4. Graph of the percentage of cells in the S-phase
detected by BrdU incorporation in primary murine colonocytes
after exposure to exogenous mouse Shh-N recombinant
peptide (Shh-Np) for 72 h in serum-free medium
and rhabdomyosarcoma are associated with mutations
that either activate SMOH or inactivate PTCH, causing
Hh-independent activation of the pathway. PTCH and
] Pathol 2004; 203: 000-000
48 hours 72 hours 48 hours 72 hours
Figure 5. Graph of the percentage of cells in the S-phase
detected by BrdU incorporation in primary murine colonocytes
after exposure for 48 and 72 h to exogenous anti-Shh antibody
(5EI) and exogenous isotype control antibody (IgG,) for 48 and
72 h
SMOH expression was stronger where the lesions dis¬
played a higher malignant grade. Compared with nor¬
mal colonic tissue, where we detected expression only
in neuroendocrine cells (for PTCH) and at the brush
border (for SMOH), expression was up-regulated in
adenoma and carcinoma of the colon. These findings
suggest spatially aberrant Hh signalling or epigenetic
activation of the genes.
Interaction between Ptch and p53 has been recently
suggested. Ptch mutant mice on a p53-null genetic
background show a marked increase in the incidence
of medulloblastoma [31]. As many colorectal carci¬
nomas have mutations or deletion of p53, an addi¬
tional mutation or inactivation of PTCH may cause
survival and continuous proliferation of cycling cells
carrying damaged DNA. Such cells may give rise to
tumours.
In summary, the Hh signalling pathway is an
important regulator of body plan patterning, growth,
and cellular proliferation during embryogenesis, and
we have shown that the pathway is expressed in adult
colonic tissues. Altered patterns of the expression of
Hh pathway genes in colonic neoplasia suggest a role
in human tumourigenesis.
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